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This thesis consists of five chapters. 
Chapter 1 gives an introduction into the threat posed to human health 
by cancer, and the inorganic anti-cancer drug, cisplatin. The 
disadvantages of this drug are described, as are the benefits of drug 
delivery to the tumour within a larger vector. The basic principles and 
strategies of metallosupramolecular synthesis are then laid out, and 
potential applications where they act as a host to an internally 
encapsulated guest are discussed. A cisplatin-encapsulating [Pd2(L)4]4+ 
cage developed by the Crowley group is introduced, and the goals of 
this project are named; being an investigation into the biological 
stability of this system, and a study into increased functional scope and 
complexity for these systems.  
Chapter 2 introduces the role of metallosupramolecular architectures 
as cytotoxic agents, and the reliance of this activity on their stability in 
biological conditions. Work improving the stability of [M2(L)3]n+ cylinders 
using oxidation of the cobalt metal ions from +2 to +3 is described. The 
assessment of ligand donor strength in [Pd2(L)4]4+ architectures using a 
carbene palladium(II) 13C NMR probe is discussed, as are stability 
testing of the complexes through competition experiments against 
biological nucleophiles. A trend between donor strength and stability is 
established, but steric protection of the palladium(II) metal ion is also 
found to be necessary for these systems. The most stable compound is 
built from a hexyl-substituted, 1,3-phenyl linked bis-triazole ligand, 
and this compound demonstrates high cytotoxicity.  Tripyridyl 
[Pd2(L)4]4+ cages were also kinetically stabilised through amino 
substitution in the 2-position, but this increase in stability 
unfortunately was at the cost of the capacity to bind cisplatin. 
Chapter 3 discusses controllable and reversible release and reuptake of 
guests from metallosupramolecular cages. The addition of chloride to a 
[Pd2(L)4]4+ cage is found to switch the cage into an open [Pd2(L)2Cl4] 
macrocycle and free ligand. Silver(I) can be used to strip the chloride 
anions back off to reform the cage. Two guests that interact with the 
cage (cisplatin which binds within the cage cavity, and mesylate which 
binds on the external face of the palladium(II) metal ions) can be 
present during the switching process, and are released upon formation 




Chapter 4 details the types of self-sorting that have been investigated in 
palladium(II) architectures, and notes the difficulty in cleanly and 
controllably accessing heteroleptic structures. A series of competition 
experiments are then discussed, in which it is shown that introduction 
of the 2-amino ligand introduced in chapter 2 to a preformed 
unsubstituted [Pd2(L)4]4+ cage brings about displacement of two of the 
unsubstituted tripyridyl ligands. Consideration of NMR spectroscopic 
evidence in tandem with DFT calculations suggests that it is the cis 
isomer that is formed, and that this product is a highly stable kinetic 
product energetically uphill from the tetra-substituted product.  
Chapter 5 introduces larger metallosupramolecular achitectures that 
have been used to bind multiple guests, in some cases with 
simultaneous binding of different guest types. While excellent examples 
of complementary multiple guest-binding within a single architecture 
have been reported, encapsulation of different guests in an independent 
fashion have not. An approach using polytopic ligands which forms 
quadruply stranded palladium(II) cages with multiple cavities is 
detailed, and used to form a triple cavity cage in which the peripheral 
cavities have an internally directed pyridyl core, and the central cavity 
has a phenyl core. It is shown that the peripheral cavities bind 
cisplatin, while triflate binds in the central cavity, and to the exohedral 
faces of the cage. Simultaneous segregated guest binding is 





acac   Acetylacetonate 
AIBN  2,2’-Azobisisobutyronitrile 
AMBN  2,2’-Azobis(2-methylbutyronitrile)  
AMMVN 2,2’-Azobis(4-methoxy-2,4-dimethylvaleronitrile)  
CAN   Cerium ammonium nitrate 
CD   Circular dichroism 
CuAAC Copper(I)-catalysed azide-alkyne cycloaddition  
DCM  Dichloromethane 
DMAP  4-Dimethylaminopyridine 
DMF  N,N-Dimethylformamide 
DMSO  Dimethylsulfoxide 
DNA   Deoxyribonucleic acid 
dppf   bis-(Diphenylphosphine)ferrocene 
en   Ethylenediamine 
eq.   Equivalents 
EPR   Enhanced permeability and retention 
FDA   Federal drug administration 
HAT   Hexaphenylhexaazatriphenylene 
HMG  High mobility group 
IC50   Concentration required for 50% inhibition of cell viability 
(k)Da  (kilo)Dalton 
LD   Linear dichroism 
LDH   Lactate dehydrogenase 
NHC  N(itrogen)-Heterocyclic carbene 
NMR  Nuclear magnetic resonance 
vi 
 
NOESY Nuclear Overhauser SpectroscopY 
PAHs  Polyaromatic hydrocarbons 
PEG   Polyethylene glycol 
ROE   Rotating-frame nuclear Overhauser effect 
TEM   Transmission electron microscopy 
terpy  Terpyridine 
THF   Tetrahydrofuran 
TMS   Trimethylsilyl 






Unless otherwise stated, all reagents were purchased from commercial 
sources and used without further purification. Solvents were laboratory 
reagent grade. Petroleum ether refers to the fraction of petrol boiling in 
the range 40-60 °C, isopropyl alcohol (IPA), methanol (MeOH), 
dichloromethane (DCM), ethylenediaminetetraacetate (EDTA), 
ethynyltrimethylsilane (TMS-acetylene), tetrahydrofuran (THF), dimethyl 
sulfoxide (DMSO), dimethylformamide (DMF). 1H and 13C NMR spectra 
were recorded on either a 400 MHz Varian 400-MR or Varian 500 MHz 
AR spectrometer. Chemical shifts are reported in parts per million and 
referenced to residual solvent peaks (CDCl3: 1H δ 7.26 ppm, 13C δ 77.16 
ppm; CD3CN: 1H δ 1.94, 13C δ 1.32, 118.26 ppm, d6-DMSO: 1H δ 2.50 
ppm; 13C δ 39.52 ppm, d3-nitromethane: 1H δ 4.30, 13C δ 57.3). 
Coupling constants (J) are reported in Hertz (Hz). Standard 
abbreviations indicating multiplicity were used as follows: m = 
multiplet, q = quartet, quin = quintet, t = triplet, sept = septet, dt = 
double triplet, d = doublet, dd = double doublet, s = singlet, br = broad. 
IR spectra were recorded on a Bruker ALPHA FT-IR spectrometer with 
an attached ALPHA-P measurement module. Microanalyses were 
performed at the Campbell Microanalytical Laboratory at the University 
of Otago. Electrospray mass spectra (ES-MS) were collected on a Bruker 
micrOTOF-Q spectrometer.  
CAUTION: Azides are explosive and care should be taken when 









Colour-coding for representations of X-ray crystal 
structures and molecular models 
Unless otherwise specified in a figure caption, the elements throughout 
this thesis have been assigned the following colours: 
Boron (salmon) 
Bromine (brown) 







Fluorine (lime green) 









Sulphur (pastel yellow) 
Zinc (metallic grey) 
In the main body of the thesis the X-ray crystal structures are depicted 
in a variety of styles. The asymmetric units of reported structures as 
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1.1. Cancer, cisplatin and other platinum-based therapeutics 
1.1.1. Cancer 
Cancer kills one in seven people (Figure 1.1).[1] The name is a catch-all 
term for a broad collective of diseases all characterised by neoplasia; 
uncontrolled cell growth and division, and the breakdown of normal 
apoptotic pathways. This breakdown in normal cellular activity prompts 
malignant tumour development, and the resultant tumour can both 
interfere with normal organ function and spread cancer throughout the 
rest of the body. If untreated, death can ensue.     
 
Figure 1.1 Pie chart showing worldwide causes of death as percentages, 
2013.[1]  
Treatment of cancer generally involves the attempted destruction of the 
tumour.  The tumour can be eradicated through one or a combination 
of weapons, such as surgery, radiation therapy, and chemotherapy. 
Chemotherapy is the use of drug molecules to kill cancer cells. 
  
1.1.2. Cisplatin and analogues: mode of action and resistance 
Three platinum(II)-based compounds are FDA-approved anti-cancer 
drugs: cisplatin (cis-diamminedichloroplatinum(II)), oxaliplatin, and 
carboplatin (Figure 1.2).[2] Cisplatin is the oldest of the triad, with its 
antiproliferative activity discovered through fortuitous accident in 
1965.[3] Cisplatin is used to treat ovarian, bladder, head and neck, 
cervical, lung and, importantly, testicular cancer,[4] against which the 




Figure 1.2 Chemical and X-ray crystal structures of a) cisplatin,[5]  
 b) oxaliplatin,[6] and c) carboplatin.[7]  
The drug is administered intravenously. Due to the high concentration 
of chloride ions in the bloodstream, the relatively unreactive dichloro-
species is favoured, but a complex set of equilibria exists with exchange 
between mono- and disubstituted chloride-, aqua- and hydroxyl-
substituted complexes (Figure 1.3).[8] Entry into the cell for neutral 
variants is via cellular diffusion, while positively charged versions enter 
through membrane transportation proteins such as the organic cation 
transporter OCT-2 or the copper transporter CTR-1.[9] Within the cell, 
the chloride concentration decreases, and the diaquated platinum 
species predominates.  
 
Figure 1.3 Administration and mode of action of the intravenously-
administered drug cisplatin, which 1. in the bloodstream favours the dichloro-
species but also exists in hydrolysed and hydroxyl forms. Ingress to the cell 
occurs 2. through the membrane for neutral species or 3. via transport 
proteins for charged species. In the cytosol where chloride ion concentration 
decreases, 4. hydrolysis of the drug is favoured. The drug enters the nucleus 
and binds to two nucleic bases in varying combinations.   
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Within the nucleus the aqua ligands can be displaced where platinum 
fills one of the vacated coordination sites with the N7 nitrogen of a 
guanine base from DNA, the most nucleophilic site on the bases.[10] 
Cisplatin then forms an adduct through displacement of the other 
water, and binding a second base. This binding is predominantly to two 
intrastrand guanines (65% of adducts), but also between an adjacent 
intrastrand adenine and guanine (25%), two intrastrand guanines 
separated by a single nucleotide (6%) or two interstrand guanines (1-
2%) (Figure 1.3).[11] All intrastrand adducts introduce a kink into the 
DNA double-helix of between 32 and 35° (Figure 1.4).[12]  
 
Figure 1.4 X-ray crystal structure of the 1,2-intrastrand adduct between 
cisplatin and a dodecamer DNA duplex.[12b] Chloride ions shown in dark blue. 
Adduct formation appears to bring about apoptosis through influencing 
DNA-protein interactions. The kink induced in DNA provides a binding 
site for proteins such as those in the high mobility group (HMG) 
family.[13] Proteins might thus be deflected from their normal cellular 
roles, or prevent DNA-repair or replication.[14] Interference with RNA 
transcription is also possible.[13] The cancer against which cisplatin has 
most success, testicular cancer, is unusual in that the testes reportedly 
have additional HMG proteins; a potential explanation for the high cure 
rates.[8]   
 Nonetheless, the drug has two failings. The first is cytotoxicity. 
Cisplatin is not selective for tumours over healthy tissue, and causes 
kidney and nerve damage, nausea and suppression of bone marrow.[8] 
Efforts to sidestep this problem through usage of mechanistically 
similar but more inert analogues such as oxaliplatin or carboplatin 
have not been fully successful. At the same time, some cancers can 
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either acquire or inherently possess resistance to the drug. This 
resistance can be due to numerous combinatory effects including 
decreased uptake and cellular accumulation, increased drug 
inactivation, increased drug removal, increased DNA repair and altered 
regulatory protein expression.[15] Resistance could be overcome through 
increased dosage, but this must be balanced against the cytotoxic 
effects of the drug. 
 New platinum(II) compounds are being continually evaluated for 
suitability as anti-cancer drugs, but they often face similar challenges 
to cisplatin.[16] An alternative would be to encapsulate the drug within a 
delivery vector which in itself does not interact with healthy tissue, and 
give this carrier specificity for tumour tissue. This would both avert 
unwanted cytotoxic effects and allow increased dosage to overcome 
tumoral resistance. 
 
1.1.3. Active and passive targeting 
A drug delivery vector can be targeted to the tumour through either 
active or passive targeting. Tumour cells have altered regulatory protein 
expression, and membrane receptors are often overexpressed, with the 
receptor in question often varying with the cancer.[17] Attaching ligands 
specific to these receptors to the carrier therefore allows active targeting 
of the tumour and cellular uptake. Overexpressed receptors include 
transferrin receptors, folate receptors, the epidermal growth factor 
receptor, and carbohydrate receptors.[18]   
 Passive targeting utilises a differentiating characteristic of the 
tumour itself. The attribute of the tumour most targeted by potential 
drug delivery vectors is its enhanced permeability and retention (EPR) 
of macromolecular objects.   
 
1.1.4. The enhanced permeability and retention (EPR) effect 
Tumour tissue proliferates rapidly. The diffusional transport of oxygen 
and nutrients which serves normal tissue is not sufficient for the 
tumour, and it is forced to develop its own vasculature, which is large 
and abnormally shaped.[19] Macromolecules that cannot pass through 
the endothelial walls of healthy tissue can enter the tumour through 
these large fenestrations (Figure 1.5). Enhanced permeability of tumour 
tissue is then complemented by the poor lymphatic drainage possessed 




Figure 1.5 Cartoon representation showing the large endothelial fenestrations 
of tumour tissue as opposed to healthy tissue, giving the capacity for 
macromolecular drug delivery vectors to selectively penetrate the tumour 
environment. 
Carriers must be large enough to exploit the EPR effect and also avoid 
renal clearance, but also small enough to avoid hepatic capture.[20] 
Maeda et al. first explored the size window of the EPR effect using dyes 
bound to proteins or synthetic molecules, and colour ratios as a proxy 
for uptake into tumours versus healthy tissue in in vivo mouse 
models.[21] Selective accumulation was shown to occur upwards of 4.5 
kiloDaltons (kDa), with selectivity increasing up to 40 kDa.  
 
1.1.5. Macromolecular drug delivery vectors 
There are a variety of vehicles for drug delivery, both potential and 
realised. Liposomal formulations, such as FDA-approved cisplatin-
containing LipoplatinTM and doxorubicin-containing Doxil®, hold drugs 
within a lipid bilayer (Figure 1.6). Both these formulations have shown 
increased efficacy and lower cytotoxicity than their respective free 




Figure 1.6 Cartoon representation of a liposomal drug delivery vector with a 
lipid bilayer, and encapsulated drug molecules. 
Other potential vectors include polymers, dendrimers, nanoparticles, 
cucurbiturils, and carbon nanotubes.[23] This last example sees 
cisplatin, in a platinum(IV) prodrug form, bound axially to two 
carboxylates (Figure 1.7). One carboxylate is part of the carbon 
nanotube, attaching the prodrug to the macromolecular carrier. The 
other links the prodrug to a folate moiety, incorporating active targeting 
towards cancers with folate receptor overexpression. In the reductive 
environment of the tumour, the prodrug is reduced back to Pt(II), and 
the drug in its active form is released from the carrier. In addition to 
these examples, in recent years, various metallosupramolcular 
architectures have also been appraised as candidates for drug delivery.  
 
Figure 1.7 Carbon nanotubes as a drug delivery vector for cisplatin in a Pt(IV) 
prodrug form, also incorporating active targeting of cancers overexpressing 
folate receptors.[23c]  
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1.2. Metallosupramolecular chemistry 
1.2.1. Self-assembly 
Self-assembly refers to the capacity of various systems to self-organise 
with high fidelity to give the energetically favoured thermodynamic 
product. This organisation requires self-corrective capacity, which is 
possible when the interactions giving rise to the assembly process are 
reversible. Reversibility arises more readily for ‘weaker’ interactions 
than covalent bonds: the domain of supramolecular chemistry. For the 
purposes of this definition, these interactions include hydrogen or 
anion bonding,  bonding, ion and/or dipole interactions, and 
coordination bonds between a metal and donor atom. 
 The formation of discrete metallosupramolecular architectures 
depends on self-assembly, as exemplified by the formation of the 
original ‘Fujita square’, four palladium(II) metal ions bridged by cis-
coordinating 4,4-bipyridine ligands, with the vacant Pd(II) coordination 
sites ‘blocked’ by cis-coordinating ethylenediamine (en) (Figure 1.8). 
 
Figure 1.8 Tube representation of the crystal structure of a ‘Fujita square,’ 
from ethylenediamine cis-capped Pd(II) metal ions and 4,4-bipyridine.[24] 
Hydrogen atoms and counterions excluded for clarity. 
It can be seen that a metallosupramolecular assembly is defined by 
ligand geometry and the coordination preference of the metal. The 
structure of the thermodynamic product is decided by both entropic 
and enthalpic components, and both of these contributions favour the 
formation of the smallest possible cyclic product without undue strain 
or torsion being placed on the bonds of the resulting structure. Various 
strategies have therefore emerged to guide the assembly process 
towards the formation of the discrete, thermodynamic product, rather 
than polymeric kinetic products.  
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1.2.2. Symmetry interaction approach 
In the symmetry interaction approach, the donor atoms of the ligand 
have the capacity to align with bonding directionality roughly parallel to 
one another (Figure 1.9a), while a ‘naked’ metal ion is used with free 
orthogonal/antiparallel coordination sites (Figure 1.9b). The bonding 
sites on the ligand can be both mono- or poly-dentate, and likewise the 
coordination sites on the metal ion can be considered singly or in 
groups. Coordination sites on the metal can in some cases be filled with 
ancillary ligands such as solvent molecules or counterions.[25] Using 
this approach a large array of structural types have been accessed 
(Figure 1.9c and d), including macrocycles,[26] [M2(L)4]n+ assemblies,[27] 
octahedra,[28] cylinders,[29] grids,[25c, 30] tetrahedra,[28, 31] and cubes.[28, 32]   
 
Figure 1.9 The symmetrical bonding approach; selected examples of a) 
ligands with parallel bonding directionality, b) metals displaying 
orthogonal/antiparallel coordination modes, c) assemblies consisting of 
ligands with monodentate bonding functionalities, and d) assemblies 
consisting of ligands with polydentate bonding functionalities.  
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1.2.3. Ligand-directed approach 
In contrast, in the ligand-directed (or directional bonding) approach, the 
bonding directionalities of the ligands are non-parallel (Figure 1.10a). 
Thus the metal ions require blocking of coordination sites with capping 
units to leave cis-sites vacant, and act as the corners of the assembly 
(Figure 1.10b). An array of capping units have been utilised, including 
ethylenediamine[24, 33] and bis-phosphines[34] for square planar metals, 
and arenes bonded in a ‘half-sandwich’ fashion[35] or bis-2,2-
bipyridine,[36] for octahedral metals. Again, many structural types have 
been thereby formed, such as squares,[24, 34] rectangles,[37] octahedra[36] 
and prisms (Figure 1.10c).[35b, 38]          
 
Figure 1.10 The ligand directing approach; selected examples of a) ligands 
with non-parallel bonding directionality, b) cis-protected metal ions, and c) 
assemblies made using the ligand-directing approach.  
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1.2.4. Weak link approach 
The avoidance of kinetic trapping of oligomeric or polymeric species en 
route to the thermodynamic product is aided in the methods above by 
the use of rigid ligands with limited degrees of conformational freedom. 
An alternative method pioneered by Mirkin and coworkers and known 
as the ‘weak-link approach’ uses ligands with bidentate hemilabile 
binding pockets which consist of both a strong (phosphorus) and weak 
(ether oxygen) donor, connected through a flexible linker (Figure 
1.11).[39] Complex formation is a two-stage process: firstly, in what is 
effectively a symmetrical bonding approach, the ligand is combined with 
rhodium(I) to give a [n + n] ‘closed’ macrocycle. Secondly, a stronger 
monodentate ligand (such as chloride or carbon monoxide) is 
introduced, displacing the ether oxygen donor, and giving a flexible 
‘open’ metallacycle. In addition to bis-bidentate ligands, a tris-bidentate 
ligand has been used to give the trinuclear equivalent.[40]      
 
Figure 1.11 Cartoon representation of the ‘weak-link approach’; a bis-
bidentate ligand with phosphorus and oxygen donors separated by a flexible 
linker is combined with rhodium(I) to give a ‘closed’ macrocycle. Addition of an 
additional monodentate ligand displaces oxygen and forms a flexible ‘open’ 
metallacycle. The X-ray crystal structure of the initial macrocycle is shown, 




Metallacycles thus generated can then undergo further displacement 
reactions with bridging ligands, either between the two rhodium(I) 
centres,[39] or forming cylinders through linking rhodium(I) metal ions 
on different metallacycles.[41] Chromium(III)-salen-containing analogues 
of these systems have been demonstrated to possess greater catalytic 
activity than monomeric catalysts, with the ‘open’ form having greater 
activity than the initial ‘closed’ form.[42]   
 
1.2.5. Host-guest chemistry 
The cyclisation inherent in the nature of metallosupramolecular 
architectures means that they often possess an internal cavity of well-
defined shape and chemical character. Both these components can 
often be readily tuned, which in turn provides the opportunity for 
binding guests within the cavity. Just as with nature, these host-guest 
interactions can be used for a wide scope of purposes, and it is in the 
capacity for host-guest chemistry that many of the potential 
applications of metallosupramolecular architectures exist. 
 
Hosts as molecular reaction flasks 
Guests which have poor solubility in a solvent system can be effectively 
solubilised with a cavity of the host architecture. The size of the cavity 
can allow multiple guest encapsulation but restrict their orientation, 
and this can allow them to be used as molecular reaction flasks.[43] For 
example, the [2+2] photo-induced cycloaddition of acenaphthylene, 
which proceeds in poor yield and with no syn- or anti-selectivity in 
benzene, gives 98% conversion to the syn-napthoquinone product when 
carried out in D2O in the presence of an octahedral [Pd6(en)6(2,4,6-
tris(pyridin-3-yl)-1,3,5-triazine)4]12+ palladium(II) cage (Figure 1.12).[44] 
This is presumably because the cage solubilises the guest, but cavity 
size prevents cycloaddition in the anti-configuration. Similar systems 
have been subsequently used for a wide range of reaction and guest 




Figure 1.12 Depiction of the X-ray crystal structure of the host-guest adduct 
[syn-napthoquinonePd6(en)6(2,4,6-tris(pyridin-3-yl)-1,3,5-triazine)4]12+ (left) 
and the reaction scheme for photodimerisation of acenaphthylene, either 
assisted (syn only) or unassisted (syn and anti) by the metallosupramolecular 
reaction flask (right).[44] Hydrogen atoms, counterions, and solvent molecules 
omitted for clarity.  
 
Figure 1.13 Cartoon representation of the solution-phase reduction of CO2 to 
oxalate via a dinuclear Cu(I/II) macrocycle. X-ray structures of the 
oxalate/macrocycle host-guest adduct and the free macrocycle shown to the 




In addition to providing a suitably sized reaction environment, elements 
of the host structure can participate directly in guest reactions. 
Maverick and coworkers have utilised a dinuclear macrocycle formed 
from two bis-bidentate copper-catalysed azide-alkyne cycloaddition 
(CuAAC) “click” derived ligands and Cu(I/II) in dimethylformamide 
(DMF) solution (Figure 1.13).[46]  The Cu(II) metal ions are reduced with 
ascorbate to Cu(I), before two CO2 molecules bind in the cavity and are 
reduced to oxalate concurrent with oxidation of the metal centres back 
to the +2 state. Treatment of acid brought about liberation of the guest 
as oxalic acid and regeneration of the free macrocycle. 
Sequestering environmental pollutants 
The internal environment of metallosupramolecular cages can be 
tailored to promote sequestering of substances detrimental to the 
environment. For example, building on previous work,[47] a metallacycle 
was formed by Peinador and coworkers using the ligand-directing 
strategy between a cationic diazapyrenium-based or bipyridinium 
ligand and ethylenediamine-capped palladium(II) and platinum(II) metal 
ions.[37] The aromatic and positively charged environment thus created 
an excellent host environment for the encapsulation of a variety of 
hydrophobic polyaromatic hydrocarbons (PAHs) in aqueous or 
acetonitrile solution (Figure 1.14a), with binding affinities increasing 
with -surface area of both the guest and ligand.    
 
Figure 1.14 Depictions of X-ray structures of environmental pollutants 
sequestered within host assemblies, a)  [triphenylenePd2(en)2(2-(4-(pyridin-4-
ylmethyl)phenyl)-1,9-dihydrobenzo[lmn][3,8]phenanthrolin-2-ium)2]6+,[37] and 
b) [SF6Fe4(4,4'-bis((E)-(pyridin-2-ylmethylene)amino)-[1,1'-biphenyl]-2,2'-di-
sulfonate)6]5-.[31c] Guests depicted in space-filling form, hydrogen atoms, 





An Fe(II) (N(Bu)4)[M4(L)6]6- tetrahedron previously reported by Nitschke 
and coworkers[48] has also been demonstrated by the same group to 
bind SF6,[31c] the most potent greenhouse gas evaluated.[49] Bubbling 
SF6 through a solution of the cage in D2O resulted in encapsulation of 
the pollutant within the hydrophobic cavity, seen in a downfield shift of 
the 19F NMR fluoride signal of SF6, and in downfield shifts of the cage 
signals in the 1H NMR spectrum. Encapsulation in solution phase was 
incomplete; signals pertaining to both the host-guest adduct and the 
free host could be observed, in a 3:1 ratio at best, but leaving the 
solution open to air showed no evidence of loss of the guest over the 
period of a week. Binding was also demonstrated in solid phase through 
X-ray crystallography (Figure 1.14b). The guest could then be released 
from solution either by increasing the temperature, or disassembly of 
the cage through addition of tris(2-ethylamino)amine. 
 
Molecular storage 
Metallosupramolecular cages have also shown the capacity to act as 
molecular containers that store reactive species or intermediates, and 
equilibrium mixtures shifted to a single product when that compound is 
selectively encapsulated in a host. [45d, 50] Supramolecular containers 
can provide impressively inert environments for highly reactive guests. 
One such guest is ‘white phosphorus,’ P4, a highly explosive compound 
used in incendiary munitions. The highly explosive nature of P4 arises 
from the weak nature of the P–P bonds making it extremely air 
sensitive.[51] Solid P4 has been quantitatively encapsulated by Nitschke 
and coworkers into an aqueous solution of the same Fe(II) tetrahedron 
mentioned above,[52] and the host-guest complex could then be 
precipitated out through vapour diffusion of acetone into the solution, 
with the resulting X-ray crystal structure showing white phosphorus 
within the central cavity (Figure 1.15a). The encapsulated explosive was 
now water and air-stable, and can be released in solution through the 
introduction of benzene as a competing guest. In a similar vein, the 
radical initiators 2,2’-azobisisobutyronitrile (AIBN), 2,2’-azobis(2-
methylbutyronitrile) (AMBN) and 2,2’-azobis(4-methoxy-2,4-
dimethylvaleronitrile) (AMMVN) have been encapsulated within a 
[Pd2(L)4]4+ cage formed from a dianthracenyl ligand.[53] The host-guest 
adducts (again in some cases crystallographically characterised, for 
example Figure 1.15b) were formed through suspension of the 
respective initiators in a 9:1 D2O/CD3CN solution of the cage. Despite 
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being one of the most thermally reactive AIBN derivatives, the 
encapsulated AIBN or AMMVN guests were stable at room temperature 
for several weeks and at 50 °C for over 10 hours, in addition to highly 
improved photo-stability in the presence of UV light. This thermal 
stability did not interfere with the capacity of the guests to initiate 
polymerisation of methyl methacrylate to polymethyl methacrylate with 
comparable results to the use of the free initiator.     
 
Figure 1.15 Depictions of X-ray structures of reactive species within 
molecular containers, a) [P4Fe4(4,4'-bis((E)-(pyridin-2-ylmethylene)amino)-
[1,1'-biphenyl]-2,2'-disulfonate)6]4-[52] and b) [AIBNPd2(3,3'-((4,5,6-tris(2-
methoxyethoxy)-1,3-phenylene)bis(anthracene-10,9-diyl))dipyridine)4]4+.[53] The 
guests are depicted in space-filling form, and hydrogen atoms, solvent 
molecules, counterions and sulfonate substituents (for a) are omitted for 
clarity. 
 
1.2.6. Drug encapsulation in metallosupramolecular architectures 
The benefits of delivering drugs in a carrier which passively or actively 
targets the delivery site have already been discussed. 
Metallosupramolecular cages, with their readily tunable binding 
environment and functionality, are an attractive choice for delivery 
vectors. The first of these was reported by Therrien and coworkers, with 
a hexaruthenium(II) prism as the host architecture.[35b] The cage was 
assembled from a 3:2 ratio of a dinuclear [Ru2(iPr-C6H4Me)2(2,5-
dihydroxy-1,4-benzo-quinonato)Cl2] clip with 2,4,6-tris(pyridin-4-yl)-
1,3,5-triazine, in the presence of Ag(I) in methanol (Figure 1.16a). This 
metalloprism encapsulated square planar [M(L)2] complexes where M 
was Pd(II) or Pt(II) and the ligand was acetylacetonate (acac), 
sandwiching the planar guest within the electron rich triazine faces 
with the driving force for encapsulation being -stacking and the 
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hydrophobic effect. Evidence for encapsulation was shown in solution 
phase through 1H NMR spectroscopy in d6-acetone, through multiple 
ROE through space couplings between host and guest, and through X-
ray crystallography (Figure 1.16b and c), and the host-guest adduct 
was shown through 1H NMR spectroscopy to be stable in D2O, with slow 
guest release. 
 
Figure 1.16 a) Synthesis by Therrien and coworkers of a hexaruthenium 
prism,[35b] and depictions of the X-ray crystal structure of the host 
encapsulating [Pt(acac)2] from b) the side and c) above. Hydrogen atoms, 
counterions and solvent molecules excluded for clarity.  
Taken singly, neither component of the host-guest complex displayed 
high cytotoxicity against A2780 human ovarian cancer cells, with the 
cage having an IC50 (concentration required for 50% inhibition of cell 
viability) of 23 µM, and [Pd(acac)2] being inactive presumably due to low 
solubility. However, the combined host-guest adduct displayed high 
cytotoxicity of 1 µM, explicable if the host is viewed as a vehicle for 
solubilisation and intracellular delivery of the guest. This hypothesis 
was tested through the encapsulation of a pyrene-containing 
fluorescent probe within the host. Within the host, the fluorescence was 
quenched, and fluorescent monitoring of the host-guest adduct 
incubated with A2780 cells showed fluorescence due to the guest being 
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released within the cells, while treatment with the free guest alone gave 
far lower uptake.[54] 
 Other cages have subsequently been used to encapsulate platinum-
based cytotoxic agents,[55] including, by the Crowley group, cisplatin.[5] 
The ligand used in this system is 2,6-bis(pyridin-3-ylethynyl)pyridine 
(L1), which has been utilised in the group in the formation of Ag(I) 
coordination polymers,[26a] and solid state solvent- and counterion-
dependent coordination polymers, macrocycles and cages with Cu(II).[56] 
In a 4:2 combination with palladium(II) however, a lantern shaped 
[M2(L1)4]4+ cage is formed both in solution and solid state (Figure 
1.17a).   
 
Figure 1.17 a) formation of a [Pd2(L1)4]4+ cage from a 4:2 ratio of 2,6-
bis(pyridin-3-ylethynyl)pyridine and palladium(II), b) cartoon representation 
showing  encapsulation of Cisplatin within the cage, and subsequent guest 
release through cage disassembly with DMAP or [N(Bu)4]Cl. The cage can be 
reformed via treatment with tosylic acid or camphor-10-sulfonic acid (for 
DMAP) or AgSbF6 (for chloride). 
This cage has shown the ability to encapsulate small anions,[57] and 
more importantly, the introduction of cisplatin to a solution of the cage 
in CD3CN brought about downfield shifts of the internally directed cage 
protons, indicative of encapsulation (Figure 1.17b). The nature of this 
encapsulation was determined through X-ray crystallography of the 
host-guest adduct: two cisplatin molecules were arranged in a head-to-
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tail fashion within the cavity (Figure 1.18a). A chloride atom of the 
guest is positioned over the axial site of the palladium(II) metal ion, 
hydrogen bonding with the internally directed pyridyl protons (hence 
the downfield shift of these protons in the 1H NMR), while the amino 
group hydrogen bonds to the central pyridyl nitrogen (Figure 1.18b). 
The other chloride and amino groups of each cisplatin molecule 
hydrogen bond to their opposite in the second guest, and the two 
platinum(II) metal ions undergo platinum-platinum interactions. 
 
Figure 1.18 a) Depiction of the X-ray crystal structure of 
[(cisplatin)2Pd2(L1)4]4+ (L1 = 2,6-bis(pyridin-3-ylethynyl)pyridine, guest shown 
in spacefilling mode), and b) the same structure with a portion of the host 
architecture cut away for clarity and key interactions shown as dotted lines. 
Solvent molecules, counterions, and externally directed host hydrogen atoms 
omitted for clarity. 
It was found that disassembly of the cage with concurrent guest release 
could be achieved through treatment of a solution of the host-guest 
adduct with either DMAP or [N(Bu)4]Cl, giving free ligand, the formation 
of [Pd(L)4]2+ (L = DMAP or Cl-) and liberated guest (Figure 1.17b). The 
cage could subsequently be reformed upon addition of acid (for DMAP) 
or Ag(I) (for Cl-) with reuptake of Cisplatin. 
 Subsequent work concentrated on functionalisation of these cages, 
through CuAAC “click” chemistry, where the central pyridine of the 
ligand was appended with a methylene azide and combined with an 





Figure 1.19 Ligand functionalisation with triazole linkages, a) general 
synthetic scheme for formation of functionalised ligands (L1-trz-R, R = a wide 
range of solely organic or metal-chelated groups), b) [Ru(bpy)2(L1-trzpy)]2+, c) 
[Re(CO)3(L1-trzpy)Cl], and d) [(cisplatin)2 Pd2(L1-Fc)4]4+, solvent molecules, 
counterions and externally directed hydrogen atoms omitted for clarity.  
A wide array of groups were appended to give functionalised ligands 
and their respective cages. Organic moieties included sugars, a 
dipeptide, estradiol, and the fluorescent dye 4-amino-1,8-
naphthalimide. Metallic functionalisation was also achieved, either 
through the formation of a 2-pyridyl-1,2,3-triazole  group which could 
be complexed with ruthenium(II) (Figure 1.19b) or rhenium(I) (Figure 
1.19b), or through direct attachment of ferrocene (Figure 1.19c). 
Despite this additional functionalisation, the cage retained the ability to 
bind cisplatin. 
 
1.3. Project aims 
With the character of the [(cisplatin)2Pd2(L1)4]4+ host-guest system well 
established, an assessment of its suitability as a biological agent is 
required. In large part this requires an investigation of the stability of 
the host architecture under (pseudo)biological conditions. The 
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mechanism for disassembly of the cage and guest release through 
treatment with nucleophiles, while chemically elegant, suggests low 
kinetic stability. The first aim of this project is to probe this stability 
and, should it be lacking, attempt to improve it. 
 The second goal of the project is more esoteric. The principles of 
metallosupramolecular self-assembly are now well established for 
simple systems consisting of one ligand type and one metal ion. There 
is now a drive towards introduced complexity and additional 
functionality. The [Pd2(L)4]4+ system developed in the group is a simple 
and understandable system with reliable host-guest chemistry with 
Cisplatin. As such, it is perfect for enquiry into methods of introducing 
additional complexity. Questions to be asked include: 1) can guest 
release be achieved without complete disassembly of the host (in other 
words, a structural transformation), 2) can functional complexity be 
increased through the formation of heteroleptic [Pd2(L)4]4+ assemblies, 
and 3) how can the binding environment be altered to give varied guest 
binding? An exploration of these questions comprises the second thrust 




















Some parts of this chapter have been published: 
Preston D.,* Tucker R. A. J., Garden A. L., Crowley J. D., 
“Heterometallic [MnPtn(L)2n]x+ macrocycles from dichloromethane-
derived bis-2-pyridyl-1,2,3-triazole ligands,” Inorg. Chem. 2016, 55, 
8928. 
Vasdev R. A. S., Preston D., Scottwell S. Ø., Brooks H. J. L., Crowley J. 
D., Schramm M. P., “Oxidatively locked [Co2L3]6+ cylinders derived from 
bis(bidentate) 2-pyridyl-1,2,3-triazole “click” ligands: synthesis, stability 
and antimicrobial studies,” Molecules 2016, 1548. 
McNeill S. M., Preston D., Lewis J.E.M., Robert A., Knerr-Rupp K., 
Graham D.O., Wright J.R., Giles G.I., Crowley J.D.,* “Biologically active 
[Pd2L4]4+ quadruply-stranded helicates: stability and cytotoxicity,” 
Dalton Trans. 2015, 44, 11129. 
Preston D., McNeill S. M., Lewis J. E. M., Giles G. I., Crowley J. D.,* 
“Enhanced kinetic stability of [Pd2L4]4+ cages through ligand 
substitution,” Dalton Trans. 2016, 45, 8050. 
The assistance of Samantha McNeill and Dr. Greg Giles (Department of 
Pharmacology and Toxicology) with pharmacological training is greatly 
appreciated as is the assistance of Dr. James Wright for providing 
[Pd2(NHC)2Br4] and the X-ray crystal structure of [Pd(NHC)(L4mono)Br2], 
and the crystallographic expertise of Dr. James Lewis.  
 
2.1. Metallosupramolecular architectures as cytotoxic agents 
The utility of metallosupramolecular systems is not confined to their 
host-guest chemistry. Many architectures have shown considerable 
promise as cytotoxic agents in their own right, including examples from 
multiple classes of structure, including square and rectangular 
metallocycles,[59] prisms,[60] and helicates.  In 1995 Jean Marie-Lehn 
reported the binding of double-stranded Cu(I) helicates to DNA.[61] Since 
then, Hannon and coworkers have carried out extensive work with 
[M2(L)3]4+ helicates. An imine-based ligand was formed in 1997 from a 
Schiff-base condensation between pyridine-2-carbaldehyde and 4,’4-
methylene-dianiline ((NE,N'E)-4,4'-methylenebis(N-(pyridin-2-ylmethyl-
ene)aniline)).[62] This ligand could be combined in a 3:2 ratio with 
nickel(II) or iron(II) to give the corresponding helicate (Figure 2.1). 
Despite the lability of these metal ions and the fragility of the imine 




Figure 2.1 a) [M2(L)3]4+ helicates formed where L = (NE,N'E)-4,4'-
methylenebis(N-(pyridin-2-ylmethylene)aniline), and b) depiction of the X-ray 
crystal structure of [Ni2(L)3](BF4)4.[62] The ΔΔ (P) isomer is shown, and hydrogen 
atoms, solvent and counterions omitted for clarity. 
The ability of both the ΔΔ (P) and ΛΛ (M) optical isomers of the 
[Fe2(L)3]Cl4 cylinder (separable through passing through chiral filter 
paper) to interact with DNA was probed using circular and linear 
dichroism (CD and LD), and 1H nuclear magnetic resonance (NMR) 
nuclear Overhauser spectroscopy (NOESY) confirmed that the binding 
was a non-covalent interaction in the major groove of the DNA double 
helix.[63] This interaction was strong: ethidium bromide displacement 
studies gave a binding affinity of higher than 107 M-1.[64] The adduct of 
the Fe(II) cylinder with a double-stranded DNA oligonucleotide (5’-d-
(CGTACG)-3’) crystallised showing the helicate at the centre of a three-
way DNA junction. Interactions arose not only from the electrostatic 
attraction between the cationic helicate and the negatively charged 
phosphate backbone of DNA, but also -stacking between the phenyl 
rings of the helicate ligand and DNA bases (Figure 2.2).[65]  
 
Figure 2.2 Depiction of the X-ray crystal structure of Hannon’s [Fe2(L)3]4+ 
helicate bound in a three-way oligonucleotide DNA junction from a) above and 
b) the side. The different DNA strands are coloured red, blue, and yellow.[65] 
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 This system has exhibited biological activity: The Fe(II) and Ru(II) 
helicates[66] have shown micromolar-level cytotoxicity against several 
cancer lines, and the Fe(II) helicate has displayed modest antibacterial 
activity.[67] Another system, synthesised by Scott and coworkers, 
incorporated a chiral, flexibly-linked bis-bidentate ligand again based 
around the pyridyl-imine binding motif, with octahedral Fe(II) or Zn(II). 
In contrast to normal cylinder synthesis, where the linker defines the 
relative stereochemistry at each metal centre, as either meso (ΔΛ) or a 
racemic mixture of enantiomers (ΔΔ and ΛΛ), the resulting [M2(L)3]4+ 
cylinders, termed flexicates, were synthesised optically pure depending 
on the chirality of the ligand (R,R giving ΔΔ and S,S giving ΛΛ, Figure 
2.3).[68] 
 
Figure 2.3 a) The combination of a chiral ligand with a flexible linker with 
Fe(II) or Zn(II) by Scott and coworkers gave helicates the chirality of which was 
decided by the ligand (note the ligand is generated in situ with a metal salt 
from the appropriate aldehyde and amine), b) depiction of the crystal structure 
of the ΔΔ-[Zn2(LR,R)3]4+ flexicate, with counterions, solvent and hydrogen atoms 
omitted for clarity.[68]   
This neatly sidestepped problems with separating racemic mixtures or a 
lack of stereochemical communication and fidelity between metal 
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centres with long, flexible linkers. Additionally, both enantiomers 
bound in the major groove of DNA strongly, and flexicates have shown 
good antimicrobial activity against Escherichia coli and methicillin-
resistant Staphylococcus aureus as well as anticancer activity.[68-69]  
 
2.2. Self-correction and biological stability 
A prerequisite characteristic for the success of these previously 
mentioned examples is biological stability. The human body is rife with 
nucleophiles that can swiftly break down metallosupramolecular 
assemblies that are not sufficiently inert. But conversely, the self-
assembly process that produces these architectures as the 
thermodynamic product is dependent on the system possessing 
sufficient lability to facilitate self-correction. Put simply, there is often a 
trade-off between ease of synthesis and biological longevity.  
 This was nicely demonstrated by a series of [M2(L)3]4+ cylinders where 
M = Fe(II) or Ru(II) and L = various bis-2,pyridyl-1,2,3-triazole ligands 
with a variety of linker units (Figure 2.4).[70]  
 
Figure 2.4 Scheme showing the formation of bis-2-pyridyl-1,2,3-triazole 
ligands, and the subsequent complexation to form the [M2(L)3]4+ cylinders. 
Linkers successfully used with each metal (Fe(II) or Ru(II)) shown on right 
together with a depiction of the X-ray structure of [Ru2(bis-(2-pyridyl-1,2,3-
triazole)-1,4-xylene)3]4+, with counterions, solvent and hydrogen atoms omitted 
for clarity.[70]  
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These ligands were derived from the CuAAC “click” reaction between 2-
ethynylpyridine and the appropriate dibromide converted to the diazide 
in situ. Synthesis of the cylinders constructed from labile iron(II) was 
facile: stirring in acetonitrile gives the desired [M2(L)3]4+ complex, and 
this ease of synthesis with bis-pyridyl-triazole ligands has been 
demonstrated not only for iron(II) but also other first row transition 
metals.[71] But the same lability which allowed the ready formation of a 
family of cylinders proved to be their undoing in a biological 
environment. In contrast to the iron(II) cylinders of Hannon and Scott, 
these complexes were not stable against nucleophiles (decomposing 
immediately to free ligand in DMSO), with the lower stability 
attributable to the weaker donor strength of the 2-pyridyl-1,2,3-triazole 
binding motif and inter-triazole lone pair-lone pair repulsions in the 
cylinders.  
 In contrast, only a single [Ru2(L)3]4+ cylinder could be synthesised, 
from a bis-(2-pyridyl-1,2,3-triazole)-1,4-xylene ligand. Only this ligand 
had the required geometry to provide sufficient preorganisation to lead 
to the cylinder. Other related bis-(2-pyridyl-1,2,3-triazole) ligands when 
combined with inert Ru(II) ions gave mixtures of kinetically trapped 
polymeric products. The one Ru(II) helicate synthesised was kinetically 
inert, biologically stable, and exhibited modest antimicrobial activity.[70a]  
 Improving biological stability without sacrifice of synthetic ease could 
possibly be achieved in two ways. The first would involve targeting the 
metal ion, the second through tuning of ligand design.   
 
2.3. Oxidatively locked Co(III) assemblies 
In the +2 oxidation state cobalt exhibits lability comparable to iron(II), 
while in the +3 state it is significantly more inert. This character has 
been cleverly exploited by Lusby and coworkers to form oxidatively 
locked structures.[31a] A polyethylene glycol- (PEG) or adamantane-
substituted phenyl-linked bis-pyridyl-triazole ligand was combined with 
Co(II), forming the thermodynamically-favoured [Co4(L)6]8+ tetrahedron, 
before oxidising the cobalt centres to Co(III) using cerium ammonium 
nitrate (Figure 2.5). These structures were then determined to be 
kinetically inert via competition experiments, and able to bind organic 




Figure 2.5 Depiction of the formation of an oxidatively locked Co(III) 
tetrahedron from a bis-pyridyl-triazole ligand, by Lusby and coworkers. The 
structure is first formed with labile Co(II) prior to oxidation to inert Co(III) 
using cerium ammonium nitrate (CAN).[31a] Hydrogen atoms and counterions 
were omitted for clarity. 
  
2.4. Increased biological stability of cylinders through use of 
oxidative locking 
A wide range of bis-2-pyridyl-1,2,3-triazole ligands with diverse linkers 
have been synthesised,[70b, 71-72] but the shortest member of the family 
with the least degrees of freedom, the methylene-linked example, had 
not, presumably due to the dangers involved in dealing with the 
nitrogen-rich diazidomethane intermediate.[73] This ligand could in fact 
be synthesised generating the diazidomethane intermediate safely in 
situ from sodium azide and dichloromethane (DCM) heated in a 
microwave reactor at up to 110 °C in DMF in the presence of carbonate 
(Scheme 2.1). The diazide was then combined with 2-ethynyl pyridine 
under standard CuAAC “click” conditions to give the target ligand, L2 





Scheme 2.1 Formation of L2 and two [M2(L2)3](X)n cylinders. Conditions: (i) 
NaN3, Na2CO3, DMF, microwave 60 °C for 20 minutes then 110 °C for 20 
minutes, then 2-ethynylpyridine, CuSO4∙5H2O, sodium ascorbate, H2O, 
overnight at RT (85%); (ii) either a) [Co(H2O)6](BF4)2 in CH3CN, then cerium 
ammonium nitrate, then [NH4](PF6) (60%), or b) [Fe(H2O)6](BF4)2 in CD3CN 
(78%). 
The product had the expected 1H NMR spectrum, with the peak 
pertaining to the methylene protons being significantly downfield 
shifted due to its position between two electron-deficient triazole rings 
(Figure 2.6a). L2 was also characterised utilising other methods, 
including by X-ray crystallography (Figure 2.7a, crystals obtained 
through leaving a concentrated solution of L2 in acetonitrile to stand 




Figure 2.6 Partial stacked 1H NMR spectra (298 K, CD3CN, 400 MHz) of a) L2, 





Figure 2.7 Depictions of the X-ray crystal structures of a) L2 and b) 
[Fe2(L2)3](BF4)4. Counterions and solvent molecules in the lattice for the 
cylinder have been omitted for clarity.  
The strategy employed by Lusby and coworkers was then utilised to 
form a Co(III) cylinder from a 2:3 combination of [Co(H2O)6](BF4)2 and 
L2, followed by oxidation with cerium ammonium nitrate and anion 
exchange with [NH4](PF6) (Scheme 2.1, 60%).[75] The 1H NMR spectrum 
from the reaction indicated the formation of a cylinder, with the 
splitting of the methylene protons (Hf) into the AB quartet characteristic 
of cylinder formation, with the sharply defined peaks suggesting that 
the cobalt metal ion was in the diamagnetic +3 oxidation state (Figure 
2.6b). The mass spectrum of the compound confirmed the 2:3 ratio 
between metal ion and ligand, and the oxidation state of the metal ions, 
with peaks at m/z = 488.3749 [M – 3PF6]3+ (calc. 488.3709) and 
805.0449 [M – 2PF6]2+ (calc. 805.0387).  
It was unclear from these data however whether the compound was a 
helicate or mesocate, and attempts to crystallise the compound were 
unsuccessful. For this reason, the iron(II) analogue was synthesised 
from [Fe(H2O)6](BF4)2, giving a 1H NMR spectrum similar in nature to 
the cobalt(III) cylinder, with broader, further upfield peaks, due to the 
fluxional nature and lower charge of iron(II) (Figure 2.6c). The iron(II) 
cylinder was successfully crystallised from vapour diffusion of diethyl 
ether into acetonitrile (Figure 2.7b, P1̅, R1: 9.7%), as a mesocate, in 
agreement with the odd-even rule describing the relationship between 
the number of carbon atoms in a ligand alkyl linker and the 
configuration of the cylinder (odd = mesocate, even = helicate),[76] and 





Subsequently, a small family of Co(III) cylinders were synthesised, 
with either a methylene or 1,4-xylene linker, with either no substitution 
on the pyridine rings or a hexyloxy substituent, and with triflate 
counterions to provide water solubility. While these compounds 
unfortunately did not display antimicrobial activity, they were far more 
stable in DMSO, D2O and D2O in the presence of nucleophiles than 
iron(II) cylinders, confirming the success of the strategy. Interestingly, 
the compounds formed from the ligands with hydrophobic and electron-
donating hexyloxy substituents were more stable than those without. 
This suggested that even systems formed from (semi-)labile metal ions 
such as palladium(II) might be tuned towards greater kinetic stability 
through ligand substitution.†    
 
2.5. Quadruply-stranded [Pd2(L)4]4+ helicates  
With confirmation that ligand donor strength could improve kinetic 
stability, attention was turned to the stability and biological activity of 
palladium(II) cages. In addition to an investigation of the stability and 
biological activity of [Pd2(L1)4](BF4)4, it was decided to scrutinise an 
additional three quadruply-stranded Pd(II) helicates (Figure 2.8).[77] The 
three other helicates were chosen to contrast with the cisplatin-binding 
cage due to structural differences. The coordinating heterocycle on all of 
the three ligands was a triazole ring rather than pyridine, and unlike 
[Pd2(L1)4]4+ they did not have a readily accessible cavity. Furthermore, 
they were all exohedrally substituted and it was of interest to see 
whether, as with the Co(III) cylinders, these substitutions lent 
additional stability to the complexes. Lastly, supramolecular 
palladium(II) architectures had hardly been examined as biological 
agents, and thus the other assemblies had the potential to be 
biologically interesting in their own right. Three phenyl-linked bis-
triazole helicates were investigated (Figure 2.8). The three triazole-based 
helicates were chosen to contrast with the cisplatin-binding cage due to 
structural differences. Two of these had been previously synthesised: 
one with a bis-benzyl substituted ligand (L4),[78] and the other with 
hexyl chains (L5).[79] The last helicate was designed with a novel ligand 
(L3) intended to be isostructural to L5, but hydrophilic in nature, to 
investigate the role of hydrophobicity. L3 was synthesised via a CuAAC 
“click” reaction in a manner analogous to L4 and L5 (Scheme 2.2, 
72%). 
                                       
† This family of additional Co(III) cylinders was synthesised by Roan Vasdev, who also 
carried out the stability testing. One of these cylinders, also with a methylene bridge, 




Figure 2.8 [Pd2(L)4]4+ helicates assessed for donor strength, stability, and 
cytotoxicity, helicate on left, ligand on right. Depictions a) [Pd2(L1)4]4+ and c) 
[Pd2(L4)4]4+ are from X-ray crystal structures,[5, 77] b) [Pd2(L3)4]4+ and d) 
[Pd2(L5)4]4+ from MMFF modelling.[77] 
 
Scheme 2.2 Synthesis of L3 and [Pd2(L3)4](BF4)4. Conditions: (i) 1-chloro-2-(2-
methoxyethoxy)ethane, NaN3, DMF/H2O (4:1), microwave 110 °C 3.5 hours, 
then 1,3-diethynylbenzene, CuSO4∙5H2O, sodium ascorbate, overnight at RT 
(72%), (ii) [Pd(CH3CN)4](BF4)2, acetonitrile, 75 °C 3 hours (86%). 
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The hydrophilic 1-chloro-2-(2-methoxyethoxy)ethane chain[80] was 
converted in situ to the azide using NaN3 in a DMF/H2O mixture in a 
microwave reactor, prior to addition of 1,3-diethynylbenzene, Cu(II) and 
a reducing source (Scheme 2.2). The 1H NMR spectrum in CD3CN was 
characteristic of the family of these bis-triazole ligands, with the 
aromatic region containing the three phenyl proton environments and 
the triazole proton peak, and further upfield the expected pattern of a 
diglyme chain was evident (Figure 2.9a).   
 
Figure 2.9 Partial stacked 1H NMR spectra (298 K, CD3CN, 400 MHz) of a) L3 
and b) [Pd2(L3)4](BF4)4. 
The combination of a 4:2 ratio of L3 and [Pd(CH3CN)4](BF4)2 in 
acetonitrile gave the desired helicate, [Pd2(L3)4](BF4)4 (86%). The 
internally directed phenyl proton peak (Ha) in the 1H NMR spectrum 
shifted significantly downfield (Δδ = 1.88 ppm, Figure 2.9b) as usual 
with the formation of these helicates, indicative of facing into the inside 
of the structure, while the first methylene group split in the spectrum 
into two resonances, due to the conformational helical locking of the 
molecule. Mass spectrometry additionally confirmed the stoichiometry 
and molecular weight of the compound with peaks corresponding to the 
sequential loss of two to four counterions: m/z = 469.6712 [M – 4BF4]4+, 
(calc., 469.6693), m/z = 655.2315 [M – 3BF4]3+ (calc., 655.2271), m/z = 
1026.3470 [M – 2BF4]2+ (calc., 1026.3428). With this, the last of the 
four helicates in hand, assessment of their stability could be 
undertaken.    
2.6. Measuring ligand donor strength with Huynh’s Pd(II) NHC 
carbene probe  
Contributions to the stability of a Pd(II) metallosupramolecular complex 
are made by both the donor strength of the ligand and the steric 
protection it affords the vulnerable axial sites of the metal cation, which 
for palladium(II) undergoes ligand substitution via an associative 
interchange mechanism.[81] By independently investigating the donor 
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strength of the ligands from each of the helicates prior to stability 
testing via competition experiments, decoupling of the two factors 
would be possible. It was decided to measure ligand donor strength 
using the 13C NMR N-heterocyclic carbene probe developed by Huynh 
and coworkers (Figure 2.10).[82] They used a [Pd2(NHC)2Br4] dimer which 
could be combined in a 1:2 ratio with the donor of interest, forming a 
[Pd(NHC)(L)Br2] complex. Due to the trans effect, the chemical 
environment of the carbene carbon is influenced significantly by the 
donor strength of the opposing ligand.  
 
 
Figure 2.10 The NHC carbene probe developed by Huynh and coworkers for 
measurement of ligand donor strength through 13C NMR spectroscopy, using 
the chemical shift of the carbene peak.[82b] 
Huynh and coworkers have shown over a wide range of monodentate 
donors such as NHCs, phosphines, imidazoles, pyridines, amines,[82b] 
pyrazoles,[82a] 1,2,3-triazolin-5-yldines[82d] and bidentate chelating 
ligands such as bis-NHCs, bis-imines and bipyridine-type ligands,[82c]  
there is a clear trend between stronger ligand donor capacity and 
downfield shifting of the 13C NMR carbene resonance. Crowley and 
coworkers have also used this probe for 1,2,3-triazole-based mono- and 
bidentate ligands and reported the same correlation.[83] The free carbene 
has partial triplet character and hence a slight paramagnetic 
contribution to the NMR chemical shift, and thus, as stronger donor 
ligands weaken the palladium(II)-carbene bond, the chemical shift 
moves downfield.   
 
2.7. Polynuclear palladium(II) NHC probe complexes 
The syntheses of two probe complexes were initially attempted: that of 
the tripyridyl L1 ligand, and one of the bis-triazole ligands, L4, through 
simply dissolving a 1:1 ratio of the palladium(II) NHC dimer and the 




Scheme 2.3 Synthesis of polynuclear palladium(II) NHC probe complexes. 
Conditions: (i) L1 (69%) or L4 (product not formed selectively), CDCl3. 
The synthesis of [Pd2(NHC)2(L1)Br4] was successful (69%). The clean 
and symmetrical 1H NMR spectrum of the product showed downfield 
shifts of the peaks pertaining to the protons proximal to the nitrogen 
atoms on the outer pyridine rings of L1 (He and Hf), indicating that 
these were the sites of coordination (Figure 2.11). The integration of the 
peaks between L1 and the NHC ligand suggested a 2:1 ratio between 
them (as did elemental analysis and the mass spectrum: m/z = 1241.8 
[M + Na]+ (calc., 1241.8)), and there was only one carbene signal in the 
13C NMR spectrum (δ = 158.8 ppm), suggesting that the central pyridine 
core of L1 was not bound to palladium(II).  
 
Figure 2.11 Partial stacked 1H NMR spectra (298K, CDCl3, 400 MHz) of a) L1 
and b) [Pd2(NHC)2(L1)Br4]. 
However, the synthesis of [Pd2(NHC)2(L4)Br4] was not a complete 
success. The 1H NMR spectrum of the reaction mixture suggested the 
formation of an equilibrium mixture containing the desired product, 
and the dipalladium(II) probe dimer starting material, and careful 
titration of reagents back and forth did not bring about the formation of 
the clean product (Figure 2.12). In addition, there was evidence of a 
lower symmetry species, most probably the monosubstituted product, 
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and, depending on equivalencies, free L4 ligand. Additionally, there was 
broadening of two peaks, Hc and Hd, that did not resolve with 
increasing temperature. These are the two protons that would be most 
affected by hindered rotation, and it seems likely that the crowded 
sterics not only result in hindered rotation on the 1H NMR timescale, 
but also lower the energetic favourability of the disubstituted product, 
resulting in the untidy equilibrium of products. 
 
Figure 2.12 Partial 1H NMR spectrum (298 K, CDCl3 400 MHz) of 
[Pd2(NHC)2(L4)Br4]. Colour coding: ●disubstituted compound, ● 
dibromobis(benzimidazolin-2-ylidene)dipalladium(II) probe, ● side-product, 
most probably monosubstituted compound. 
X-ray quality crystals were grown of both systems, and ironically in the 
crystal solid state the problems with speciation were reversed. Despite 
clear solution and crystalline solid state evidence of coordination solely 
through the outer pyridine rings of L1 and a 2:1 ratio of L1 to the 
palladium NHC probe, slow evaporation of a chloroform solution of 
[Pd2(NHC)2(L1)Br4] gave crystals of [Pd3(NHC)3(L1)Br6] (Figure 2.13a, P1̅, 




Figure 2.13 Depictions of the X-ray crystal structures of a) [Pd3(NHC)3(L1)Br6] 
and b) [Pd2(NHC)2(L4)Br4]. Hydrogen atoms and solvent molecules have been 
omitted for clarity. 
The equilibrium mixture containing the L4 system was evaporated to 
dryness in CDCl3, and crystals thus obtained showed the desired 
disubstituted species, [Pd2(NHC)2(L4)Br4] (Figure 2.13b, P1̅, R1: 7.30%). 
The material displayed a solvent accessible void of diffuse electron 
density that could not be appropriately modelled. This was resolved 
through use of the SQUEEZE routine within PLATON, with the results 
suggesting the cavity contained four chloroform (CDCl3) molecules.  
Nonetheless, in order to gain useful information about the ligand 
donor strengths of the various ligand systems, it is a requirement to 
generate the NHC probe complexes in a pure form (in solution). 
Therefore it was decided to avoid problems with the bis-triazole ligands 
through using monodentate donors as models for each of the ligands.    
 
2.8. Mononuclear palladium(II) NHC probe complexes 
The model for L1 was chosen to be 3-ethynylpyridine (L1mono, Figure 
2.14a). The unsubstituted probe complex (i.e., with pyridine as the 
ligand) had already been synthesised[82b] (13C δcarbene = 159.3 ppm, 
obtained for our repeat of Huynh’s experiment), but it was  important to 
investigate whether the ethynyl substitution would result in the 
chemical shift of the carbene in the probe complex being more 
representative of the ditopic ligand L1. The monodentate triazole 
ligands had the appropriate exo-substitution (R = PEG, benzyl or hexyl) 
and were C4-bound to a phenyl group. One of these ligands (L4mono)[78] 
had previously been reported, and the other two were synthesised by 
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analogous procedures (yields: L3mono 67%, L5mono 70%): standard 
conditions for generating an azide in situ from sodium azide in a 
microwave reactor in the presence of sodium iodide, followed by 
combination with Cu(II), a reducing agent, and ethynylbenzene (Figure 
2.14b).     
 
Figure 2.14 a) Monodentate ligands used as models in mononuclear Pd(II) 
NHC probe complexes; b) scheme for synthesis of L3mono (67%) and L5mono 
(70%), conditions: (i) 1-chloro-2-(2-methoxyethoxy)ethane or 1-bromohexane, 
NaN3, NaI, DMF/H2O (4:1), microwave 125 °C 45 minutes, then CuSO4∙5H2O, 
ethynylbenzene, sodium ascorbate, overnight at RT; c) scheme for synthesis of 
[Pd(NHC)(Lmono)Br2] complexes, conditions: (ii) Lmono, CDCl3, RT, (L1mono: 95%, 
L3mono: 91%, L4mono: 71%, L5mono: 76%). 
The required probe complexes were then obtained through the 
combination of the palladium(II) NHC dimer and the ligands in a 1:2 
ratio in CDCl3 (Figure 2.14c). All complexations were successful 
(respective yields: [Pd(NHC)(L1mono)Br2] 95%, [Pd(NHC)(L2mono)Br2] 91%, 
[Pd(NHC)(L3mono)Br2] 71%, [Pd(NHC)(L5mono)Br2] 76%), and the problems 
40 
 
encountered in the attempted synthesis using L4 were not evident in 
the mononuclear analogues. Confirmation of synthesis came from a 
variety of techniques including NMR spectroscopies, mass 
spectrometry, and X-ray crystal structures of all four probe complexes 
were successfully obtained (Table 2.1 and Figure 2.15).‡ 
Table 2.1 Crystallisation conditions, space groups and R1 for mononuclear 
palladium(II) probe complexes. 
Compound Conditions Space group R1 (%) 
[Pd(NHC)(L1mono)Br2] 




Diethyl ether into 
DCM and acetone 
Pna21 3.3 
[Pd(NHC)(L4mono)Br2] 








All three triazole-based complexes crystallised in the same 
orthorhombic space group, Pna21, in very similar unit cells (note: 
[Pd(NHC)(L4mono)Br2] had a DCM solvent molecule in the asymmetric 
unit, while the other two were solvent free), and if appropriately 
translated, the structures to a large degree superimpose (Figure 2.16). 
Examination of the 13C NMR chemical shifts of the carbene carbon 
for the four probe complexes was informative as to the donor strength 
of the ligands (Figure 2.15). The chemical shift for [Pd(NHC)(L1mono)Br2] 
was 158.7 ppm, very similar to that for [Pd2(NHC)2(L1)Br4], and also 
similar to that for the unsubstituted pyridine probe complex (159.3 
ppm) suggesting that the monodentate complex was a good model for 
donor strength of L1. It was however, significantly less downfield than 
the carbene signal for the three triazole-based model complexes. These 
followed the order that might be qualitatively expected (benzyl < diglyme 
< hexyl), but their chemical shifts (respectively, 161.3, 161.4 and 161.5 
ppm) were not separated by enough to convincingly argue real 
difference. Thus, all that could be safely asserted from the data was 
that they were similar in terms of donor strength, and all were stronger 
than the pyridyl donor.   
                                       





Figure 2.15 Depictions of the X-ray crystal structures of mononuclear 
palladium(II) NHC probe complexes (hydrogen atoms omitted), together with 
the 13C NMR chemical shifts of their respective carbene carbon atoms (298 K, 
CDCl3, 100 MHz); ● carbene chemical shift for dinuclear [Pd2(NHC)2(L1)Br4], ● 
carbene chemical shift for [Pd(NHC)(pyridine)Br2]. 
 
Figure 2.16 Depiction of the superimposed crystal structures of 
[Pd(NHC)(Lmono)Br2]; L3mono:  blue, L4mono: yellow, L5mono: green. Note the DCM 
molecules in the lattice for [Pd(NHC)(L4mono)Br2].    
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2.9. Stability testing through competition experiments 
The relative stability of the [Pd2(L)4]4+ helicates was examined via 
timecourse 1H NMR experiments, in a 3:2 d6-DMSO/D2O solvent system 
with initial helicate concentration constant at 2 mM. Three biologically 
relevant nucleophiles were examined: chloride (tetrabutylammonium 
chloride) and two amino acids, L-histidine and L-cysteine. The helicates 
were treated with eight equivalents of each nucleophile, and the 
reactions monitored via 1H NMR spectroscopy over a 20 hour period, 
with the decomposition of the helicates measured against the 
integration of trimethylsilyl propanoic acid in an external reference 
capillary, relative to the integration of the helicate peaks in a separate 
“time-zero” sample (Figure 2.17).  
 
Figure 2.17 Time course partial 1H NMR stackplot of [Pd2(L3)4](BF4)4 against 8 
equivalents cysteine (298 K, 3:2 d6-DMSO/D2O, 500 MHz). Colour coding: 
cage in blue, free ligand in red. 
The only exception to this was [Pd2(L4)4]4+, which, interestingly, was not 
fully stable in the presence of DMSO, and existed in an equilibrium 
between the helicate and free ligand. In this case, the relative amount of 
helicate was calculated through comparison to the integration of the 
free ligand. The point at which half of the helicate had decomposed (if it 
occurred) was recorded as the half-life (t½) (Table 2.2). Against all 
nucleophiles, the decomposition of [Pd2(L1)4]4+ was rapid. Against the 
smallest nucleophile, chloride, which could approach the unprotected 
palladium(II) ion from both faces, and cysteine, which has a high 
affinity for palladium(II), the cage was dismantled in less than a minute. 
Against histidine, the t½ was only five minutes. The triazole-containing 
helicates fared better. All of them were stable in the presence of 
chloride. This could be due to a combination of higher donor strength, 
inaccessible central cavity, and steric protection by their respective 
substituents. Interestingly, [Pd2(L3)4]4+ and [Pd2(L4)4]4+ were still 
disassembled, at a much slower rate, by histidine (t½ = 12 hours in both 
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cases) and cysteine (t½  = 20 to 30 minutes), whereas the hexyl-
substituted [Pd2(L5)4]4+ helicate underwent no decay. Given the very 
similar nature of their donor strengths as assessed using the NHC 
probe system, the difference is presumably due to the hydrophobic 
character of the hexyl chains, which can potentially “clump” together 
through hydrophobic interactions, further protecting the palladium(II) 
ions from nucleophiles, enhancing the stability of the cage structure. 
DOSY 1H NMR established that in the conditions in which the 
experiments were carried out, [Pd2(L5)4]4+ diffused at a similar rate to 
diglyme-substituted  [Pd2(L3)4]4+ (0.74 x 10-10 m2 s-1 versus 0.63 x 10-10 
m2 s-1), indicating that these hydrophobic interactions were 
intramolecular rather than part of a larger  intermolecular aggregation.  
 
Table 2.2 The 13C NMR carbene chemical shift of the model mononuclear NHC 
complexes, together with the half-lives of the helicates against 8 equivalents of 
biologically relevant nucleophiles, as measured by timecourse 1H NMR (298 K, 
d6-DMSO/D2O (3:2), 500 MHz, initial helicate concentration 2 mM). 
Compound 
13C δcarbene  
(ppm) 
Half-life (t½) against 8 equivalents of: 
chloride L-histidine L-cysteine 
[Pd2(L1)4](BF4)4 158.7 <1 minute 5 minutes <1 minute 
[Pd2(L3)4](BF4)4 164.4 >20 hours 12 hours 20 minutes 
[Pd2(L4)4](BF4)4 164.3 >20 hours 12 hours 30 minutes 
[Pd2(L5)4](BF4)4 164.5 >20 hours >20 hours >20 hours 
 
These results suggested that 1) the parent [Pd2(L1)4]4+ cage required 
tuning to be able to persist in biological conditions and be a useful drug 
delivery vector, and 2) improving N-donor strength was not in itself 
sufficient to kinetically stabilise [Pd2(L)4]4+ architectures, and an 
element of steric protection was also required. It was therefore decided 
to synthetically tune the tripyridyl ligand system with a view to 




2.10. Mononuclear aminopyridine NHC palladium(II) probe 
complexes 
Improvement of donor strength of the coordinating pyridine ring was 
anticipated to be possible through substitution with a mesomerically 
donating amino group. Mononuclear probe complexes using 2- and 3-
aminopyridine were therefore synthesised to attempt to quantify any 
electronic improvements the amino group might make (Scheme 2.4).[84] 
In this case, as all tripyridyl ligands subsequently synthesised would be 
the same excepting amino substitution, there was no need to internally 
control via appending an ethynyl group; the carbene chemical shift 
could be compared to that of the unsubstituted pyridine complex. The 
syntheses were, as before, facile, involving a 1:2 ratio of the Pd(II) dimer 
with the appropriate aminopyridine (yields: [Pd(NHC)(L6mono)Br2] 68%, 
[Pd(NHC)(L7mono)Br2] 64%).  
 
Scheme 2.4 Synthesis of mononuclear aminopyridine Pd(II) NHC probe 
complexes. Conditions: (i) L6mono (68%) or L7mono (64%), CDCl3. 
Mass spectral analysis confirmed synthesis: for [Pd(NHC)(L6mono)Br2], 
m/z = 483.0167 [M – Br]+ (calc., 483.0215), 584.9237 [M + Na]+ (calc., 
584.9284), and for [Pd(NHC)(L6mono)Br2], m/z = 401.0923 [M – Hr – 
2Br]+ (calc., 401.0952). Both compounds were also successfully 
crystallised, [Pd(NHC)(L6mono)Br2] from vapour diffusion of diethyl ether 
into DCM, giving a structure solved in the primitive orthorhombic space 
group Pna21, and refined to an R1 value of 2.3%, and 
[Pd(NHC)(L7mono)Br2] from evaporation of DCM, solved in P21/c and 
refined to an R1 value of 5.9% (Figure 2.18). NMR spectroscopies 
confirmed the clean formation of the new probe complexes, and the 13C 
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NMR carbene carbon chemical shifts authenticated that amino 
substitution had enhanced donor strength of the pyridyl ligands. The 
chemical shift for [Pd(NHC)(L7mono)Br2] was 159.8 ppm, compared to 
159.3 ppm for pyridine, while that of [Pd(NHC)(L6mono)Br2] was 164.3 
ppm, comparable to the triazole-containing ligands (Figure 2.18). Given 
the fact that amino substitution in the 2-position was also most likely 
to provide steric impingement of nucleophilic approach, it appeared 
that a 2-amino substituted ligand was likely a good candidate for the 
generation of a more robust pyridine-based [Pd2(L)4]4+ cage.  
 
Figure 2.18 Depiction of the X-ray crystal structures of [Pd(NHC)(L6mono)Br2] 
and [Pd(NHC)(L7mono)Br2] (hydrogen atoms omitted for clarity) together with 
the 13C NMR chemical shifts of their respective carbene carbon atoms (298 K, 
CDCl3, 100 MHz); ● carbene chemical shift for dinuclear [Pd2(NHC)2(L1)Br4],  
carbene chemical shift for [Pd(NHC)(pyridine)Br2]. 
 
2.11. Synthesis of 2nd generation tripyridyl ligands 
Two amino-substituted tripyridyl ligands were targeted: with the amino 
groups in the 2-position (L6) or in the 3-position (L7) (Scheme 2.5a). 
The   central  pyridine  was  also  to  be  substituted  with  a  methylene 




Scheme 2.5 a) Targeted aminopyridyl ligands L6 and L7, and previously 
reported methylene alcohol substituted ligand, L8;[58c] b) precursor conditions: 
(i) acetic anhydride, DCM/TEA, overnight at RT (77%), (ii) TMS-acetylene, 
[Pd(PPh3)2Cl2], CuI, TEA, 2 days at 50 °C (97%), (iii) NaOH, MeOH, 2 hours at 
reflux (70%), (iv) TMS-acetylene, [Pd(dppf)Cl2], CuI, diisopropylamine, 3 days 
at 60 °C (94%), (v) Na2CO3, MeOH, 1.5 hours (96%), c) ligand conditions: (vi) 
[Pd(PPh3)2Cl2], CuI, THF/diisopropylamine, 2 days at 40 – 50 °C (79 – 56%).    
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improve solubility, and secondly, it would provide potential access to 
added functionality through the “clicking” on of substituents as 
previously demonstrated in the group.[58b, 58c] The analogue with the 
methylene alcohol group but unsubstituted terminal pyridines had 
previously been reported,[58c] and this ligand (L8) was to be used as a 
control for an “untuned” cage to compare to the amino systems. 
The appropriate amino-substituted 5-ethynylpyridines were first 
synthesised (Scheme 2.5b). As the Sonogashira cross-coupling reaction 
would not proceed with the carbon-iodide bond in para position to the 
amino group, 5-iodo-2-aminopyridine was first converted into 5-
iodopyridin-2-acetamide (1, 77%) with acetic anhydride. This increased 
polarity of the carbon-iodide bond sufficiently for carbon-carbon bond 
formation, and TMS-acetylene was appended under standard 
Sonogashira conditions, forming N-(5-((trimethylsilyl)ethynyl)pyridin-2-
yl)acetamide (2, 97%). The alkyne could then be deprotected in tandem 
with conversion of the acetamide group back to the amine via treatment 
with hydroxide, giving 5-ethynyl-2-aminopyridine (3, 70%). In the case 
of the 3-amino counterpart, no masking of the amine was required, and 
a Sonogashira reaction directly provided N-(5-((trimethylsilyl)ethynyl)-
pyridin-3-yl)amine (4, 94%), which was deprotected in the milder 
conditions using Na2CO3 to provide  5-ethynyl-3-aminopyridine (5, 
96%). 
 The ligands L6 and L7 were then synthesised through combination of 
3 or 5 with the methylene-substituted core, (2,6-dibromopyridin-4-
yl)methanol,[85] again under standard Sonogashira conditions (Scheme 
2.5c, respective yields: L6 79%, L7 56%). In addition to NMR 
spectroscopic and mass spectral evidence of their formation, both 
ligands were successfully crystallised (Figure 2.19).  
 
Figure 2.19 Depictions of the X-ray crystal structures of a) L6 and b) L7. 
Acetonitrile solvent molecule excluded in the case of L6. 
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L6 crystallised from vapour diffusion into a DMSO/acetone solution of 
the compound, giving a structure solved in primitive monoclinic space 
group P21/c and refined to an R1 value of 6.5%. L7 crystallised directly 
out of the column chromatography fractions with the eluent system 
being a 90:9:1 ratio of DCM/methanol/aqueous ammonia solution, in 
the monoclinic space group P 21/c and refined to an R1 value of 8.8%. 
The structures were unremarkable but confirmed the connectivity of 
the new tripyridyl ligands. 
 
2.12. Cage synthesis and characterisation 
The three targeted cages were synthesised through a 4:2 combination of 
the respective ligands and [Pd(CH3CN)2](BF4)2 (Scheme 2.6). The 
formation of [Pd2(L8)4](BF4)4 proceeded in CH3CN (85%), while the lower 
solubility of the amino-substituted ligands and cages required the use 
of DMSO as the solvent. [Pd2(L7)4](BF4)4 and [Pd2(L8)4](BF4)4 formed at 
room temperature (75%), but the more donating and sterically 
demanding L6 ligand required heating at 50 °C for four hours to enable 
the self-correction process (57%). This in itself was a good sign: the 
most stable triazole cage, [Pd2(L5)4](BF4)4, had also required heating in 
order to assemble. Formation of the desired architectures was 
confirmed via mass spectrometry. In all cases ions pertaining to the 
respective [Pd2(L)4]4+ cages were identifiable, with the loss of two 
counterions for  [Pd2(L8)4](BF4)4 (m/z = 816.1313 [M – 2BF4]2+ (calc. for 
C80H52N12O4Pd2, 816.1313)), and for the amino cages with all 
counterions lost (for example, for [Pd2(L8)4](BF4)4, m/z = 394.5820 [M – 
4BF4]4+ (calc. for C80H60N20O4, 394.5797) Figure 2.20).  
The 1H NMR spectra of the cages in d6-DMSO showed the expected 
downfield shifts upon complexation relative to the free ligands, 
especially of the protons proximal to the coordinating pyridyl nitrogen 
atoms (Figure 2.21).1H DOSY NMR spectroscopy revealed that the 
ligands all had similar diffusion coefficients (D =  1.73 – 2.34 x 10-10 m2 
s-1) and thus similar sizes, as did their respective cages (D =  0.89 – 
1.03 x 10-10 m2 s-1), and the diffusional ratio of ligand to cage was 
roughly 1:2, consistent with the solution-phase formation of [Pd2(L)4]4+ 









Scheme 2.6 Cage synthesis. Conditions: [Pd(CH3CN)4](BF4)2, CH3CN 
([Pd2(L8)4](BF4)4 (85%)) or DMSO ([Pd2(L6)4](BF4)4 (57%) and ([Pd2(L7)4](BF4)4 
(75%)). The formation of [Pd2(L6)4](BF4)4 required heating at 50 °C for four 




Figure 2.20 Mass spectrum (DMSO/CH3CN) of [Pd2(L7)4](BF4)4. 
 
Figure 2.21 Stacked partial 1H NMR spectra (298 K, d6-DMSO, 500 MHz) for 
a) L6, b) [Pd2(L6)4](BF4)4, c) L7, d) [Pd2(L7)4](BF4)4, e) L8, and f) [Pd2(L8)4](BF4)4.   
    
51 
 
Table 2.3 Diffusion coefficients for 2nd generation tripyridyl ligands and their 
cages, as calculated through 1H DOSY NMR spectroscopy. 
Compound 
Diffusion coefficient 
(D, x 10-10 m2 s-1 ) for: 
Ligand Cage 
L6, [Pd2(L6)4](BF4)4 1.73 0.89 
L7, [Pd2(L7)4](BF4)4 1.90 0.97 
L8, [Pd2(L8)4](BF4)4 2.34 1.03 
 
Of special interest was the spectrum of [Pd2(L6)4](BF4)4, which exhibited 
a large downfield shift of the amino peak upon complexation (Δδ = 1.56 
ppm, compared to [Pd2(L6)4](BF4)4, Δδ = 0.81 ppm). This was suggestive 
of an interligand hydrogen bonding interaction between adjacent amino 
groups of the L6 ligand which could not occur with the 3-substituted 
L7 ligand. This was confirmed in the solid state X-ray crystal structure 
of [Pd2(L6)4](BF4)4, which was crystallised from vapour diffusion of 
diethyl ether into a solution of the cage in acetonitrile and DMSO. The 
structure was solved in the primitive tetragonal space group P4/m and 
refined to an R1 value of 14.4%. Significant twisting was evident in 
comparison to the structure of [Pd2(L1)4](BF4)4, with the amino cage 
adopting a solid-state meso conformation (Figure 2.22a and b)), 
presumably to relieve steric clash between the amino groups and 
facilitate interligand hydrogen bonding (N---HN distance of 2.84 Å, N---
3.70(5) Å). The coordinating pyridine rings twisted 34.44 – 34.64° out of 
the plane running through the principal rotation axis of the molecule, 
with the central pyridine being thus canted 35.10° sideways.  
 Comparison with the X-ray crystal structure of [Pd2(L1)4](BF4)4 
(Figure 2.22c) shows that the amino groups also provide a greater level 
of occlusion of the palladium(II) centre. It was therefore hoped that this 
combination of steric protection, enhanced donor strength, and the 
interligand hydrogen bonding evident in both solution and solid state 





Figure 2.22 a) Depiction of the X-ray crystal structure of [Pd2(L6)4](BF4)4, b) a 
partial section of the cage, from above in spacefilling view, showing the torsion 
allowing relief of steric strain and interligand N---HN hydrogen bonding 
(distance: 2.84 Å), with greater occlusion of the palladium(II) metal ion than 
that seen for c) the same view of [Pd2(L1)4](BF4)4. 
 
2.13. Competition experiments on 2nd generation cages 
The conditions under which the new series of competition experiments 
were carried out were similar to described previously for the triazole 
series. The one exception was that, while the number of equivalencies of 
chloride added were held constant (eight), the equivalencies of histidine 
and cysteine were halved (Table 2.4). This was to allow greater 
resolution of the differences in stability. The trend in stability was 
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consistent with the results for the probe complexes: [Pd2(L8)4]4+ < 
[Pd2(L7)4]4+ << [Pd2(L6)4]4+, with the half-life of [Pd2(L8)4]4+ and 
[Pd2(L7)4]4+ being measured in minutes, and [Pd2(L6)4]4+ in hours.  
Table 2.4 The 13C NMR carbene chemical shift of the model mononuclear NHC 
complexes, together with the half-lives of the cages against 8 equivalents of 
chloride or 4 equivalents of L-histidine or L-cysteine, as measured by 
timecourse 1H NMR (298 K, d6-DMSO/D2O (3:2), 500 MHz, initial cage 
concentration 2 mM). 
Compound 
13C δcarbene  
(ppm) 







[Pd2(L6)4](BF4)4 164.3 2 hours 46 hours 3 hours 
[Pd2(L7)4](BF4)4 159.8 10 minutes 25 minutes 10 minutes 
[Pd2(L8)4](BF4)4 159.3 <1 minute 18 minutes 6 minutes 
 
Chloride was the most effective nucleophile against all of the cages, 
with the most resilient cage [Pd2(L6)4]4+ having a half-life of two hours. 
It seems likely that this is because the cavity of the cage is accessible to 
the small chloride anion, which can then attack from the unprotected 
face. The bulkier histidine molecule cannot freely enter the cavity and is 
instead confined to attacks from the outer face. In the case of the 
sterically protected [Pd2(L6)4]4+ cage, this resulted in a half-life of 46 
hours. Nonetheless, the similarly-sized cysteine was able to decompose 
the most stable cage to t½ in 3 hours, due to the higher affinity of the 
softer sulfur-based nucleophile for palladium(II) ions.   
 
2.14. Cisplatin-binding studies 
The ability of these cages to bind cisplatin in an analogous fashion to 
that of the parent system was also investigated. The introduction of 
cisplatin to a solution of [Pd2(L8)4](BF4)4 or [Pd2(L7)4](BF4)4 in d7-DMF 
(due to low solubility of the latter in acetonitrile) brought about a 
downfield shift of the peak due to the internally directed cage proton 
(Hc) indicative of cisplatin encapsulation and interaction with the 




Figure 2.23 Partial stacked 1H NMR spectra (298 K, d7-DMF, 400 MHz) for a) 
[Pd2(L8)4](BF4)4, b) [(cisplatin)2Pd2(L8)4](BF4)4, c) [Pd2(L7)4](BF4)4 and d) 
[(cisplatin)2Pd2(L7)4](BF4)4. 
 
Figure 2.24 Depiction of the X-ray crystal structure of 
[(cisplatin)2Pd2(L8)4](BF4)4∙4DMF. Solvent molecules and some counterions 
omitted for clarity. 
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The downfield shift was greater for [(cisplatin)2Pd2(L8)4](BF4)4 than 
[(cisplatin)2Pd2(L7)4](BF4)4 (Δδ = 0.24 ppm and 0.07 ppm respectively), 
potentially because the palladium(II) metal centre is more electron 
deficient and the internal protons more acidic in the cage without 
electron-donating amino groups, resulting in a stronger interaction with 
the chloride of the cisplatin molecule. It must be noted that in D2O, 
which can more effectively compete with the guest for hydrogen-
bonding sites within the cage, there was no evidence of binding. The 
host-guest adduct, [(cisplatin)2Pd2(L8)4](BF4)4, was also crystallised 
from vapour diffusion of diethyl ether into a solution of the cage and 
cisplatin in DMF (Figure 2.24). The X-ray structure was solved in the 
primitive monoclinic space group P21/n with an R1 of 14.4%. The 
structure was similar to those previously obtained of the adduct in 
related systems,[5, 58c] showing two guests within the cavity in a head-to-
tail arrangement, with the same interactions discussed in the 
introduction; chlorides interacting with the palladium(II) metal ion and 
the internally directed protons, amino groups with the central pyridine, 
and platinum(II)-platinum(II) interactions between the guest molecules 
(Table 2.5). The BF4- counterions were both located, with one sitting 
over the exohedral face of each palladium(II) metal ion, hydrogen 
bonding to the external hydrogen atoms ortho to the coordinating 
nitrogen.  
Table 2.5 Selected bond distances and bond angles from 
[(cisplatin)2Pd2(L8)4](BF4)4∙4DMF. 
Interaction Distance (Å) Bond angle (°) 
F---HC 2.31 – 2.61 - 
F---Pd(II) 3.26(1) - 
Cl---HC 2.55 -2.86 - 
Cl---Pd(II) 3.209(3) - 
NH---N(py) 2.01 165.02 
Pt---Pt 3.332(1) - 
While the cages formed from L7 and L8 encapsulated cisplatin, the 2-
amino substituted cage showed no 1H NMR spectral shifts in the 
presence of cisplatin in a wide variety of deuterated solvents. The 
inability of [Pd2(L6)4]4+ to bind the guest, while disappointing, was not 
surprising. As with L7, the amino group will lower the acidity of the 
internally directed aryl CH groups, as well as the electropositivity on the 
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palladium(II) metal centre. In addition, guest binding requires specific 
hydrogen bonding contacts and cavity size, and the twisting evident in 
the X-ray crystal structure of [Pd2(L6)4]4+ deviates cavity shape and 
contact points considerably. 
 
2.15. Cytotoxicity studies 
Irrespective of cisplatin-binding capacity, the cytotoxic capabilities of 
the quadruply stranded architectures were of interest in their own 
rights. The bis-mondentate ligands (L1, L3 – L8) and their respective 
[Pd2(L)4](BF4)4 cages were tested for cytotoxicity against up to four cell 
lines (Table 2.6).§ Cisplatin was also tested, as a positive control. 
Table 2.6 IC50 values of ligands and their [Pd2(L)4](BF4)4 cages against A549 
(lung), MDA MB231 (breast), DU145 (prostate) and MCF109A (immortalised 
normal human breast) cell lines. IC50 values determined using the MTT 
assay.[86] 
Compound IC50 (µM) against: 
A549 MDA MB231 DU145 MCF10A 
L1 95.3 9.7 >100 >100 >100 
L3 >100 - - - 
L4 >100 >100 >100 88.6  5.4 
L5 28.5  2.6 89.8  10.7 28.5  1.3 18.1  3.1 
L6 >200 >200 - - 
L7 >200 >200 - - 
L8 >200 >200 - - 
[Pd2(L1)4](BF4)4 41.4  3.9 56.7  2.2 70.1  13.8 71.4  3.9 
[Pd2(L3)4](BF4)4 >100 - - - 
[Pd2(L4)4](BF4)4 55.5  1.2 18.1  2.7 34.1  0.9 51.9  0.7 
[Pd2(L5)4](BF4)4 6.9  0.9 6.0  0.6 3.4  0.4 8.1  1.2 
[Pd2(L6)4](BF4)4 >50 36.4  1.9 - - 
[Pd2(L7)4](BF4)4 >50 >50 - - 
[Pd2(L8)4](BF4)4 >50 >50 - - 
cisplatin 9.4  0.3 41.2  3.9 - - 
                                       
§ The testing on L1, L3 – L5 and their respective cages for all cell lines, as well as on 
cisplatin against MDA MB231, was carried out by researchers within the Department 
of Pharmacology and Toxicology, University of Otago, primarily by Samantha McNeill, 
who also carried out the mechanistic testing. 
57 
 
Against the four cell lines (A549 (lung), MDA MB231 (breast), DU145 
(prostate) and MCF109A (immortalised normal human endothelial 
breast, a model for healthy cells), the only ligand that exhibited 
cytotoxicity was L5; IC50 = 18.1 3.1 to 89.8  10.7 µM.  Regarding the 
cages, the hydrophilic [Pd2(L3)4](BF4)4 helicate had no cytotoxicity 
against A549. Neither [Pd2(L7)4](BF4)4 nor [Pd2(L8)4](BF4)4 were cytotoxic 
against the two cell lines tested against, and the cages sourced from 
ligands L1, L4 and L6 were only moderately cytotoxic. The most 
cytotoxic complex was also the most stable; [Pd2(L5)4](BF4)4 had IC50 
values of 3.4  0.4 to 8.1  1.2 µM (compared with cisplatin, A549: IC50 
= 9.4  0.3 µM; MDA MB231 (cisplatin resistant): IC50 = 41.2  3.9 µM). 
These values are less than a quarter than that of L5, and 
[Pd(CH3CN)4](BF4)4 was independently determined to not be cytotoxic, 
hence cytotoxicity was not caused from a cumulative effect of ligand 
and metal ion. Testing using time-course experiments indicated that 
cell death was rapid. Lactate dehydrogenase (LDH) is an intracellular 
enzyme, and its extracellular presence (and hence, membrane 
permeabilisation) can be measured through the rate of oxidation of its 
substrate, H-nicotinamide adenine dinucleotide (NADH), and this assay 
connoted membrane damage. A double labelling experiment using 
Hoechst 33342 (a membrane permeable dye that stains all cells) and 
propidium iodide (a non-membrane permeating dye that only enters 
non-viable cells), confirmed that cell death was rapid, and involved a 
loss of membrane integrity. Subsequent transmission electron 
microscopy (TEM) images have shown that in contrast to untreated cells 
(Figure 2.25a), cells treated with the compound developed blebs, which 
are rounded outgrowths from the membrane associated with 
detachment of the intracellular skeletal network from the membrane 
(Figure 2.25b and c).[87] 
 
Figure 2.25 TEM images of a) cells untreated with [Pd2(L5)4](BF4)4, and cells 
demonstrating blebbing upon treatment with [Pd2(L5)4](BF4)4, from b) afar and 
c) close. Dyes: mitochondria (red, MitoTracker Red CMXRos), membrane 
(green, Oregon Green 488 Phalloidin), nucleus (blue, Hoechst). 
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2.16. Conclusions and future directions 
Ligand design was used to improve the stability of [Pd2(L)4]4+ cages. 
Donor strength could be measured using Huynh’s NHC probe system, 
and there was a trend between enhanced strength and stability. Greater 
donor capacity was not sufficient in itself to make a complex sufficiently 
stable against biological nucleophiles, and steric protection was also 
required. It is likely therefore that the hexyl chains on [Pd2(L5)4](BF4)4 
fulfil a dual role, both increasing the stability of the complex and adding 
valuable hydrophobicity and thus a cytotoxic effect to the compound. 
Unfortunately, this cytotoxicity was not selective for cancer cell lines 
over the model for healthy cells, MCF10A. It might be possible to mask 
the activity of the helicate through producing it as a pro-drug, attaching 
groups such as sugars or PEG chains to the hexyl chain via a linker 
that is cleaved within the tumour.   
Stability is more problematic for the ‘lantern-shaped’ tripyridyl cages, 
which have open cavities accessible to chloride, and enhancements to 
stability were made at the expense of cisplatin-binding. In any case, 
cisplatin binding in all cages was not observed in D2O. The use of 
platinum(II) in the place of palladium(II) would give an inert and 
kinetically stable cage. While [Pt2(L)4]4+ cages have been made and 
tested for biological activity,[88] only in one case was this with the added 
complication of a central pyridyl ring, which leads to the formation of 
unwanted polymers, and reduced yields.[89] The stability of octahedral 
systems was readily improved without loss of synthetic ease by using 
the ‘assembly followed by oxidation’ using Co(II/III). It might therefore 
be possible to use a similar method with palladium(II) to solve both the 
problem with stability and cisplatin-binding at the same time (Figure 
2.26). Taking a solution of host-guest adduct, [(cisplatin)2Pd2(L)4]4+, 
the square planar palladium(II) metal centres could be oxidised to the 
more inert +4 oxidation state. Palladium(IV) adopts an octahedral 
coordination geometry, and the chloride of the cisplatin guest molecule 
could thus bridge to the palladium(IV) metal ion, with the exohedral 
axial site occupied by solvent or counterion (Figure 2.26). The resultant 
complex would be kinetically inert to nucleophilic attack, and the drug 
would be sequestered firmly within the cavity. Within a reducing 
environment in the tumour, the palladium cations would be able to 
reduce to the +2 oxidation state, bringing about disassembly of the 




Figure 2.26 Proposed oxidation of host-guest adduct [(cisplatin)2Pd2(L)4]4+ to 
the complex [Pd2(L)4(cisplatin)2]8+. Exohedral axial coordination of the 



























Figure 2.27 Compounds from this chapter that did not previously have 





2.17.1.1. 5-iodopyridin-2-acetamide (1) 
A solution of 5-iodo-2-aminopyridine[37] (2.50 g, 11.4 mmol) in TEA, (10 
mL) and DCM (50 mL) was degassed with N2 for 15 minutes. Acetic 
anhydride (10.7 mL, 110 mmol) was added and the mixture was stirred 
at room temperature for 18 hours. After removal of solvents under 
vacuum, the crude mixture was dissolved in 3:1 CHCl3/IPA (150 mL), 
and washed with saturated aqueous NaHCO3 solution (2 x 75 mL), and 
brine (75 mL). The organic layer was dried over MgSO4, filtered and the 
solvent removed under vacuum. Column chromatography on silica 
(1:19 acetone/DCM) gave the product as a brown solid (2.3 g, 8.8 mmol, 
77%). 1H NMR (298 K, d6-DMSO, 400 MHz) δ: 10.58 (1H, s, HNH), 8.50 
(1H, d, J = 2.3 Hz, Ha), 8.07 (1H, d, J = 8.8 Hz, Hb), 7.94 (1H, d, J = 8.8 
Hz, Hc), 2.08 (3H, s, Hd). 13C NMR (298 K, d6-DMSO, 100 MHz) δ: 169.4, 
153.3 (Ca), 151.2, 145.8 (Cb), 115.3 (Cc), 85.7, 23.9 (Cd). HR ESI-MS 
(CHCl3) m/z = 284.95 [M + Na]+ (calc. for C7H7IN2NaO, 284.95). Anal. 
calcd. for: C7H7IN2O: C, 32.08; H, 2.69; N, 10.69%. Found: C, 32.30; H, 
2.55; N, 10.71%. IR: v (cm-1) 3215, 3139, 3079, 3018, 1676, 1660, 




A round bottom flask containing 1 (1.00 g, 3.82 mmol), CuI (0.07 g, 0.4 
mmol) and [Pd(PPh3)2Cl2] (0.19 g, 0.27 mmol) was purged with N2. TEA 
(20 mL) was added via syringe and the solution was degassed with N2 
for 15 minutes. After adding TMS-acetylene (0.68 g, 0.93 mL, 6.8 mmol) 
via syringe, the reaction was heated at 50 °C under N2 for 48 hours. 
The solvent was removed under vacuum, and the resulting solid was 
taken up in 3:1 CHCl3/IPA (40 mL). The solution was stirred with 
aqueous 0.1 M EDTA/NH4OH solution (40 mL) for 1.5 hours. After 
washing with aqueous 0.1 M EDTA/NH4OH (50 mL) and brine (100 
mL), the organic layer was dried with Na2SO4, filtered, and the solvent 
removed under vacuum. The solid was purified through column 
chromatography on silica (1:19 acetone/DCM), giving the product (0.86 
g, 3.72 mmol, 97%). 1H NMR (298 K, CDCl3,  500 MHz) δ: 8.34 (1H, d, J 
= 1.6 Hz, Hd), 8.17 (1H, d, J = 8.7 Hz, Hb), 8.07 (1H, br, HNH), 7.77 (1H, 
dd, J = 8.7 Hz, 2.1 Hz, Hc), 2.21 (3H, s, Ha), 0.25 (15H, s, He). 13C NMR 
(298 K, CDCl3,  125 MHz) δ: 168.5, 150.9 (Cd), 150.3, 141.4 (Cc), 116.0, 
112.9 (Cb), 101.4, 97.1, 24.8 (Ca), -0.1 (Ce). HR ESI-MS (CHCl3) m/z = 
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255.09 [M + Na]+ (calc. for C12H16N2NaOSi, 255.09). Anal. calcd. for 
C12H16N2Si∙0.5acetone: C, 62.03; H, 7.14; N, 11.35%. Found: C, 61.94; 
H, 7.29; N, 11.35%. IR: ν (cm-1) 3243, 2955, 2161, 1697, 1579, 1526, 
1380, 1303, 1246, 1030.   
 
2.17.1.3. Synthesis of 5-ethynylpyridin-2-amine (3) 
A solution of 2 (0.63 g, 2.7 mmol) and NaOH (1.08 g, 27.0 mmol) in 
methanol (30 mL) was heated at reflux for 1.5 hours before removal of 
solvent under vacuum, with the resultant residue taken up in 3:1 
CHCl3/IPA (100 mL) and washed with water (100 mL) and brine (100 
mL). After drying with Na2SO4 and filtration, the solvent was removed 
under vacuum, and purification through column chromatography on 
silica (1:8 acetone/DCM) gave the product as a brown solid (0.22 g, 
1.90 mmol, 70%).  1H NMR (298 K, CDCl3, 500 MHz) δ: 8.22 (1H, dd, J 
= 2.2 Hz, 0.8 Hz, Hc), 7.53 (1H, dd, J = 8.6 Hz, 2.3 Hz, Hb), 6.46 (1H, dd, 
J = 8.6 Hz, 0.8 Hz, Ha), 4.69 (2H, br, HNH), 3.06 (s, Hd). 13C NMR (298 K, 
CDCl3, 125 MHz) δ: 157.6, 151.6 (Cc), 141.0 (Cb), 108.7, 108.0 (Ca), 
81.2, 77.8 (Cd). Anal. calcd. for C7H6N2∙0.1acetone: C, 70.74; H, 5.37; N, 
22.60%. Found: C, 70.44; H, 5.17; N, 22.56%. IR: ν (cm-1) 3326, 3295, 
3163, 2148, 1645, 1585, 1424, 1329, 1246, 1156. 
 
2.17.1.4. N-(5-((trimethylsilyl)ethynyl)pyridin-3-yl)amine (4) 
A glass tube containing diisopropylamine (7 mL) degassed with N2 was 
charged with 5-bromopyridin-3-amine (500 mg, 2.89 mmol), CuI (55 
mg, 0.29 mmol), [Pd(dppf)2Cl2] (85 mg, 0.17 mmol) and TMS-acetylene 
(1.17 mL, 852 mg, 8.67 mmol) against a positive N2 flow. The tube was 
sealed and stirred at 60 °C for 72 hours. 3:1 CHCl3/IPA (100 mL) and 
aqueous 0.1 M EDTA/NH4OH solution (100 mL) were added and the 
mixture stirred for one hour. The organic layer was washed with water 
(50 mL) and brine (50 mL), dried over Na2SO4, filtered, and the solvent 
was removed under vacuum. The resultant solid was purified by 
column chromatography (1:8 acetone/DCM) to give the product as a 
brown solid (512 mg, 2.71 mmol, 94%). 1H NMR (298 K, CDCl3,  500 
MHz) δ: 8.10 (1H, d, J = 1.5 Hz, Hc), 8.01 (1H, d, J = 2.7 Hz, Ha), 7.04 
(1H, dd, J = 2.7 Hz, 1.7 Hz, Hb), 0.25 (9H, s, Hd). 13C NMR (298 K, 
CDCl3,  125 MHz) δ: 142.9 (Cc), 141.9, 136.8 (Ca), 124.1 (Cb), 120.3, 
101.9, 97.6, 0.0 (Cd). HR ESI-MS (CH3OH) m/z = 191.10 [M + H]+ (calc. 
for C10H15N2Si, 191.10). Anal. calcd. for C10H14N2Si: C, 63.11; H, 7.41; 
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N, 14.62%; found: C, 63.40; H, 7.48; N, 14.62%. IR: ν (cm-1) 3327, 
3295, 3162, 2147, 1585, 1424, 1329, 1245. 
 
2.17.1.5. Synthesis of 5-ethynylpyridin-3-amine (5) 
A solution of 4 (0.43 g, 2.3 mmol) in methanol (30 mL) with Na2CO3 
(0.48 g, 4.5 mmol) was stirred at room temperature for 1 h. After 
filtration, the solvent was removed under vacuum, and the resultant 
solid was purified by column chromatography on silica (1:8 
acetone/DCM) to give the product as a brown solid (0.25 g, 2.1 mmol, 
96%). 1H NMR (298 K, CDCl3,  500 MHz) δ: 8.13 (1H, d, J = 2.7 Hz, Hc), 
8.05 (1H, d, J = 2.7 Hz, Ha), 7.06 (1H, dd, J = 2.7 Hz, 2.7 Hz, Hb), 3.71 
(2H, br, HNH), 3.14 (1H, s, Hd). 13C NMR (298 K, CDCl3,  125 MHz) δ: 
143.0 (Cc), 141.8, 137.1 (Ca), 124.0 (Cb), 119.1, 80.7, 79.8 (Cd). Mass 
spectral analysis was not successful for this compound. Anal. calcd. for 
C7H6N2∙0.1acetone: C, 70.74; H, 5.37; N, 22.60%. Found: C, 70.96; H, 
5.14; N, 22.80%. IR: ν (cm-1) 3328, 3295, 3163, 3020, 2148, 1644, 
1585, 1424, 1329, 1246. 
 
2.17.2. Ligands 
2.17.2.1. Bis(4-(pyridin-2-yl)-1H-1,2,3-triazol-1-yl)methane (L2) 
A mixture of Na2CO3 (126 mg, 1.18 mmol), NaN3 (77 mg, 1.2 mmol), and 
DCM (0.510 mL, 8.00 mmol) in DMF (8 mL) was heated in a microwave 
(200 W) for 20 minutes at 60 °C then 20 minutes at 110 °C. After 
addition of sodium ascorbate (94 mg, 0.47 mmol), CuSO4∙5H2O (59 mg, 
0.24 mmol), 2-ethynylpyridine (134 mg, 0.132 mL, 1.30 mmol) and 
water (2 mL), the reaction mixture was stirred at room temperature 
overnight. It was then added to 0.1 M EDTA/NH4OH aqueous solution 
(150 mL) and 3:1 CHCl3/IPA solution (100 mL) and stirred vigorously 
for one hour. The organic layer was then washed with water (100 mL) 
and brine (100 mL), dried with Na2SO4, filtered, and the solvents 
removed under vacuum. Column chromatography (silica gel, DCM then 
2:1 acetone/DCM) afforded the product as a colourless powder (153 mg, 
50 mmol, 85%). 1H NMR (298 K, d6-DMSO, 400 MHz) δ: 8.99 (2H, s, He), 
8.62 (2H, d, J = 4.5 Hz, Ha), 8.04 (2H, d, J = 7.8 Hz, Hd), 7.90 (2H, td, J 
= 7.9, 2.2 Hz, Hc), 7.37 (2H, dd, J = 4.8 Hz, 1.5 Hz, Hf). 13C NMR (298 K, 
d6-DMSO, 100 MHz) δ: 149.7 (Ca), 149.2, 147.9, 137.3 (Cc), 123.9 (Ce), 
123.4 (Cb), 119.6 (Cd), 60.4 (Cf). HR ESI-MS (MeOH) m/z = 305.1258 [M 
+ H]+ (calc. for C15H13N8, 305.1242), m/z = 327.1027 [M + Na]+ (calc. for 
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C15H12N8Na, 327.1052). Anal. calcd. for C15H12N8: C, 59.20; H, 3.97; N, 
36.82%. Found: C, 59.39; H, 3.98; N, 37.06 %. IR: ν (cm-1) 3087, 3059, 




To a stirred solution of 1-chloro-2-(2-methoxyethoxy)ethane[80] (500 mg, 
3.61 mmol) in DMF/H2O (4:1, 10 mL) was added NaN3 (246 mg, 3.78 
mmol) and the solution was microwaved at 125 °C for 3.5 hours. After 
adding sodium ascorbate (299 mg, 1.72 mmol), CuSO4∙5H2O (214 mg, 
0.860 mmol) and 1,3-diethynylbenzene (217 mg, 1.72 mmol), the 
solution was stirred at room temperature overnight. The reaction 
mixture was poured into a 0.1 M EDTA/NH4OH aqueous solution (50 
mL) and stirred vigorously for 30 minutes. The suspension was 
extracted into DCM (2 x 100 mL), and the combined organic layers were 
dried with Na2SO4, filtered, and the solvent removed in vacuo. The 
residue was purified via column chromatography on silica (1:1 
DCM/Petroleum ether to DCM to 1:5 acetone/DCM) to give the product 
as a green oil (515 mg, 1.24 mmol, 72%). 1H NMR (298 K, CDCl3,  400 
MHz) δ: 8.36 (t, 1H, J = 1.6 Hz, Ha), 8.27 (s, 2H, Hd), 7.84 (dd, 2H, J = 
7.3 Hz, 1.7 Hz, Hc), 7.53 (t, 1H, J = 7.8 Hz, Hb), 4.58 (t, 4H, J = 5.1 Hz, 
He), 3.92 (t, 4H, J = 5.2 Hz, Hf), 3.62-3.60 (m, 4H, Hg), 3.49-3.47 (m, 
4H, Hh), 3.30 (s, 6H, Hi). 13C NMR (298 K, CDCl3,  100 MHz) δ: 146.7, 
131.8, 129.5 (Cb), 124.8 (Cc), 122.2 (Ca), 121.5 (Cd), 71.5 (Ch), 70.0 (Cg), 
68.9 (Cf), 58.0 (Ci), 50.1 (Ce). HR ESI-MS (CH3CN) m/z = 417.2218 [M + 
H]+ (calc. for C20H29N6O4, 417.2245), m/z = 439.2046 [M + Na]+ (calc. 
for C20H28N6NaO4, 439.2064), m/z = 855.4161 [2M + Na]+ (calc. for 
C40H56N12NaO8, 855.4236). Anal. calcd. for C20H28N6O4: C, 57.68; H, 
6.78; N, 20.18; Found: C, 57.64; H, 6.91; N, 20.17. IR: v (cm-1) 3120, 




A solution of sodium azide (70 mg, 1.1 mmol), sodium iodide (73 mg, 
0.49 mmol) and 1-chloro-2-(2-methoxyethoxy)ethane (142 mg, 1.03 
mmol) in 4:1 DMF/H2O (15 mL) was microwaved at 125 °C at 250 W for 
3 hours. After cooling to room temperature, ethynylbenzene (107 µL, 
100 mg, 0.980 mmol), sodium ascorbate (194 mg, 0.980 mmol) and 
CuSO4∙5H2O (244 mg, 0.980 mmol) were added and the resulting 
66 
 
suspension was stirred at room temperature for 20 hours, before 
adding 0.1 M EDTA/NH4OH aqueous solution (20 mL) and stirring 
vigorously for 30 minutes. The organic extract was then washed with 
0.1 M EDTA/NH4OH aqueous solution (40 mL), water (40 mL) and brine 
(40 mL) then dried over MgSO4, before filtration and removal of the 
solvent under vacuum. The resulting residue was then purified by 
column chromatography on silica (DCM then 3:2 DCM/acetone) to give 
the product as a colourless oil (163 mg, 0.660 mmol, 67%). 1H NMR 
(298 K, CDCl3,  400 MHz) δ: 8.00 (1H, s, Hd), 7.85 (2H, d, J = 8.0 Hz, 
Hc), 7.42 (2H, t, J = 7.6 Hz, Hb), 7.32 (1H, t, J = 7.4 Hz, Ha), 4.60 (2H, t, 
J = 5.1 Hz, He), 3.91 (2H, t, J = 5.0 Hz, Hf), 3.63-3.61 (2H, m, Hg), 3.53-
3.51 (2H, m, Hh), 3.37 (3H, s, Hi). 13C NMR (298 K, CDCl3,  100 MHz) δ: 
147.7, 130.8, 128.8 (Cb), 128.0 (Ca), 125.6 (Cc), 120.9 (Cd), 71.7 (Ch), 
70.5 (Cg), 69.5 (Cf), 59.0 (Ci), 50.3 (Ce). HR ESI-MS (CH3OH) m/z = 
248.1371 [M + H]+ (calc. for C13H18N3O2, 248.1394), m/z = 270.1215 [M 
+ Na]+ (calc. for C13H17N3NaO2, 270.1213). Anal. calcd. for 
C13H17N3O2∙0.1H2O: C, 62.68; H, 6.96; N, 16.87; Found: C, 62.50; H, 
7.01; N, 17.16. IR: v (cm-1) 3126, 3095, 2953, 2925, 2870, 1464, 1104, 
1077, 1048. 
 
2.17.2.4. 1,(1-hexyl)-1H-1,2,3-triazol-4-yl)benzene) (L5mono) 
A solution of sodium azide (70 mg, 1.1 mmol), sodium iodide (73 mg, 
0.49 mmol) and 1-bromohexane (170 mg, 1.03 mmol) in 4:1 DMF/H2O 
(15 mL) was microwaved at 125 °C at 250 W for 45 minutes. After 
cooling to room temperature, ethynylbenzene (107 µL, 100 mg, 0.980 
mmol), sodium ascorbate (194 mg, 0.980 mmol) and CuSO4∙5H2O (244 
mg, 0.980 mmol) were added and the resulting suspension was stirred 
at room temperature for 20 hours, before adding 0.1 M EDTA/NH4OH 
aqueous solution (20 mL) and stirring vigorously for 30 minutes. The 
organic extract was then washed with 0.1 M EDTA/NH4OH aqueous 
solution (40 mL), water (40 mL) and brine (40 mL) then dried over 
MgSO4, before filtration and removal of the solvent under vacuum. The 
resulting residue was then purified by column chromatography on silica 
(DCM) to give the product as a colourless solid (158 mg, 0.690 mmol, 
70%). 1H NMR (298 K, CDCl3,  400 MHz) δ: 7.84 (2H, d, J = 7.1 Hz, Hc), 
7.74 (1H, s, Hd), 7.42 (2H, t, J = 7.6 Hz, Hb), 7.33 (1H, t, J = 7.5 Hz, Ha), 
4.39 (2H, t, J = 8.0 Hz He), 1.95 (2H, q, J = 7.1 Hz, Hf), 1.38-1.31 (6H, 
m, Hg, Hh, Hi), 0.89 (3H, t, J = 7.0 Hz, Hj). 13C NMR (298 K, CDCl3,  100 
MHz) δ: 147.7, 130.7, 128.8 (Cb), 128.0 (Ca), 125.7 (Cc), 119.3 (Cd), 50.4 
(Ce), 31.2 (Ch), 30.3 (Cf), 26.2 (Cg), 22.4 (Ci), 13.9 (Cj). HR ESI-MS 
(CH3OH) m/z = 230.1632 [M + H]+ (calc. for C14H20N3, 230.1652), m/z = 
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252.1453 [M + Na]+ (calc. for C14H19N3Na, 252.1471). Anal. calcd. for 
C14H19N3∙0.1H2O: C, 72.75; H, 8.37; N, 18.18; Found: C, 72.83; H, 8.50; 





In a round bottom flask, diisopropylamine (20 mL) and THF (20 mL) 
were degassed with N2, before addition of 3 (400 mg, 3.39 mmol), 
dibromopyridin-4-yl)methanol,[85] (362 mg, 1.35 mmol), CuI (25 mg, 
0.14 mmol), and [Pd(PPh3)2Cl2] (38 mg, 0.050 mmol) against a positive 
N2 flow. The solution was heated at 50 °C for 48 hours. After removal of 
the solvent under vacuum, the resultant solid was taken up in 3:1 
CHCl3/IPA (150 mL) and aqueous 0.1 M EDTA/NH4OH solution (50 mL) 
and stirred for 40 minutes. The organic layer was washed with brine, 
dried with Na2SO4, filtered and then the solvent was removed under 
vacuum. Purification of the resultant solid on a silica column 
deactivated with 3:97 TEA/DCM (0.5/4.5/95 then 1/9/90 saturated 
aqueous NH4OH solution/CH3OH/DCM) gave the product as a brown 
solid (364 mg, 1.07 mmol, 79%). 1H NMR (298 K, d6-DMSO, 400 MHz) 
δ: 8.18 (2H, dd J = 2.3 Hz, 0.5 Hz, Hc), 7.57 (2H, dd, J = 8.6 Hz, 2.3 Hz, 
Hd), 7.42 (2H, s, Hb), 6.55 (4H, s, HNH), 6.49 (2H, dd, J = 8.6 Hz, 0.6 Hz, 
He), 5.51 (1H, t, J = 5.8 Hz, HOH), 4.54 (2H, d, J = 5.7 Hz, Ha). 13C NMR 
(298 K, d6-DMSO, 100 MHz) δ: 159.7, 153.0, 152.0 (Cc), 142.9, 139.7 
(Cd), 122.6 (Cb), 107.7 (Ce), 104.9, 88.8, 88.0, 60.9 (Ca). HR ESI-MS 
(CH3CN) m/z = 683.26 [2M + H]+ (calc. for C40H31N10O2, 683.26), 342.13 
[M + H]+ (calc. for C20H16N5O, 342.14). Anal. calcd. for 
C20H15N5O∙CH2Cl2: C, 69.00; H, 4.38; N, 20.02%. Found: C, 69.12; H, 
4.51; N, 20.33%. IR: ν (cm-1) 3307, 3145, 2920, 2201, 1670, 1634, 




In a round bottom flask, diisopropylamine (20 mL) and THF (20 mL) 
were degassed with N2, before 5 (365 mg, 3.09 mmol), dibromopyridin-
4-yl)methanol,[85] (275 mg, 1.03 mmol), CuI (20 mg, 0.10 mmol), and 
[Pd(PPh3)2Cl2] (36 mg, 0.050 mmol) were added against a positive N2 
flow. The solution was heated at 40 °C for 48 hours. After removal of 
the solvent under vacuum, the resultant solid was taken in 3:1 
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CHCl3/IPA (150 mL) and aqueous 01. M EDTA/NH4OH solution (50 mL) 
and stirred for 40 minutes. The organic layer was washed with brine 
(100 mL), dried with Na2SO4, filtered, and then the solvent was removed 
under vacuum. Purification of the resultant solid in a silica column 
deactivated with 3:97 TEA/DCM (0.5/4.5/95 then 1/9/90 saturated 
aqueous NH4OH solution/CH3OH/DCM) gave the product as a brown 
solid (197 mg, 0.580 mmol, 56%). 1H NMR (298 K, d6-DMSO, 500 MHz) 
δ: 7.99 (2H, d, J = 2.9 Hz, He), 7.96 (2H, d, J = 1.6 Hz, Hc), 7.59 (2H, s, 
Hb), 7.09 (2H, t, J = 2.2 Hz, Hd ), 5.60 (5H, m, HNH & HOH), 4.59 (2H, d, J 
= 5.8 Hz, Ha). 13C NMR (298 K, d6-DMSO, 125 MHz) δ: 153.6, 144.5, 
142.2, 139.2 (Cc), 136.9 (Ce), 124.2 (Cb), 121.3 (Cd), 117.8, 89.8, 86.4, 
60.8 (Ca). HR ESI-MS (CH3CN) m/z = 340.1190 [M + H]+ (calc. for 
C20H14N5O, 340.1204. Anal. calcd. for C20H15N5O: C, 70.37; H, 4.43; N, 
20.52%. Found: C, 70.21; H, 4.54; N, 20.52%. IR: ν (cm-1) 3326, 3294, 




A solution of [Co(H2O)6](BF4)2 (31 mg, 91 µmol) in acetonitrile (0.055 
mL) was added to a suspension of L2 (41 mg, 137 µmol) in acetonitrile 
(1 mL). Addition of a solution of (NH4)2[Ce(NO3)6] (75 mg, 14 µmol) in 
acetonitrile (0.440 mL) to this solution resulted in precipitation of a 
fluffy yellow solid. After centrifugation (13,000 RPM, 5 minutes) the 
filtrate was discarded, and the pellet was suspended in acetonitrile and 
collected by filtration. The solid obtained was dissolved in a minimal 
amount of water before addition of a saturated aqueous solution of 
[NH4]PF6 (10 mL). The resulting precipitate was collected by filtration, 
washed with water (2 x 5 mL), dissolved in acetonitrile (5 mL), and 
filtered through cotton wool. Vapor diffusion of diethyl ether into this 
solution gave the product as yellow crystals (38 mg, 27 µmol, 60%). 1H 
NMR (298 K, d6-DMSO, 500 MHz) δ: 9.71 (s, 6H, He), 8.90 (dd, J = 7.9, 
1.4 Hz, 6H, Hd), 8.66 – 8.62 (t, J = 7.0 Hz, 6H, Hb), 7.97 (d, J = 6.0 Hz, 
6H, Ha), 7.89 (dt, J = 6.8, 1.5 Hz, 6H, Hc), 7.67 & 7.00 (ABq, JAB = 14.2 
Hz, 6H, Hf). 13C NMR (298 K, CD3CN, 125 MHz) δ: 153.9, 148.9, 148.4, 
145.4, 131.0, 130.1, 127.0, 64.1. HR-ESMS (CH3CN) m/z = 805.0449 
[M – 2PF6]2+ (calc. for C45H36Co2F24N24P4, 805.0387), 488.3749 [M – 
3PF6]3+ (calc. for C45H36Co2F18N24P3, 488.3709). Anal. calcd. for 
C45H36Co2F36N24P6: C, 28.44; H, 1.91; N, 17.69%. Found: C, 28.49; H, 





A solution of L2 (4 mg, 13 µmol) and [Fe(H2O)6](BF4)2 (3 mg, 9 µmol) in 
acetonitrile (0.5 mL) was filtered through cotton wool, before vapor 
diffusion with diethyl ether gave a red crystalline solid (3 mg, 2 µmol, 
78%). 1H NMR (298 K, CD3CN, 500 MHz) δ: 8.99 (6H, s, He), 8.23 (6H, s, 
Hd), 8.10 (6H, s, Hc), 8.03 (6H, s, Ha), 7.46 (6H, s, Hb), 6.77 & 6.46 (6H, 
ABq, JAB = 17.6 Hz, Hf). 13C NMR (298 K, CD3CN, 125 MHz) δ: 155.9 
(Ca), 153.0, 150.3, 140.1 (Cc), 126.8 (Cb), 125.6 (Ce), 123.5 (Cd), 62.4 
(Cf). Mass spectral analysis was not successful for this compound. Anal. 
calcd. for C45H36B4F16Fe2N24∙4H2O: C, 37.43; H, 3.07; N, 23.28%. 
Found: C, 37.66; H, 2.67; N, 22.94%. 
 
2.17.3.3. [Pd2(L3)4](BF4)4 
A solution of L3 (100 mg, 0.240 mmol) and [Pd(CH3CN)4](BF4)2 (53 mg, 
0.12 mmol) in CD3CN (0.75 ml) was heated at 75 °C for 3 hours. 
Addition of diethyl ether (5 mL) brought about formation of a green oil. 
The solvent was decanted and the sample dried in vacuo, giving the 
product as an oil (115 mg, 0.0520 mmol, 86%). 1H NMR (298 K, CDCl3, 
400 MHz) δ: 10.24 (s, 1H , Ha), 8.10 (s, 2H, Hd), 7.48 (t, 1H, J = 8.3 Hz, 
Hb), 7.36 (dd, 2H, J = 8 Hz, 1.4 Hz, Hc), 4.34 - 4.21 (m, 4H, Hf), 3.71 - 
3.66 (m, 2H, He1), 3.54, 3.44 (m, 10H, He2, Hg, Hh), 3.30 (s, 6H, Hi). 13C 
NMR (298 K, CDCl3, 100 MHz) δ: 146.2, 131.1 (Cb), 130.0 (Cc), 127.0 
(Cd), 125.9, 121.6 (Ca), 71.4 (Cg or Ch), 69.9 (Cg or Ch), 67.4 (Cf), 58.0 
(Ci), 52.4 (Ce). HR ESI-MS (CH3CN) m/z = 469.6712 [M – (BF4)4]4+ (calc. 
for C80H112N24O16, 469.6693), m/z = 655.2315 [M – (BF4)3]3+ (calc. for 
C80H112BF4N24O16, 655.2271), m/z = 1026.3470 [M – (BF4)2]2+ (calc. for 
C80H112B2F8N24O16, 1026.3428). Anal. calcd. for C80H112B4F16N24O16Pd2: 
C, 43.17; H, 5.07; N, 15.10; Found: C, 42.87; H, 5.24; N, 14.82. IR: v 
(cm-1) 3150, 2883, 2821, 1566, 1454, 1367, 1353, 1095, 1049. 
 
2.17.3.4. [Pd2(NHC)2(L1)Br4] 
A solution of tripy (6 mg, 0.02 mmol) and dibromobis(benzimidazolin-2-
ylidene)dipalladium(II)[82b] (20 mg, 0.021 mmol) in CDCl3 (0.75 mL) was 
sonicated for 30 seconds. Vapour diffusion of diethyl ether gave a yellow 
semi-crystalline solid (18 mg, 0.015 mmol, 69%) 1H NMR (298 K, CDCl3, 
100 MHz) δ: 9.38 (2H, s, He), 9.14 (2H, d, J = 5.7 Hz, Hf), 7.99 (2H, d, J 
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= 6.5 Hz, Hh), 7.79 (1H, t, J = 7.9 Hz, Hj), 7.61-7.59 (6H, m, Hb & Hi), 
7.39 (2H, dd, J = 7.9 Hz, 5.8 Hz, Hg), 7.22 (4H, dd, J = 6.1 Hz, 3.1 Hz 
Ha), 6.33 (4H, sept, J = 6.6 Hz, Hc), 1.81 (24 H, d, J = 7.0 Hz, Hd). 13C 
NMR (298 K, CDCl3, 100 MHz) δ: 158.8 (carbene), 155.6 (Ce), 152.4 (Cf), 
143.1, 140.9 (Ch), 137.0 (Cj), 133.7, 127.4 (Ci), 124.2 (Cg), 122.4 (Ca), 
120.5, 112.8 (Cb), 92.2, 84.8, 54.8 (Cc), 20.8 (Cd). Anal. calcd. for 
C45H49Br4N7Pd2∙1.5CHCl3: C, 39.91; H, 3.64; N, 7.01; Found: C, 39.73; 
H, 3.60; N, 6.83. ESI-MS (CDCl3/MeOH) m/z = 1241.8 [M + Na]+ (calc. 
for C45H47Br4N7NaPd2, 1241.8). IR: v (cm-1) 3275, 2974, 2932, 2225, 
1640, 1553, 1473, 1405, 1363, 1312. 
 
2.17.3.5. [Pd(NHC)(L1mono)Br2] 
A solution of 3-ethynylpyridine (L1mono) (4 mg, 0.04 mmol) and 
dibromobis(benzimidazolin-2-ylidene)dipalladium(II)[82b] (20 mg, 0.020 
mmol) in CDCl3 (0.75 mL) was sonicated for 30 seconds. Vapour 
diffusion of ether into DCM gave orange block X-Ray quality crystals (23 
mg, 0.040 mmol, 95%). 1H NMR (298 K, CDCl3, 400 MHz) δ: 9.25 (1H, s, 
He) 9.12 (d, J = 5.5 Hz, Hf), 7.86 (1H, d, J = 7.6 Hz, Hh), 7.59 (2H, dd, J 
= 2.7 Hz, 6.2 Hz, Hb), 7.33 (1H, dd, J = 6.7 Hz, 7.9 Hz, Hg), 7.22 (2H, 
dd, J = 3.4 Hz, 5.9 Hz, Ha), 6.31 (2H, sept, J = 7.0 Hz, Hc), 3.29 (1H, s, 
Hi), 1.80 (12H, d, J = 7.0 Hz, Hd). 13C NMR (298 K, CDCl3, 100 MHz) δ: 
158.7 (carbene), 155.7 (Ce), 152.2 (Cf), 141.0 (Ch), 133.6, 124.0 (Cg), 
122.4 (Ca), 120.5, 112.8 (Cb), 82.3 (Ci), 78.9, 54.8 (Cc), 20.7 (Cd). Mass 
spectral analysis was not successful for this compound. Anal. calcd. for 
C20H23Br2N3Pd: C, 42.02; H, 4.06; N, 7.35; Found: C, 42.23; H, 4.04; N, 




A solution of L3mono (10 mg, 0.040 mmol) and 
dibromobis(benzimidazolin-2-ylidene)dipalladium(II)[82b] (20 mg, 0.020 
mmol) in CDCl3 (0.75 mL) was sonicated for 30 seconds. Vapour 
diffusion of diethyl ether into CDCl3 gave yellow X-ray quality crystals 
(28 mg, 0.038 mmol 91%). 1H NMR (298 K, CDCl3, 400 MHz) δ: 8.27 
(2H, d, J = 7.3 Hz, Hg), 8.02 (1H, s, Hh), 7.59-7.51 (5H, m, Hb, He, Hf), 
7.18  (2H, dd, J = 3.1 Hz, 6.1 Hz), 6.29 (2H, sept, J = 7.2 Hz, Hc), 4.66 
(2H, t, J = 5.4 Hz, Hi), 3.94 (2H, t, J = 4.6 Hz, Hj), 3.65-3.63 (2H, m, Hk), 
3.53-3.51 (2H, m, Hl), 3.35 (3H, s, Hm), 1.71 (12H, d, J =7.0 Hz, Hd). 13C 
NMR (298 K, CDCl3, 100 MHz δ: 161.4 (carbene), 148.9, 133.6, 129.7, 
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129.6 (Cg), 129.2 (Ce), 128.4 (Cf), 124.1 (Ch), 122.2 (Ca), 112.7 (Cb), 71.8 
(Cl), 70.7 (Ck), 69.0 (Cj), 59.1 (Cm), 54.5 (Cc), 51.6 (Ci), 20.7 (Cd). HR ESI-
MS (CDCl3/MeOH) m/z = 636.0920 [M – Br]+ (calc. for C26H35BrN5O2Pd, 
738.0076), m/z = 738.0000 [M + Na]+ (calc. for C26H35Br2N5NaO2Pd, 
738.0076). Anal. calcd. for C26H35Br2N5Pd: C, 43.63; H, 4.93; N, 9.78; 
Found: C, 43.49; H, 4.78; N, 9.75. IR: v (cm-1) 3125, 3098, 3067, 2976, 
2918, 2871, 1411, 1365, 1315, 1141, 1115, 1091. 
 
2.17.3.7. [Pd(NHC)(L4mono)Br2] 
A solution of L4mono[78] (10 mg, 0.040 mmol) and 
dibromobis(benzimidazolin-2-ylidene)dipalladium(II)[82b] (20 mg, 0.020 
mmol) in CDCl3 (0.75 mL) was sonicated for 30 seconds. A yellow 
crystalline material was obtained through vapour diffusion of ether into 
CDCl3 (21 mg, 0.030 mmol, 71%). 1H NMR (298 K, CDCl3, 400 MHz) δ: 
8.20 (2H, d, J = 6.7 Hz, Hg), 7.56-7.50 (6H, m, Hb, He, Hf, Hh), 7.43-7.36 
(5H, m, Hj, Hk, Hl), 7.18 (2H, dd, J = 6.2 Hz, 3.1 Hz, Ha), 6.30 (2H, sept, 
J = 7.0 Hz, Hc), 5.64 (s, 2H, Hi), 1.73 (12H, d, J = 7.0 Hz, Hd). 13C NMR 
(298 K, CDCl3, 100 MHz) δ: 161.3 (carbene), 149.3, 133.6, 133.1, 129.6 
(Cg), 129.5 (Ck), 129.4, 129.4, 129.3, 128.8 (Cj), 128.5 (Cf), 122.3 (Ch), 
122.2 (Ca), 112.7 (Cb), 55.5 (Ci), 54.5 (Cc), 20.7 (Cd). HR ESI-MS 
(CDCl3/MeOH) m/z = 725.9821 [M + Na]+ (calc. for C28H31Br2N5NaPd, 
723.9874). Anal. calcd. for C28H31Br2N5Pd∙0.4CDCl3: C, 45.28; H, 4.23; 
N, 9.30; Found: C, 45.18; H, 4.25; N, 9.19. IR: v (cm-1) 2976, 1407, 
1366, 1315, 1143, 1092. 
 
2.17.3.8. [Pd(NHC)(L5mono)Br2] 
A solution of L5mono (10 mg, 0.040 mmol) and 
dibromobis(benzimidazolin-2-ylidene)dipalladium(II)[82b] (20 mg, 0.020 
mmol) in CDCl3 (0.75 mL) was sonicated for 30 seconds. Vapour 
diffusion of diethyl ether into CDCl3 gave yellow X-ray quality crystals 
(22 mg, 0.032 mmol 76%). 1H NMR (298 K, CDCl3, 400 MHz) δ: 8.24 
(2H, d, J = 7.1 Hz, Hg), 7.69 (1H, s, Hh), 7.58-7.51 (5H, m, Hb, He, Hf), 
7.17 (2H, dd, J = 3.1 Hz, 6.2 Hz), 6.28 (2H, quin, J = 6.4 Hz), 4.44 (2H, 
t, J = 7.1 Hz), 2.00 (2H, t, J = 7.5 Hz Hj), 1.72 (12H, d, J =7.0 Hz), 1.43-
1.34 (6H, m, Hk, Hl, Hm), 0.91 (3H, t, J = 7.0 Hz, Hn). 13C NMR (298 K, 
CDCl3, 100 MHz) δ: 161.5 (carbene), 148.9, 133.6, 129.6 (Hg), 129.6, 
129.3 (Ce), 128.5 (Cf), 54.5 (Cc), 51.9 (Ci), 31.2 (Cl or Cm), 30.2 (Cj), 26.3 
(Ck), 22.5 (Cl or Cm), 20.7 (Cd), 14.1 (Cn). HR ESI-MS (CDCl3/MeOH) m/z 
= 618.1224 [M – Br]+ (calc. for C26H35BrN5O2Pd, 618.1259), m/z = 
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720.0295 [M + Na]+ (calc. for C26H35Br2N5NaO2Pd, 720.0343). Anal. 
calcd. for C27H37Br2N5Pd: C, 47.47; H, 5.24; N, 9.96; Found: C, 46.39; 
H, 5.24; N, 9.96. IR: v (cm-1) 3096, 2979, 2932, 2856, 1423, 1409, 
1316, 1144, 1092. 
 
2.17.3.9. [Pd(NHC)(L6mono)Br2] 
A solution of 2-aminopyridine (L6mono) (4 mg, 0.04 mmol) and 
dibromobis(benzimidazolin-2-ylidene)dipalladium(II)[82b] (20 mg, 0.020 
mmol) in CDCl3 (0.75 mL) was sonicated for 30 seconds. Vapour 
diffusion of diethyl ether into this solution gave a yellow semi-
crystalline precipitate (15 mg, 0.026 mmol, 64%). 1H NMR (298 K, 
CDCl3, 400 MHz) δ: 8.47 (1H, d, J = 7.0 Hz, He), 7.60 (2H, dd, J = 8.2 
Hz, 3.2 Hz, Hb), 7.44 (1H, t, J = 8.2 Hz, Hg), 7.24 (2H, dd, J = 8.2 Hz, 3.2 
Hz, Ha),   6.69 (1H, t, J = 5.9 Hz, Hf), 6.57 (1H, d, J = 8.3 Hz, Hh), 6.35 
(2H, sept, J = 7.0 Hz, Hc), 5.56 (2H, br, HNH), 1.83 (12 H, d, J = 7.0 Hz, 
Hd). 13C NMR (298 K, CDCl3, 100 MHz) δ: 161.2 (Ccarbene), 158.5, 150.0 
(Ce), 138.8 (Cg), 133.6, 122.4 (Ca), 114.4 (Cf), 112.8 (Cb), 115.5 (Ch), 54.8 
(Cc), 20.9 (Cd). HR ES-MS (CH3OH) m/z = 483.0167 [M – Br]+ (calc. for 
C18H24BrN4Pd, 483.0215), 584.9237 [M + Na]+ (calc. for 
C18H24Br2N4NaPd, 584.9284). Anal. calcd. for C18H24Br2N4Pd: C, 38.42; 
H, 4.30; N, 9.96. Found: C, 38.69; H, 4.32; N, 9.94%. IR: ν (cm-1) 3419, 
3326, 2977, 1623, 1410, 1364, 1306, 1141, 744. 
 
2.17.3.10. [Pd(NHC)(L7mono)Br2] 
A solution of 3-aminopyridine (L7mono)  (10 mg, 0.040 mmol) and 
dibromobis(benzimidazolin-2-ylidene)dipalladium(II)[82b] (20 mg, 0.020 
mmol) in CDCl3 (0.75 mL) was sonicated for 30 seconds. Vapour 
diffusion of diethyl ether into this solution gave a yellow precipitate (16 
mg, 0.028 mmol, 68%). 1H NMR (298 K, CDCl3, 400 MHz) δ: 8.52 (1H, 
d, J = 2.4 Hz, Hh), 8.46 (1H, d, J = 5.1 Hz, He),  7.58 (2H, dd, J = 6.2 Hz 
3.2 Hz, Hb),  7.21 (2H, dd, J = 6.1 Hz, J = 3.1 Hz, Ha),  7.07 (1H, dd, J = 
8.6 Hz, 5.7 Hz,   Hf),  7.00 (2H, d, J = 8.3 Hz, Hg),  6.33 (2H, sept, J = 
7.0 Hz, Hc),  3.84 (2H, br, HNH), 1.80 (12H, d, J = 6.9 Hz, Hd). 13C NMR 
(298 K, CDCl3, 100 MHz) δ: 159.9 (Ccarbene), 143.3, 142.7 (Ce), 139.9 
(Ch), 133.6, 124.6 (Cf), 123.1 (Cg), 122.3 (Ca), 112.7 (Cb), 54.6 (Cc), 20.7 
(Cd). HR ES-MS (CH3OH) m/z = 401.0923 [M – Hr – 2Br]+ (calc. for 
C18H23N4Pd, 401.0952). Anal. calcd. for C18H24Br2N4Pd: C, 38.42; H, 
4.30; N, 9.96%; found: C, 38.42; H, 4.37; N, 9.91%. IR: ν (cm-1) 3419, 





A solution of L6 (40 mg, 0.12 mmol) and [Pd(CH3CN)4](BF4)4 (26 mg, 
0.060 mmol) in 1.5 mL d6-DMSO in a tube was purged with N2 and was 
heated at 45 °C for 6 hours. Diethyl ether (30 mL) was added and the 
solution shaken vigorously. After decanting the liquid portion, the 
precipitate was suspended in DCM (5 mL) and isolated by filtration. 
After washing with DCM (5 mL), the solid was dried under vacuum at 
60 °C for 4 days to give the product as a red solid (32  mg, 0.017 mmol, 
57%). 1H NMR (298 K, d6-DMSO, 500 MHz) δ: 8.77 (8H, d, J = 1.6 Hz, 
Hc), 8.11 (8H, s, HNH), 7.84 (8H, dd, J = 8.9 Hz, 1.5 Hz, Hd), 7.56 (8H, s, 
Hb), 6.73 (8H, d, J = 8.9 Hz, He), 4.53 (8H, s, Ha). 13C NMR (298 K, d6-
DMSO, 125 MHz) δ: 159.8, 153.5, 149.4 (Cc), 142.7 (Cd), 142.1, 125.3 
(Cb), 112.6 (Ce), 107.7, 90.5, 84.6, 60.6 (Ca). ESI-MS (DMSO/CH3CN) 
m/z = 394.60 [M – 4(BF4)]4+ (calc. for C80H60N20O4Pd2, 394.58), 394.10 
[Pd(L6)2]2+ (calc. for C40H30N10O2Pd, 394.08). Anal. calcd. for 
C80H60B4F16N20O4Pd2∙5H2O∙4DMSO: C, 45.50; H, 4.07; N, 12.03%. 
Found: C, 45.24; H, 3.78; N, 12.29%. IR: v (cm-1) 337, 3194, 2210, 
1637, 1546, 1513, 1411, 1025.    
 
2.17.3.12. [Pd2(L7)4](BF4)4 
A solution of L7 (60 mg, 0.18 mmol) and [Pd(CH3CN)4](BF4)4 (39 mg, 
0.090 mmol) in d6-DMSO (0.75 mL) was sonicated for five minutes. 
Addition of ethyl acetate (20 mL) resulted in precipitation of the 
product. The precipitate was collected by filtration, and washed with 
ethyl acetate (15 mL) and diethyl ether (15 mL) to give a brown solid (64 
mg, 0.030 mmol, 75%). 1H NMR (298 K, d6-DMSO, 500 MHz) δ: 8.36 
(8H, s, He), 8.26 (8H, s, Hc), 7.63 (8H, s, Hb), 7.30 (2H, s, Hd), 6.41 (8H, 
s, HNH), 5.59 (4H, br, HOH), 4.55 (8H, s, Ha). 13C NMR (298 K, d6-DMSO, 
125 MHz) δ: 154.0, 146.9, 141.4, 138.3 (Cc), 135.9 (Ce), 125.3 (Cd), 
125.1 (Cb), 120.7, 119.1, 91.9, 83.3, 60.7 (Ca). HR ES-MS 
(DMSO/CH3CN) m/z = 394.5820 [M – 4(BF4)4]4+ (calc. for C80H60N20O4, 
394.5797), 342.1401 [L7 + H]+ (calc. for C20H16N5O, 342.1401). Anal. 
calcd. for C80H60B4F16N20O4Pd2∙5H2O∙4DMSO: C, 45.50; H, 4.07; N, 
12.03%. Found: C, 45.20; H, 3.77; N, 12.28%. IR: ν (cm-1) 3468, 3384, 






A solution of L8 (62 mg, 0.20 mmol) and [Pd(CH3CN)4](BF4)2 (44 mg, 
0.10 mmol) in acetonitrile (6 mL) was stirred for 1 hour. Vapour 
diffusion with diethyl ether gave a white solid (76 mg, 0.040 mmol, 
85%). 1H NMR (298 K, CD3CN, 500 MHz) δ: 9.32 (8H, d, J = 1.8 Hz, Hc), 
9.05 (8H, dd, J = 6.1 Hz, 1.1 Hz, Hf), 8.17 (8H, dt, J = 8.0 Hz, 1.4 Hz, 
Hd), 7.65 (8H, ddd, J = 8.0 Hz, 5.9 Hz, 0.6 Hz, He), 7.64 (8H, t, J = 0.8 
Hz, Hb), 4.63 (8H, dd, J = 5.6 Hz, 0.8 Hz, Ha), 3.57 (4H, t, J = 5.6 Hz, 
HOH). 13C NMR (298 K, CD3CN, 125 MHz) δ: 154.5, 154.4 (Cc), 151.4 
(Cf), 144.5 (Cd), 143.2, 128.5 (Ce), 126.5 (Cb), 124.1, 94.8, 83.2, 62.2 
(Ca). HR ES-MS (CH3CN) m/z = 816.1313 [M – (BF4)2]2+ (calc. for 
C80H52N12O4Pd2, 816.1313). Anal. calcd. for C80H52B4F16N12O4Pd2∙3H2O: 
C, 51.67; H, 3.14; N, 9.04%. Found: C, 51.87; H, 3.09; N, 8.71%. IR: ν 
(cm-1) 3211, 3097, 2976, 2921, 2852, 2220, 1685, 1595, 1545, 1483, 
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3.1. Controlling uptake and release 
The ability of metallosupramolecular assemblies to bind guests, and the 
manifold potential applications as a result of this, have already been 
discussed. But simply being able to encapsulate a guest is not enough; 
applications such as delivery, storage and catalysis are dependent on 
the capacity to controllably take up and release the guest in response to 
stimuli. Controllable catch-and-release of guest molecules has been 
targeted in a few ways. The character of the guest can be modified to 
promote binding or leaving (Figure 3.1a), or the host can be targeted, 
either by modification of the cavity environment, or complete or partial 
disassembly of the metallosupramolecular skeleton (Figure 3.1b – d). 
 
Figure 3.1 Cartoon depiction of strategies for controlled release and reuptake 
of a guest from a host; a) modification of the character of the guest, b) 
modification of the binding environment provided by the host, c) complete 
disassembly of the host, and d) partial disassembly of the host. 
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3.2. Guest modification for uptake and release 
Guest modification has taken two forms; changing the charge of the 
guest through redox or acid-base chemistry, or cleavage of the guest 
molecule and release of the desired component. An example of the first 
type was reported by Ward and coworkers, who used a bis-pyrazoyl-
pyridine ligand in 12:8 ratio with Co(II) to form a [Co8(L)12]16+ cubic cage 
as a host for pH-driven reversible guest binding (Figure 3.2).[32] 
 
Figure 3.2 a) Synthesis of a [Co8(L)12]16+ cage by Ward and coworkers (L = 
(2,2'-(1,1'-(naphthalene-1,5-diylbis(methylene))bis(1H-pyrazole-3,1-diyl))bis 
(pyridine-4,2-diyl))dimethanol), b) depiction of the X-ray crystal structure of 
[(1-adamantane-carboxylic acid)Co8(L)12]16+, with 1-adamantane-carboxylic 
acid shown in spacefilling view.   
A range of biologically relevant molecules including nicotine and aspirin 
were investigated, with all being either acidic or basic (Figure 3.3). It 
was found through 1H NMR spectroscopic studies under variable pH in 
D2O that in all cases the neutral form of the guest bound within the 
hydrophilic cavity more strongly than the charged form. Upon alteration 
of the pH to ionise the guest (i.e., decreasing the pH for acidic guests, 
increasing the pH for basic guests), the guest would be ejected. As 
might be expected, the selectivity for the neutral form was higher with 
basic guests, which when protonated experienced electrostatic 
repulsion from the cationic cage. Ward and coworkers have also been 
able to control exchange in a three guest (acidic, neutral and basic) 




Figure 3.3 Depiction of the ionisable guests bound in the [Co8(L)12]16+ cage 
reported by Ward and coworkers, with the pKa of each guest. The direction of 
the arrow (red for acidic guests, blue for basic guests) indicates that beyond 
this pH, the charged guest is expelled from the cavity.[32] Figure modified with 
permission (Creative Commons Licence, Attribution 3.0).  
In an analogous vein, Fujita and coworkers have also utilised pH 
changes, driving the catch and release of dimethylaminobenzene 
through deprotonation or protonation, with the charged variant being 
expelled from the hydrophobic interior of a [Pd6(L)4]12+ cationic host.[33] 
Similarly, Nitschke and coworkers used protonation of pyridine to 
promote guest exchange from an [Fe4(L)6]-4 tetrahedron.[91] Fujita and 
coworkers have also utilised redox chemistry. They encapsulated three 
ferrocene molecules within the [Pd6(L)4]12+ cage, and were able to 
reversibly release and reuptake using electrochemistry, monitoring the 
activity using cyclic voltammetry.[92] 
 An example of the second sort of guest modification, involving guest 
cleavage, was reported by Lippard and coworkers,[55b] and while only 
being used to bring about guest release, rather than a reversible 
process, it is still of interest as the system was designed as a biological 
cisplatin delivery vector.  Building on previous work utilising cisplatin 
in the Pt(IV) oxoplatin prodrug form,[23c] the guest contained oxoplatin 
with the axial sites of the compound occupied by succinate on one side, 




Figure 3.4 The cisplatin delivery vector reported by Lippard and 
coworkers:[55b] four of an adamantane-functionalised Pt(IV) oxoplatin derivative 
are bound within the cavity of a [Pt6(L)4]12+ cage. Upon reduction of Pt(IV) to 
Pt(II), cisplatin and other components are cleaved, and the drug is released. 
The host, a platinum(II) cage originally reported by Fujita and 
coworkers[33] has a hydrophobic interior which the adamantane groups 
have high affinity for, and 1H NMR and DOSY NMR spectroscopies 
confirmed encapsulation and a 4:1 ratio of guest to host. Under 
reducing conditions in D2O, the platinum(IV) metal ions of the guest 
were reduced to square planar Pt(II), releasing succinate, 
aminoadamantane, CO2, and cisplatin. All components were released 
from the host, including the aminoadamantane which is protonated at 
physiological pH. The host-guest complex exhibited higher cytotoxicity 
against cancerous human cell lines than the sum of the component 
parts, presumably because the charge on the host-guest complex 
facilitates intracellular access of the prodrug. 
3.3. Host modification for uptake and release 
3.3.1. Alteration of the cavity environment 
The host architecture can be modified in a fashion to leave the core 
structure unchanged but alter the cavity environment, and thus 
reversibly catch and release the guest. This was accomplished by 





Figure 3.5 a) Reversible uptake and release of croconate guest molecules from 
Nitschke’s [M4(L)2]n+ system, (modified with permission from the Journal of the 
American Chemical Society, copyright 2015 American Chemical Society) and 
b) depiction of the X-ray crystal structure of the host-guest adduct 
[(croconate)2Cd4(L)2]4+ from above (top) and the side (bottom). Counterions 
and hydrogen atoms omitted for clarity, carbon atoms from different 
metalloligands coloured grey or yellow.[93]  
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The metalloligand consisted of four pyridyl-imine arms branching from 
a [Co(cyclopentadienyl)(cyclobutadiene)] core, formed in situ from the 
combination of the appropriate aldehyde and amine with Cd(II) in 
acetonitrile to give the [Cd4(L)2]8+ complex, with the remaining two 
coordination sites of each metal ion occupied by solvent acetonitrile or 
water molecules. The introduction of the croconate dianion to the 
solution brought about displacement of the solvent and the binding of 
two croconate anions within the structure, with each croconate anion 
coordinating in a bis-bidentate fashion to two Cd(II) ions (see the X-ray 
crystal structure of the host-guest adduct in Figure 3.5b). Similar host-
guest interactions occurred with rhodinozate and squarate and UV-vis 
titration studies indicated positive cooperativity of binding. The addition 
of DMSO to the acetonitrile solution in the presence of Cu(I) resulted in 
transmetallation, and the metal ions in the [Cu4(L)2]4+ complex adopted 
a tetrahedral geometry with no vacant coordination sites, resulting in 
the release of the guest. The dicopper(II) complex could then be 
selectively precipitated with diethyl ether and retaken up in acetonitrile. 
Introduction of new Cd(II) ions promoted transmetallation back to the 
[Cd4(L)2]8+ complex, which could then bind the reintroduced guest. 
 Protonation of basic sites within the host cavity have also been used 
to expel guests. Yam and coworkers utilised a diplatinum(II) 
metallocycle with internally directed non-coordinating pyridyl nitrogen 
atoms to this end.[55a] Protonation of the pyridyl nitrogen atoms brought 
about ejection of a cytotoxic neutral platinum(II) guest through steric 
impingement and electrostatic repulsion, while subsequent treatment 
with triethylamine deprotonated the sites allowing reuptake. 
 
3.3.2. Complete structural disassembly 
While the previous strategy left the metallosupramolecular framework 
intact, another direction has been to completely dismantle the 
assembly. Nitschke and coworkers have hydrolysed the pyridyl-imine 
bond in ligands im [Fe4(L)6]6- tetrahedra through treatment with acid or 
tris-(2-ethylamino)amine and thus effected guest release.[31c, 94] The 
original [(cisplatin)2Pd2(L)4]4+ complex reported by Crowley and 
coworkers was also an example of complete disassembly, using chloride 
or DMAP as competing ligands to displace the cage ligands. 
 Other stimuli have also been employed. Yoshizawa and coworkers 
synthesised a [Ag2(L)2]2+ macrocycle using the same dianthracenyl 
ligand used in the generation of their [Pd2(L)4]4+ cages. This disilver(I) 
macrocycle was capable of selectively binding C60 from a mixture of 
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fullerene soot.[26b]  Irradiation of a solution of the host-guest adduct in 
acetonitrile promoted disassembly of the macrocycle through reduction 
of the metal ions to Ag(0), releasing the purified guest. An elegant 
example from Sallé and coworkers utilised oxidation of the ligands to 
disassemble their system.[95] A tetra-pyridyl ligand with an extended 
tetrathiafulvalene (TTF) backbone was used in conjunction with 
palladium(II) cis-protected with bis-(diphenylphosphine)ferrocene (dppf) 
to form a [Pd4(dppf)4(L)2]8+ architecture (Figure 3.6). This cage could 
encapsulate various guests, including the large and non-coordinating 
B12F122- dianion, two of which were bound, each between a pair of 
palladium(II) ions. 
 
Figure 3.6 Formation of a [Pd4(dppf)4(L)2]8+ cage from a tetra-monodentate 
extended TTF ligand and [Pd(dppf)]2+, by Sallé and coworkers, which forms a 
[(B12F12)2Pd4(dppf)4(L)2]2+ host-guest adduct. The cage can be reversibly 
disassembled/reassembled through redox of the extended TTF moiety.[95] X-




Introduction of four equivalents of the radical cation thianthrenium as 
an oxidising agent brought about oxidation of the ligands to the +2 
oxidation state. This planarised the molecule, in addition to lowering its 
affinity for coordination due to its cationic nature, and the cage 
disassembled, with guest release monitored by 19F NMR spectroscopy. 
Reduction of the ligands with (tetrakis(dimethylamino)ethylene) brought 
about reformation of the cage and reuptake of the guest. 
   
3.3.3. Partial structural disassembly 
Host disassembly need not be complete: partial disassembly can be 
utilised to bring about a metallosupramolecular structural 
transformation with concurrent guest release. This approach was taken 
by Yoshizawa and coworkers with a [Hg2(L)4]4+ cage using the same 
dianthracenyl-paneled ligand previously described.[25b] Due to the 
pliable coordinative character of mercury(II) ions, it was possible to 
cycle between the cage and an [Hg2(L)2]4+ macrocycle through addition 
of Hg(II) ions or ligand (Figure 3.7).   
 
Figure 3.7 Reversible uptake and release of C60 through stoichiometrically- 
induced cycling between a [Hg2(L)4]4+ cage and [Hg2(L)2]4+  macrocycle, reported 
by Yoshizawa and coworkers.[25b] 
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The cage had affinity for both the fullerenes C60 and C70, and bound the 
guests in CD3CN, but upon addition of Hg(II) ions and macrocycle 
formation, the fullerenes were released. Cage reformation through 
addition of the ligand brought about re-encapsulation of the guest. 
Additionally, C60 was preferred to C70, and introduction of C60 to a 
solution of the [(C70)Hg2(L)2]4+ host-guest adduct brought about guest 
exchange and precipitation of the C70 fullerene.  
 
3.4. A strategy for chloride/silver(I)-promoted cycling between a 
[Pd2(L)4]4+ cage and a [Pd2(L)2Cl4] metallomacrocycle 
The stimuli promoting cycling between closed cage and open 
macrocyclic structures in the Yoshizawa system, while ingenious, is not 
without drawbacks. The stepwise addition of first one component and 
then the other results in a steady molar increase with each cycle. 
Secondly, mercury(II) is potentially highly toxic, lowering the 
applicability of the system. We envisaged a related system using a 
[Pd2(L)4]4+ cage which could be converted through the addition of four 
equivalents of chloride to a [Pd2(L)2Cl4] metallomacrocycle, then 
returned to the cage through addition of Ag(I) and precipitation of AgCl 
(Figure 3.8).[96] 
 
Figure 3.8 Proposed chloride/silver(I)-stimulated interconversion between a 
[Pd2(L)4]4+ cage and a [Pd2(L)2Cl4] metallomacrocycle. 
In contrast to the Yoshizawa system, the macrocycle in this proposed 
cycle would be neutral. It was therefore decided to add polyethylene 
glycol chains to the ligand to aid solubility. A diglyme chain was added 
in the first step along the synthetic route to the ligand, through a 
Williamson ether synthesis combining 5-bromopyridin-3-ol and 1-
chloro-2-(2-methoxyethoxy)ethane in the presence of a base to give 3-




Scheme 3.1 Conditions: (i) 1-chloro-2-(2-methoxyethoxy)ethane, K2CO3, DMF, 
90 °C overnight (89%), (ii) TMS-acetylene, [Pd(PPh3)2Cl2], CuI, DIPA, under N2, 
70 °C for 2 days (86%), (iii) Na2CO3, MeOH, 2 hours (80%), (iv) 2,6-
dibromopyridine, [Pd(PPh3)2Cl2], CuI, under N2, RT for 2 days (71%).  
A palladium-catalysed Sonogashira reaction next formed a carbon-
carbon bond between 6 and TMS-acetylene, giving 3-(2-(2-
methoxyethoxy)ethoxy)-5-((trimethylsilyl)ethynyl)pyridine (7, 86%), 
which was subsequently deprotected with Na2CO3 providing a naked 
alkyne on 3-ethynyl-5-(2-(2-methoxyethoxy)ethoxy)pyridine (8, 80%). 
The combination of 8 with 2,6,-dibromopyridine under Sonogashira 
conditions gave the PEG-substituted ligand, L9 (71%). Mass 
spectrometric analysis was consistent with the proposed compound 
(m/z = 540.2093, [M + Na]+ (calc. for C29H31N3NaO6, 540.2185)), and X-
ray crystallography (P21/c, R1 = 4.2%, Figure 3.9 top) and 1H and 13C 
NMR spectroscopies (Figure 3.10a) confirmed the structural identity. 
Combination of the ligand with [Pd(CH3CN)4](BF4)2 in a 4:2 ratio in 
CD3CN at room temperature (Figure 3.9) brought about downfield shifts 
of the peaks ortho to the peripheral pyridyl nitrogen atoms, consistent 
with formation of the [Pd2(L9)4](BF4)4 cage (Figure 3.10b). The cage was 
isolated in good yield (75%) through precipitation with diethyl ether. 
Comparison of the DOSY 1H NMR-derived diffusion coefficients of the 
ligand and cage (Dligand = 4.59 x 10-10 m2 s-1, Dcage = 2.16 x 10-10 m2 s-1) 




Figure 3.9 Cage formation and switching mechanism. Conditions: (i) 
[Pd2(CH3CN)4](BF4)2, CH3CN (75%), (ii) [N(Bu)4]Cl, (iii) AgBF4, switching done in 
d7-DMF. Chemical structures shown as depictions of the X-ray crystal 





Figure 3.10 Stacked partial 1H NMR spectra (298 K, d7-DMF, 500 MHz) of a) 
L9, b) [Pd2(L9)4](BF4)4, c) introduction of 4 equivalents of [N(Bu)4]Cl to give 
[Pd2(L9)2Cl4] and L9, d) introduction of 4 equivalents of AgBF4 to give 
[Pd2(L9)4](BF4)4. Blue dotted lines go to and from peaks pertaining to the 
metallomacrocycle. The values noted in a), b) and c) are the diffusion 
coefficients (D, units: x 10-10 m2 s-1) of L9, [Pd2(L9)4](BF4)4 and [Pd2(L9)2Cl4].    
Mass spectrometry confirmed the 4:2 ratio between ligand and metal 
ion, with isotopically resolved peaks pertaining to species with the loss 
of two, three, or all four counterions (Figure 3.11, observed m/z = 
1228.3430, 789.8970 and 570.6726, calc. 1228.3518, 789.8998 and 
570.6737). 
 




Finally, the cage was crystallised through addition of diethyl ether to a 
solution of the compound in acetonitrile, with violent shaking until 
formation of a milky white suspension, and leaving the suspension to 
stand overnight. The cage crystallised in the triclinic space group P1̅, 
with an R1 of 7.5% (Figure 3.9 middle). One of the crystallographically 
independent tetrafluoroborate counterions was positioned over the 
exohedral face of the palladium(II) metal ion, and the other between 
coordinating pyridyl rings. The cavity was occupied by eight water 
molecules each with half occupancy. The cationic portion of the 
structure clearly revealed the expected cage architecture. 
 Introduction of four equivalents of [N(Bu)4]Cl to a solution of the cage 
in d7-DMF (Figure 3.9) gave a 1H NMR spectrum in which, in addition to 
peaks belonging to the free ligand, showed a new set of resonances 
(Figure 3.10c). The position of the peaks of the new species were 
intermediate in chemical shift between free ligand and cage, suggesting 
the formation of a neutral metal complex. The diffusion coefficient 
(Dmacrocycle = 3.10 x 10-10 m2 s-1) of the new species was between that of 
ligand and complex, indicative of the formation of an assembly larger 
than L9 but smaller than [Pd2(L9)4](BF4)4. Crystals obtained from 
diffusion of diethyl ether into a DMF solution of the macrocycle were of 
X-ray quality and the structure was solved in C2/m (R1 = 5.6%, Figure 
3.9 bottom), and confirmed that the species was [Pd2(L9)2Cl4], which in 
the solid state was the trans isomer. It must be noted that the 
metallacycle could not be prepared independently from L9 and 
[Pd(CH3CN)2Cl2]: without the preorganisation given by the cage, only 
insoluble polymeric material was formed.  
The solution of macrocycle could then be treated with four 
equivalents of AgBF4, bringing about the precipitation of AgCl and the 
reformation of the cage (Figure 3.10d). Repetition of these sequential 
steps thus gave controlled cycling between two different 
metallosupramolecular assemblies; the cage and macrocycle.   
 
3.5. Host-guest capacity of [Pd2(L8)4](BF4)4 
With a switching mechanism now established, the suitability of guests 
for the system was now assessed. Introduction of excess cisplatin to a 
solution of the cage in d7-DMF brought about a small downfield shift of 
the peak pertaining to the internally directed proton, Hc (Δδ = 0.05 ppm, 
Figure 3.12a and b), indicative of internal encapsulation. In contrast, 
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the addition of tetrabutylammonium mesylate brought about a 
downfield shift primarily of the peak belonging to the exohedral proton, 
He (Δδ = 0.45 ppm, Figure 3.12c) suggesting interaction on the external 
faces of the palladium(II) ions of the cage. 
 
Figure 3.12 Stacked partial 1H NMR spectra (298 K, d7-DMF, 500 MHz) of a) 
[Pd2(L9)4](BF4)4, b) [(cisplatin)2Pd2(L9)4](BF4)4, and c) [(MsO)2Pd2(L9)4](BF4)2. 
X-ray quality crystals of [Pd2(L9)4](BF4)4 in DMF with excess 
[N(Bu)4]OMs confirmed the assessment of external guest binding 
(P21/n, R1 = 11.1%, Figure 3.13).   
 
Figure 3.13 Depiction of the X-ray structure of 
[(DMF)2(MsO)2Pd2(L9)4](OMs)2. Guests shown in spacefilling mode, other 
solvent molecules and counterions omitted for clarity. 
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Two DMF molecules were encapsulated within the cavity in a head-to-
tail fashion with the aldehyde oxygen in a quadfurcated hydrogen bond 
with the Hc protons. Meanwhile symmetry-equivalent mesylate anions 
were positioned in similar fashion on the external faces of the cage, in 
accordance with the 1H NMR data (Figure 3.14a). 
 
Figure 3.14 Partial depictions of the X-ray crystal structures of a) 
[(DMF)2(MsO)2Pd2(L9)4](OMs)2, b) [(H2O)4Pd2(L9)4](BF4)4, and c) 
[(cisplatin)2Pd2(L8)4](BF4)4. The mesylate carbon atom is shown in black. See 





This is similar to the exo- and endo-hedral interactions seen with 
[(H2O)4Pd2(L9)4](BF4)4 (Figure 3.14b) and [(cisplatin)2Pd2(L8)4](BF4)4 
(Figure 3.14c), with distances between interacting components that 
range from 2.179 to 2.665 Å for CH---Anion hydrogen bonds, and 2.351 
to 2.860 Å for the endohedral hydrogen bond to the encapsulated guest 
(Table 3.1). 
 
Table 3.1 Selected crystallographic distances for host-guest adducts. 
Interaction 







CH---Anion 2.276 – 2.499 2.179 – 2.665 2.31 – 2.65 
CH---Guest 2.418 – 2.714 2.351 2.551 – 2.860 
 
With the nature of binding established for both cisplatin and mesylate, 
1H NMR titrations in d7-DMF were carried out. The mole ratio method[97] 
tracking Δδ of He confirmed solution-phase 2:1 guest to host binding for 
the mesylate anion (Figure 3.15a) and the data were fitted iteratively[98] 
to give binding constants of K1 = 1000  100 M-1 and K2 = 180  20 M-1. 
These binding constants were comparable to those observed for related 
sulfonate/palladium(II) host-guest systems.[98-99] The interaction with 
cisplatin was weak with small changes in chemical shifts of Hc, but 
appeared sigmoidal in nature (Figure 3.15b) and iterative fitting[98] gave 
binding constants of K1 = 2  1 M-1 and K2 = 5  2 M-1. This sigmoidal 
nature is characteristic of cooperativity; inspection of the crystal 
structure of the cisplatin/cage host-guest adduct suggests this 
cooperativity arises from platinum(II)-platinum(II) interactions and 
hydrogen bonding between chloride and amino groups between the two 






Figure 3.15 Plots of the change in chemical shift (Δδ, ppm, 298 K, d7-DMF, 
400 MHz, cage concentration 0.58 mM) against the equivalents of a) 
[N(Bu)4]OMs (monitoring Δδ for He) or b) cisplatin (monitoring Δδ for Hc), per 





3.6. Induced switching for catch and release of guests 
With a method for switching between a closed cage and open 
metallacycle established, and guests that interacted with the cage 
either internally or externally identified, we now sought to investigate 
via 1H NMR spectroscopy in d7-DMF whether switching in the presence 
of guests was accompanied by guest release and reuptake. Addition of 
two equivalents of mesylate brought about the expected downfield shift 
of the resonance of He consistent with association on the outside face of 
the cage (Figure 3.16d and e). Chloride could now be added, switching 
to the metallacycle and free L9 (Figure 3.16f), and the chemical shifts of 
these species were the same as when generated with no guests present 
(Figure 3.16c), confirming that the mesylate does not interact with 
metallacycle or free ligand. This is presumably due to the lower 
electropositivity of the palladium(II) ion in the neutral complex 
combined with the lower number of hydrogen bond donors. 
Precipitation of AgCl through addition of AgBF4 gave reformation of the 
host-guest adduct (Figure 3.16g). Alternatively, cisplatin could be added 
to a solution of the cage, bringing about a downfield shift in the peak 
pertaining to Hc, indicative of encapsulation (Figure 3.16h and i). 
Adding chloride formed metallacycle and free L9, again at the same 
chemical shifts as the system without a guest, and showing that 
cisplatin had successfully been released (Figure 3.16j), for similar 
reasons to the mesylate anion. Ag(I) ions could again stimulate 
reformation of the host-guest adduct (Figure 3.16k). Hence, in both 
cases, the system could be toggled between two states for the catch and 
release of two different guests. Additionally, both guests could be 
introduced to the host at the same time to interact simultaneously, and 
addition of chloride resulted in release of both. 
 
3.7. Conclusions and future directions 
An effective method for switching between two distinct 
metallosupramolecular structures using chloride and silver(I) was 
identified, and carrying out this switching in the presence of guests 
prompted guest release on conversion to the neutral metallacycle, and 
reuptake into the cationic cage. It is clear that this system could not be 
used for biological release and reuptake: the human body has a 
bloodstream chloride concentration of approximately 90 mM, requiring 





Figure 3.16 Partial stacked 1H NMR spectra (298 K, d7-DMF, 500 MHz) of a) 
L9, b) [Pd2(L9)4]4+, c) addition of four equivalents of Cl- to give [Pd2(L9)2Cl4] and 
L9, d) addition of four equivalents of AgBF4 to give [Pd2(L9)4]4+, e) addition of 
two equivalents of MsO- giving [(MsO)2Pd2(L9)4]2+, f) addition of four 
equivalents of Cl- to give [Pd2(L9)2Cl4], L9, and free MsO-, g) addition of four 
equivalents of AgBF4 for reformation of the [(MsO)2Pd2(L9)4]2+ adduct, h) 
[Pd2(L9)4]4+, i) excess cisplatin added giving [(cisplatin)2Pd2(L9)4]4+, j) addition 
of four equivalents of Cl- to give [Pd2(L9)2Cl4], L9, and free cisplatin, and k) 
addition of four equivalents of AgBF4 for reformation of the 
[(cisplatin)2Pd2(L9)4]2+ adduct.  
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But nonetheless, switching of this sort has potential in applications 
such as molecular scavenging and catalysis. Molecules such as 
environmental pollutants could conceivably be encapsulated and then 
collected via this mechanism. Catalytic processes could be turned on 
and off in this manner, giving greater control over reaction processes. In 
this regard, cages with larger cavities than the parent [Pd2(L)4]4+ 
assembly are necessary. Also useful for catalysis would be a 
methodology to controllably introduce asymmetry and differentiated 
functionality, especially to the cavity environment. To facilitate this, a 
means of controllably accessing heteroleptic assemblies is required, and 









3.8.1.1. Synthesis of 3-bromo-5-(2-(2-methoxyethoxy)ethoxy)- 
pyridine (6) 
1-Chloro-2-(2-methoxyethoxy)ethane[80] (4.82 g, 34.8 mmol), 5-
bromopyridin-3-ol (4.03 g, 23.2 mmol) and K2CO3 (6.41 g, 46.4 mmol) 
were dissolved in DMF (30 mL) and stirred overnight at 90 °C. After 
filtration the solvent was removed under vacuum. The residue was 
taken up in DCM (50 mL), washed with water (100 mL), with extraction 
of the aqueous layer with 3:1 CHCl3/IPA (50 mL). The organic layers 
were combined, dried with Na2SO4 and filtered, before the solvent was 
removed under vacuum. Column chromatography on silica (DCM, then 
1:19 acetone/DCM, then 1:4 acetone/DCM) gave the product as an 
orange oil (5.72 g, 20.6 mmol, 89%). 1H NMR  (298 K, CDCl3, 400 MHz) 
δ: 8.28 (1H, d, J = 1.8 Hz, Ha), 8.26 (1H, d, J = 2.5 Hz, Hc), 7.40 (1H, t, J 
= 2.1 Hz, Hb), 4.19-4.16 (2H, m, Hd), 3.87-3.85 (2H, m, He), 3.72-3.69 
(2H, m, Hf), 3.58-3.56 (2H, m, Hg), 3.39 (3H, s, Hh). 13C NMR (298 K, 
CDCl3, 100 MHz) δ: 155.1, 142.8 (Ca), 136.4 (Cc), 123.9 (Cb), 120.0, 71.7 
(Cd), 70.6 (Ce), 69.2 (Cf), 68.0 (Cg), 58.8 (Ch). HR-ESMS (CHCl3/MeOH) 
m/z = 298.0027 [M + Na]+ (calc. for C10H14BrNNaO3, 298.0049), m/z = 
276.0205 [M + H]+ (calc. for C10H15BrNO3, 276.0230). Anal. calcd. for 
C10H14BrNO3∙0.1acetone:  C, 43.88; H, 5.22; N, 4.97%; found: C, 43.72; 
H, 5.28; N, 4.63%. IR: ν (cm-1) 2877, 2106, 1741, 1573, 1554, 1428, 
1310, 1261, 1220, 1135, 1105, 1051, 1007, 935, 856. 
 
3.8.1.2. Synthesis of 3-(2-(2-methoxyethoxy)ethoxy)-5-
((trimethylsilyl)ethynyl)pyridine (7) 
A solution of 6 (1.00 g, 3.62 mmol) in diisopropylamine (6 mL) was 
degassed with N2 for 15 minutes. TMS-acetylene (1.470 mL, 10.86 
mmol), [Pd(PPh3)2Cl2] (0.10 g, 0.15 mmol) and copper(I) iodide (0.07 g, 
0.36 mmol) were added and the reaction mixture was heated at 70 °C 
for 2 days. A mixture of 3:1 CHCl3/IPA (50 mL) and aqueous 0.1 M 
EDTA/NH4OH solution (50 mL) were added and the mixture was stirred 
vigorously for 2 hours. After filtration through Celite and separation, 
the organic layer was washed with brine (100 mL), dried with MgSO4 
and the solvent was removed under vacuum. Column chromatography 
on silica (DCM, then 1:7 acetone/DCM) gave a brown oil (0.92 g, 3.1 
mmol, 86%). 1H NMR (298 K, CDCl3, 400 MHz) δ:  8.29 (1H, d, J = 1.6 
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Hz, Hc), 8.26 (1H, d, J = 1.8 Hz, Ha), 7.25 (1H, m, Hb), 4.18-4.16 (2H, m, 
Hd), 3.87-3.85  (2H, m, He), 3.72 – 3.70   (2H, m, Hf), 3.58-3.56  (2H, m, 
Hg), 3.39 (3H, s, Hh), 0.26  (9H, s, Hi). 13C NMR (298 K, CDCl3, 100 MHz) 
δ: 154.1, 144.9 (Cc), 138.1 (Ca), 123.1 (Cb), 120.2, 101.3, 97.8, 71.8 
(Cd), 70.7 (Ce), 69.4 (Cf), 67.8 (Cg), 58.9 (Ch), -0.3 (Ci). HR-ESMS 
(CHCl3/MeOH): m/z = 316.1332  [M + Na]+ (calc. for C15H23NNaO3Si, 
316.1339), m/z = 294.1511 [M + H]+ (calc. for C15H24NO3Si, 294.1520). 
Anal. calcd. for C15H23NO3Si∙0.7H2O: C, 58.87; H, 8.04; N, 4.58%; 
found: C, 58.50; H, 7.85; N, 4.54%. IR: ν (cm-1) 2958, 2925, 2159, 
1581, 1419, 1290, 1249, 1171, 1108, 1058, 1019, 993, 840, 759, 701. 
 
3.8.1.3. Synthesis of 3-ethynyl-5-(2-(2-ethoxyethoxy)ethoxy) 
pyridine (8) 
To a solution of 7 (0.917 g, 3.13 mmol) in methanol (40 mL) was added 
Na2CO3 (0.663 g, 6.25 mmol), and the mixture was stirred for 2 hours 
at RT. After filtration and removal of solvent under vacuum, the residue 
was purified through column chromatography on silica (DCM, then 
1:10 acetone/DCM, then 1:3 acetone/DCM) to give a brown oil (0.491 g, 
2.50 mmol, 80%). 1H NMR (298 K, CDCl3, 400 MHz) δ: 8.28 (1H, d, J = 
2.4 Hz, Ha), 8.26 (1H, d, J = 2.9 Hz, Hc), 7.26 (1H, m, Hb), 4.19-4.16 
(2H, m, Hd), 3.88-3.85 (2H, m, He), 3.72-3.70 (2H, m, Hf), 3.58-3.56 (2H, 
m, Hg), 3.35 (3H, s, Hh), 3.18 (1H, s, Hi). 13C NMR (298 K, CDCl3, 100 
MHz) δ: 154.3, 145.2 (Ca), 138.5 (Cc), 123.8 (Cb), 119.4, 80.5 (Ci), 80.3, 
72.0 (Cd), 70.9 (Ce), 69.6 (Cf), 68.0 (Cg), 59.1 (Ch). HR-ESMS (CHCl3): 
m/z = 244.09 [M + Na]+ (calc. for C12H15NNaO3, 244.09), m/z = 
222.1110 [M + H]+ (calc. for C12H16NO3, 222.1125). Anal. calcd. for 
C12H15NO3: C, 65.14; H, 6.83; N, 6.33%; found: C, 65.20; H, 6.94; N, 
6.10%. IR: ν (cm-1) 3226, 2875, 1580, 1560, 1420, 1319, 1285, 1170, 
1106, 1056, 1018, 984, 873, 847, 700. 
 
3.8.2. Ligand 
3.8.2.1. Synthesis of 2,6-bis((5-(2-(2-methoxyethoxy)ethoxy) 
pyridin-3-yl)ethynyl)pyridine (L9) 
A solution of 8 (0.13 g, 0.59 mmol) in diisopropylamine (25 mL) and 
THF (25 mL) was de-gassed with N2 for 15 minutes, before addition of 
2,6-dibromopyridine (0.07 g, 0.3 mmol), [Pd(PPh3)2Cl2] (0.01 g, 0.02 
mmol) and copper(I) iodide (0.06 g, 0.03 mmol), and the reaction was 
stirred under N2 at room temperature for 2 days. Aqueous 0.1 M 
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EDTA/NH4OH solution (50 mL) and 3:1 CHCl3/IPA (50 mL) were added 
and the solution was stirred for 2 hours. After filtration through Celite 
and separation, the organic layer was washed with brine (2 x 100 mL), 
dried with Na2SO4 and the solvent was removed under vacuum. 
Purification of the residue through column chromatography on silica 
(DCM, then 1:3 acetone/DCM, then 1:2 acetone/DCM) gave a 
colourless solid (0.11 g, 210 mmol, 71%). 1H NMR (298 K, CDCl3, 400 
MHz) δ: 8.39 (2H, d, J = 1.4 Hz, Hc), 8.31 (2H, d, J = 2.8 Hz, He), 7.83 
(1H, t, J = 1.6 Hz, Ha), 7.60 (2H, d, J = 7.8 Hz, Hb), 7.51 (2H, dd, J = 2.7 
& 1.5 Hz, Hd), 4.21-4.19 (4H, m, Hf), 3.90-3.88 (4H, m, Hg), 3.74-3.72 
(4H, m, Hh), 3.60-3.58 (4H, m, Hi), 3.40 (6H, s, Hj). 13C NMR (298 K, 
CDCl3, 100 MHz) δ: 155.5, 145.5 (Cc), 143.9, 139.9 (Ce), 138.4 (Ca), 
128.1 (Cb), 124.1 (Cd), 120.0, 91.4, 86.4, 72.6 (Ci), 71.2 (Ch), 70.0 (Cf), 
69.2 (Cg), 58.9 (Cj). HR-ESMS: (CHCl3/MeOH) m/z = 540.2093 [M + Na]+ 
(calc. for C29H31N3NaO6, 540.2185), m/z = 518.2260 [M + H]+ (calc. for 
C29H32N3O6, 518.2286). Anal. calcd. for C29H31N3O6: C, 67.30; H, 6.04; 
N, 8.12%, found: C, 67.15; H, 6.00; N, 7.98%. IR: ν (cm-1) 3046, 2887, 
2208, 1582, 1554, 1459, 1441, 1418, 1330, 1311, 1250, 1220, 1195, 
1166, 1126, 1100, 1054, 1034, 1013, 981, 965, 912, 875, 821. 
 
3.8.3. Complex 
3.8.3.1. Synthesis of [Pd2(L9)4](BF4)4 
Combination of L9 (92 mg, 0.18 mmol) and [Pd(CH3CN)4](BF4)2 (39 mg, 
0.089 mmol) in acetonitrile (5 mL) gave instantaneous product 
formation. The product was precipitated with diethyl ether to give a tan 
solid (83 mg, 33 mmol, 75%). 1H NMR (298 K, CD3CN, 400 MHz) δ: 9.00 
(2H, d, J = 1.2 Hz, Hc), 8.91 (2H, d, J = 2.6 Hz, He), 7.91 (1H, t, J = 3.2 
Hz, Ha), 7.81 (2H, dd, J = 1.3 & 2.4 Hz, Hd), 7.72 (2H, d, J =7.8 Hz, Hb), 
4.35-4.33 (4H, m, Hf), 3.86-3.85 (4H, m, Hg), 3.67-3.65 (4H, m, Hh), 
3.53-3.51 (4H, m, Hi), 3.34 (6H, s, Hj). 13C NMR (298 K, CD3CN, 100 
MHz) δ: 158.0, 146.1 (Cc), 143.3, 140.1 (Ce), 138.7 (Ca), 129.6 (Cd), 
129.4 (Cb), 123.8, 94.2, 83.4, 72.5 (Ci), 71.2 (Ch), 70.5 (Cf), 69.7 (Cg), 
58.9 (Cj). HR-ESMS (CD3CN): m/z = 1228.3430 [M – (BF4)2]2+ (calc. for 
C116H124B2F8N12O24Pd2 1228.3518), m/z = 789.8970 [M – (BF4)3]3+ (calc. 
for C116H124BF4N12O24Pd2 789.8998), m/z = 570.6726 [M – (BF4)4]4+, 
(calc. for C116H124N12O24Pd2 570.6737). Anal. calcd. for 
C116H124B4F16N12O24 Pd2∙4H2O: C, 51.56; H, 4.92; N, 6.22%, found: C, 
51.60; H, 5.04; N, 6.20%. IR: ν (cm-1) 3083, 2882, 1583, 1559, 1437, 
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4.1. Self-sorting 
The examples of metallosupramolecular architectures given so far in 
this thesis are for the most part highly symmetrical assemblies 
consisting of one ligand type (excepting capping units) and one metal 
ion. With the principles underpinning the generation of these 
assemblies now well established, there is a shift towards introducing 
additional structural complexity through combining multiple ligand 
types into a single structure, and the end goal of these efforts is the 
formation of structures with varied polyfunctionality. 
Nonetheless, the combination of two different ligand types with 
palladium(II) ions using a symmetrical bonding approach has generally 
led to a variety of different outcomes rather than controlled formation of 
a heteroleptic structure. It can lead to narcissistic self-sorting, where 
two distinct homoleptic assemblies are formed, each containing a 
particular ligand type (Figure 4.1a).[100] A narcissistic result can also be 
obtained through treatment of one assembly with a stronger ligand, 
resulting in displacement of the weaker ligand and the formation of a 
new homoleptic assembly (Figure 4.1b).[101] Where heteroleptic 
assemblies have been accessed, it has typically been achieved without 
control, leading to an equilibrium mixture of different assemblies with 
multiple combinatorial permutations present in a statistical or at best 
amplified spread (Figure 4.1c).[100, 101b, 102] Far more difficult has been 
controllable combination of different ligands into the same structure, 
either through mixing all components (Figure 4.1d) or a displacement 






Figure 4.1 Cartoon depiction of various sorting types discussed in this 
chapter: a) mixing of two ligand types and a metal ion to give a mixture of 
narcissistic homoleptic assemblies, b) ligand displacement for conversion of 
one homoleptic assembly to another, c) mixing of two ligand types and a metal 
ion to give mixed assemblies, d) mixing of two ligand types and a metal ion to 
give a uniform heteroleptic assembly, and e) ligand displacement for 
conversion of a homoleptic assembly to a heteroleptic assembly. 
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4.2. Narcissistic self-sorting 
The Clever group[100, 103] and others[104] have demonstrated that 
‘banana-shaped’ dipyridyl ligands of sufficient length can be combined 
with palladium(II) to form catenated [(Pd2(L)4)(Pd2(L)4)]8+ dimers. They 
were able to demonstrate that a 4:4:4 combination of a short ligand, a 
long ligand, and palladium(II) in CD3CN gave narcissistic self-sorting 
into a [Pd2(Lshort)4]4+ cage and a [(Pd2(Llong)4)(Pd2(Llong)4)]8+ dimer, a 
result achievable no matter the order of combination, due to the 
incompatibility of the two ligands (Figure 4.2).[100] 
 
Figure 4.2 Clever and coworker’s combination of a short ligand (Lshort), a long 
ligand (Llong), and palladium(II) gives narcissistic self-sorting into two 
homoleptic assemblies: a [Pd2(Lshort)4]4+ monomeric cage (MMFF model, 
carbons in red) and a [(Pd2(Llong)4)(Pd2(Llong)4)]8+ catenated dimer (X-ray 
crystal structure, carbons in grey or black). Hydrogen atoms, counterions and 
N-alkyl substituents omitted for clarity.[100] 
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Homoleptic assemblies have also been accessed in multiple ligand 
systems through the competitive exchange of one ligand in an assembly 
by an introduced ligand of higher donor strength. This has been 
demonstrated by Mukherjee and coworkers where a pyridine-based 
ligand introduced to a pyrimidine-based [Pd24(L)24]48+ architecture 
resulted in displacement and the formation of a [Pd12(L)12]24+ cage,[101a] 
and by Hardie and coworkers with a [Pd6(L)8]12+ system.[101b] 
 
4.3. Heteroleptic systems with varied ligand composition 
The majority of ‘naked’ heteroleptic palladium(II) architectures with 
mixed ligand systems have been achieved without control. The research 
groups of Clever,[100, 103a] Hardie,[101b] Yoshizawa,[102a] and Hooley[102a] 
have all reported statistical mixtures of ligand distribution in 
palladium(II) cages. Hooley and coworkers, however, have attained 
amplified mixtures. This was attained through endo-functionalisation of 
the phenyl core of their dipyridyl ligands with either a small group (e.g. 
hydrogen) or a bulky group (e.g. trifluoromethylamide) (Figure 4.3).[102b]  
 
Figure 4.3 Combination by Hooley and coworkers of ligands with either small 
(hydrogen) or large (trifluoromethylamide) endohedral substituents resulted in 
a mixture of a homoleptic [Pd2(Lsmall)4]4+ and heteroleptic [Pd2(Lsmall)3(Llarge)]4+ 
cages (MMFF models of products, hydrogen atoms omitted).[102b]  
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In comparison to combinations of ligands with different small 
endohedral functionality, which had resulted in all six possible 
permutations of ligand mixing, only two assemblies were seen via 1H 
NMR spectroscopy and mass spectrometry upon combination of a 3:1:2 
ratio of Lsmall, Llarge, and palladium(II): a homoleptic [Pd2(Lsmall)4]4+ cage 
and a heteroleptic [Pd2(Lsmall)3(Llarge)]4+ assembly, as the incorporation of 
more than one of the larger ligand within a cage was disfavoured due to 
steric bulk and electrostatic repulsion within the cavity. Nonetheless, 
conversion was not complete, and the bulky endohedral substituent 
prevented guest binding within the cage. 
 
4.4. Controlled formation of heteroleptic palladium(II) assemblies 
There have been some instances of controlled formation of heteroleptic 
palladium(II) assemblies. Yoshizawa and coworkers utilised two 
dianthracenyl-paneled ‘banana-shaped’ ligands with either a phenyl 
(Lshort) or napthylene (Llong) core that could be combined individually 
with Pd(II) to form their respective [Pd2(L)4]4+ cages (Figure 4.4 top), both 
of which had the capacity to bind C60.[102a] Combining the isolated cages 
in DMSO and heating at 100 °C brought about a scrambling of the 
cages into a mixture which mass spectrometry showed contained all 
possible permutations: [Pd2(Lshort)4]4+, [Pd2(Lshort)3(Llong)]4+, 
[Pd2(Lshort)2(Llong)2]4+,  [Pd2(Lshort)(Llong)3]4+, and [Pd2(Llong)4]4+.  
Heating the mixture at 80 °C in CD3CN in the presence of C60 brought 
about coalescence of the peaks into a single set of signals, and mass 
spectrometry identified only a single species: [(C60)Pd2(Lshort)2(Llong)2]4+        
(model of adduct in Figure 4.4 bottom). Forcefield calculations 
suggested that the cis configuration was significantly lower in energy 
than the trans. As both the homoleptic cages bound C60, this funneling 
into the cis-heteroleptic host-guest adduct can only be explained by its 
relative thermodynamic favourability. The combination of two ligands of 
different lengths, as the cis-isomer, appears to produce a cavity size 
optimal for guest encapsulation, with sufficiently small distortion of 
bond angles in the ligands and around the metal ion. 
Another approach to heteroleptic palladium(II) architectures has also 
taken advantage of differing ligand sizes. Fujita and coworkers found 
with ditopic dipyridyl-based ligands that the result obtained from a 
1:1:1 combination of Lshort, Llong, and Pd(II) ions was dependent on the 
homothetic ratio between the lengths between nitrogen donor atoms of 




Figure 4.4 The 4:2 combination by Yoshizawa and coworkers of either a short 
ligand (Lshort) or a long ligand (Llong) with palladium(II) gives the respective 
[Pd2(L)4]4+ homoleptic cages (X-ray crystal structures). The cages can be 
combined in a DMSO solution and scrambled through heating. However, 
heating in the presence of C60 in CD3CN brings about controlled formation of a 
cis-[(C60)Pd2(Lshort)2(Llong)2]4+ host-guest adduct (MMFF). Hydrogen atoms, 
solubilising chains, counterions and solvent molecules omitted for clarity.[102a] 
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Where this ratio of long divided by short was less than 2, a statistical 
mixture of assemblies was formed with the general formula of 
[Pd12(Lshort)m(Llong)24-m]24+. However, at a threshold ratio of around two, a 
clean heteroleptic [Pd12(Lshort)12(Llong)12]24+ assembly was formed in 
solution as both a regular cantellated tetrahedron with Td symmetry 
and its C3v-symmetric pseudoisomer, and it was the pseudoisomer that 
was successfully crystallised (Figure 4.5 bottom).  
 
Figure 4.5 Scheme showing the formation by Fujita and coworkers of a 
[Pd12(Lshort)12(Llong)12]24+ heteroleptic cage. A clean heteroleptic assembly forms 
in preference to a statistical mixture when the homothetic ratio of the length 
between the donor atoms on the ditopic dipyridyl ligands (long/short) exceeds 
two. A mixture between a regular cantellated tetrahedron and its 
pseudoisomer are formed in solution, and the psuedoisomer was successfully 
crystallised and is pictured here, with hydrogen atoms and counterions 
omitted for clarity.[105]  
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4.5. A proposed steric approach to controlled formation of 
heteroleptic architectures 
While the approaches to ordered heteroleptic palladium(II) architectures 
adopted by Yoshizawa and coworkers and Fujita and coworkers are 
adroit, both are limited in their potential applications. In the first case, 
the assembly is guest-dependent, and hence the cage loses subsequent 
alternative host-guest capability. In the second, a large cavity is formed 
which lowers guest specificity. We envisaged that a method to 
controllably form mixed ligand [Pd2(L)4]4+ cages of defined cavity size 
would be highly useful in furthering structural complexity without 
sacrifice of utility. In the investigation of a sterically-driven technique to 
accomplish this, the tripyridyl ligands L6 – L9 (and their respective 
cages) previously described in this thesis (see Chapters 2 and 3) 
appeared very well suited to the task (Figure 4.6). The 2-amino-
substituted ligand L6 was of particular interest: it had already been 
proven to be a stronger donor than L7 or L8, and had additional steric 
bulk and its complexes were thus imbued with kinetic stability. It was 
postulated that these properties might allow the formation of a 
heteroleptic cage in conjunction with L8. The 3-substituted ligands L7 
(amino) and L9 (diglyme, PEG) were useful models for ligands with 
increased donor strength without the steric component near the 
coordination sphere and thus important for control experiments. A 
series of 1H NMR spectroscopy competition experiments (298 K, d6-
DMSO, 400 & 500 MHz) were therefore carried out using these ligands 
and their cages to probe this hypothesis (Figure 4.7).[106] 
 
Figure 4.6 Ligands utilised in self-sorting experiments targeting controlled 




Figure 4.7 Scheme showing competition experiments carried out: a) 
[Pd2(L8)4]4+ + L7, b) L8 + L7 + Pd(II), c) [Pd2(L8)4]4+ + [Pd2(L7)4]4+, d) [Pd2(L8)4]4+ 
+ L9, e) [Pd2(L8)4]4+ + L6, f) [Pd2(L6)2(L8)2]4+ + L6, g) [Pd2(L6)2(L8)2]4+ + L9, h) L8 
+ L6 + Pd(II), i) [Pd2(L8)4]4+ + [Pd2(L6)4]4+. All experiments carried out in d6-
DMSO and monitored by 1H NMR spectroscopy. 
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4.6. Combination of weaker and stronger ligands with no steric 
considerations 
Initial experiments sought to investigate whether the introduction of a 
stronger tripyridyl ligand to a preformed cage would, in the absence of 
steric considerations, lead to the expected displacement of the weaker 
ligand. A solution of preformed [Pd2(L8)4]4+ was treated with the more 
strongly donating 3-amino ligand L7 (Figure 4.7a) in steadily increasing 
equivalencies (1 – 4.2 eq., Figure 4.8a – f), resulting in displacement of 
L8 and complete conversion to [Pd2(L7(4]4+ at 4.2 equivalents. Similar 
results have been reported by Mukherjee and coworkers[101a] and Hardie 
and coworkers in related palladium(II) systems.[101b] 
 
Figure 4.8 Stacked partial 1H NMR spectra (298 K, 400 MHz, d6-DMSO) for a) 
[Pd2(L8)4](BF4)4, b) [Pd2(L8)4](BF4)4 + 1 eq. L7, c) [Pd2(L8)4](BF4)4 + 2 eq. L7, d) 
[Pd2(L8)4](BF4)4 + 3 eq. L7, e) [Pd2(L8)4](BF4)4 + 4 eq. L7, f) [Pd2(L8)4](BF4)4 + 4.2 
eq. L7, g) [Pd2(L7)4](BF4)4, h) L7, i) L8, j) 2:2:2 equivalents of L8, L7, 
[Pd(CH3CN)4](BF4)4, k) [Pd2(L8)4](BF4)4 + [Pd2(L7)4](BF4)4. 
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In contrast, when L7, L8 and palladium(II) are combined in a 2:2:2 
ratio and there is no stoichiometric excess of ligands to metal ion 
(Figure 4.7b), a statistical mixture of assemblies is evident in both the 
1H NMR spectrum (Figure 4.8j) and the mass spectrum of the solution 
(Figure 4.9), where the tetracationic peaks pertaining to [Pd2(L8)4]4+, 
[Pd2(L8)3(L7)]4+, [Pd2(L8)2(L7)2]4+, [Pd2(L8)(L7)3]4+ and [Pd2(L7)4]4+, in 
addition to [Pd2(L8)4 + H2O]4+, are all clearly visible.  
 
Figure 4.9 Partial HR-ESI mass spectrum (DMSO/CH3CN) of equilibrium 
mixture of 2 eq. L7, 2 eq. L8 and 2 eq. [Pd(CH3CN)4](BF4)2 in d6-DMSO. 
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While peak height in mass spectrometry cannot be quantitatively 
equated with actual compound ratio, the relative intensities of the 
peaks are a good fit for the expected 1:4:6:4:1 ratio for a statistical 
distribution. A similar result was observed in the 1H NMR spectrum of a 
1:1 combination of preformed [Pd2(L7)4]4+ and [Pd2(L8)4]4+ where over 
time the two homoleptic cages scrambled, providing an 1H NMR 
spectrum that was essentially identical to that observed for the 
combination of free ligands and palladium(II) (Figure 4.7c, Figure 4.8k). 
It also appeared that the relative difference in donor strength was 
important in ligand displacement. Like L7, L9 is also substituted in the 
3-position with a mesomerically electron donating group, but in this 
case with an O-alkyl group instead of a primary amine which is more 
inductively electron withdrawing.  Accordingly, treatment of a solution 
of preformed [Pd2(L8)4]4+ cage with four equivalents of L9 did not result 
in complete displacement of L8 and formation of [Pd2(L9)4]4+. Instead 
the 1H NMR spectrum revealed an untidy mixture of products (Figure 
4.7d, Figure 4.10), with the mass spectrum of the reaction mixture 
confirming the presence of multiple species, even after 10 days. 
Presumably, the difference in donor strength between L8 and L9 is not 
sufficient to overcome the entropic favourability of a mixture of 
products.  
 
Figure 4.10 Partial 1H NMR spectra (298 K, 500 MHz, d6-DMSO) for a) 
[Pd2(L8)4](BF4)4, b) [Pd2(L8)4](BF4)4 + 4 eq. L9 after 10 days, and c) 
[Pd2(L9)4](BF4)4. 
 
4.7. Treatment of a preformed cage with a strongly donating and 
sterically demanding ligand 
Attention was now turned to whether the 2-amino substituted ligand 
L6, which was an even stronger donor but also possessed relevant 
steric bulk, would behave differently to L7 or L9. This indeed proved to 
be the case: the introduction of increasing equivalencies (1 – 4 eq.) of L6 
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to a solution of [Pd2(L8)4]4+ in d6-DMSO resulted in the formation of a 
new species (Figure 4.7e Figure 4.11a – e). While more than two 
equivalents were required to drive complete conversion to the new 
species, the addition of more (three or four eq.) did not prompt 
formation of [Pd2(L6)4]4+ and all that was evident in the 1H NMR 
spectrum was the new species, and the two free ligands, L6 and L8. 
 
Figure 4.11 Partial 1H NMR spectra (298 K, 400 MHz, d6-DMSO) of a) 
[Pd2(L8)4]4+, b) [Pd2(L8)4]4+  + 1 eq. L6, c) [Pd2(L8)4]4+ + 2 eq. L6, (d) [Pd2(L8)4]4+ 
+ 3 eq. L6, e) [Pd2(L8)4]4+ + 4 eq. L6, f) isolated [Pd2(L6)2(L8)2]4+, g) L8, h) L6, i) 
[Pd2(L6)4](BF4)4. Annotations in black refer to L8, annotations in green to L6. 
Peaks pertaining to both ligands were identifiable within this species. 
2D 1H NMR DOSY spectroscopy indicated that the resonances due to 
both ligands within the species were diffusing at the same rate (D = 
1.01 x 10-10 m2 s-1) and were consistent with the formation of a 
[Pd2(L)4]4+ cage,[58b, 84] and the integration of the peak areas suggested a 
2:2 ratio of the two ligands within the species. Additional evidence that 
the two ligands were in the same discrete assembly was provided via 
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the 2D ROESY NMR spectrum of the reaction mixture (Figure 4.12a). 
Through-space ROE couplings were clearly evident between the two 
endohedral Hc protons of L6 and L8 and between the amino group of 
L6 and the exohedral proton Hf of L8. Mass spectral analysis of the 
reaction mixture confirmed the 2:2 stoichiometry of the assembly: while 
the spectrum was noisy, only three peaks could be identified, those of 
free L6, free L8 and [Pd2(L6)2(L8)2]4+ (m/z = 379.5472, calc. 379.5681, 
Figure 4.12b). 
 
Figure 4.12 a) Partial 2D ROESY 1H NMR spectrum (298K, 500 MHz, d6-
DMSO) of the reaction mixture obtained from the combination of 
[Pd2(L8)4](BF4)4 with 4 eq. of L6, annotations in black refer to L8, annotations 
in green to L6, b) Partial HR-ESI Mass spectrum (DMSO/CH3CN) of 
[Pd2(L6)2(L8)2](BF4)4, taken from the reaction mixture of [Pd2(L8)4](BF4)4 with 4 
eq. of L6. 
The product could be isolated through sequential precipitation with 
ethyl acetate, precipitating first L6, and then, upon addition of 
additional ethyl acetate, the heteroleptic cage (72%). However, it was 
still unclear whether the cage had formed as the cis or trans isomer, 
and additionally a deep understanding of the formation process was yet 
to be achieved. Consequently, the DFT optimised energies of the 
relevant structures (gas phase, B3LYP with the LANL2DZ basis set for 
palladium atoms and the 6-31G(d) basis set for all other atoms, 
calculated without methylene alcohol substituents for computational 
simplicity) were obtained, and Hess’ law was employed to determine 
relative energies of formation (Figure 4.13).**  
                                       
** The calculations were carried out by Jonathan Barnsley, working in the research 




Figure 4.13 DFT calculated optimised structures with relative ΔE of formation 
for [Pd2(L8)4]4+, trans-[Pd2(L6)2(L8)2]4+, cis-[Pd2(L6)2(L8)2]4+ and [Pd2(L6)4]4+ (gas 
phase, B3LYP with the LANL2DZ basis set for palladium atoms and the 6-
31G(d) basis set for all other atoms, methylene alcohol substituents were 
omitted for computational simplicity). Non-amino hydrogen atoms omitted for 
clarity, carbon atoms of L8 shown in yellow, carbon atoms of L6 shown in 
green.   
 The calculations indicated that the cis isomer was lower in energy than 
both the [Pd2(L8)4]4+ cage (-19.3 kJ mol-1) and the trans isomer (-27.2 
kJ mol-1), and thus should form as the thermodynamic product. This 
energetic preference can be rationalised through the capacity of the 
amino groups in this configuration to hydrogen bond to one another, 
whereas they would be too distant from one another in a trans 
orientation. The chemical shifts of the exohedral ortho proton of L8 (Hf) 
and the amino group of L6 in the 1H NMR spectra of the relevant cages 
corroborates this assessment (Table 4.1). The large shift upon 
complexation for [Pd2(L6)4]4+ in comparison to [Pd2(L7)4]4+ (1.56 ppm 
compared to 0.81 ppm) has already been noted and attributed to 
interligand hydrogen bonding (Chapter 2).[84] The mixed ligand system 
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had a change in chemical shift of the 2-amino peak of 2.04 ppm upon 
complexation, highly suggestive of enhanced hydrogen bonding. 
Likewise, the chemical shift of the ortho proton of the other ligand in the 
mixed system was significantly downfield-shifted from that of the free 
ligand (Δδ = 0.42 ppm, compared with 0.23 ppm for [Pd2(L8)]4+) again 
suggestive of a hydrogen bonding interaction with the amino group.  
 
Table 4.1 1H NMR chemical shifts (298 K, d6-DMSO, 400 MHz), showing Δδ 
(ppm, cage signal minus ligand signal) for the exohedral ortho proton on L8 or 
L7, and the amino protons of L6 or L7. 
Compound 
1H NMR Δδ (ppm) 
HORTHO HNH 
[Pd2(L8)4]4+ 0.23 ― 
[Pd2(L6)2(L8)2]4+ 0.42 2.04 
[Pd2(L6)4]4+ ― 1.56 
[Pd2(L7)4]4+ 0.37 0.81 
 
Interestingly, the tetra-substituted product, [Pd2(L6)4]4+, was lower in 
energy again, by a large -87.5 kJ mol-1 from [Pd2(L8)4]4+. Thus, if wholly 
under thermodynamic control, the substitution should not have 
stopped at the heteroleptic cage. It was therefore hypothesised that the 
cis-heteroleptic cage formed due to thermodynamic favourability, but 
subsequent substitution was kinetically blocked by the bulk of the 
amino substituents. To test this, additional competition experiments 
were carried out on the isolated [Pd2(L6)2(L8)2](BF4)4 cage. 
 
4.8. Ligand displacement from the cis-heteroleptic cage 
To test whether indeed there was a kinetic impediment to further 
substitution of the mixed cage by L6, two ancillary experiments were 
undertaken. Firstly, a solution of [Pd2(L6)2(L8)2](BF4)4 in d6-DMSO was 
treated with two equivalents of L6 (Figure 4.7e,). After 40 days at room 
temperature no new species were evident (Figure 4.14b). Similarly, after 
heating at 50 °C for seven days (Figure 4.14c) resulted merely in a slow 






Figure 4.14 Partial 1H NMR spectra (298 K, d6-DMSO, 400 MHz) for a) 
[Pd2(L6)2(L8)2](BF4)4, b) [Pd2(L6)2(L8)2](BF4)4 + 2 eq. L6 after 40 days at room 
temperature, and c) [Pd2(L6)2(L8)2](BF4)4 + 2 eq. L6 after 7 days at 50 °C. 
 
In contrast, treating a solution of [Pd2(L6)2(L8)2](BF4)4 with L9 (1 – 3 
equivalents, Figure 4.7f) led to a different result. Over a ten day period, 
L8 was incompletely displaced from the complex, resulting in the 
presence of five distinct species in the 1H NMR spectrum: the free 
ligands L8  and L9, remaining [Pd2(L6)2(L8)2]4+, the analogous double-
ligand system [Pd2(L6)2(L9)2]4+ (confirmed through independent 
preparation, vide infra), and one other species which, as might be 
expected, was the triple ligand system [Pd2(L6)2(L8)(L9)]4+ (Figure 4.15c 
– g), as confirmed through mass spectrometry of the reaction mixture, 
which in addition to sundry other peaks pertaining to the double ligand 
cages and fragments also proved the presence of the tetracationic ion 
[Pd2(L6)2(L8)(L9)]4+ (Figure 4.15h m/z = 431.0966, calc. 431.0978). In 
combination with the computational data, these two experiments 
indicate that the mixed ligand system is a kinetic intermediate and that 
there is a significant barrier to the substitution of the cage with more 
than two L6 ligands. It seems likely that this barrier is sourced in the 
steric bulk and lone pair-lone pair repulsions between clashing amino 
groups on both cage and free ligand (Figure 4.16a). These unfavourable 
interactions are not present in the case of displacement by the PEG-
substituted ligand, which may in fact be aided in its approach through 
hydrogen bonding between the amino group and the exohedral ortho 




Figure 4.15 Possible isomers in the triple ligand system [Pd2(L6)2(L8)(L9)]4+ 
with a simplified labelling system; a) cis isomer, b) trans isomer; stacked 
partial 1H NMR spectra (298 K, d6-DMSO, 500 MHz) of the reaction mixture 
from formation of c)  [Pd2(L6)2(L8)2](BF4)4, d) [Pd2(L6)2(L8)2](BF4)4 treated with 1 
eq. L9, e) [Pd2(L6)2(L8)2](BF4)4 treated with 2 eq. L9, f) [Pd2(L6)2(L8)2](BF4)4 
treated with 3 eq. L9, g) reaction mixture from formation of  
[Pd2(L6)2(L9)2](BF4)4, and h) partial HR-ESI Mass spectrum (DMSO/CH3CN) of 
equilibrium mixture of 1 eq. [Pd2(L6)2(L8)2](BF4)4  with 2 eq. L9 in d6-DMSO 





Figure 4.16 Depiction of the nucleophilic approach towards [Pd2(L6)2(L8)2]4+ 
by a) L6 and b) L9. Green arrows depict positive electronic interactions, red 
arrows depict repulsive electronic interactions and steric clash.  
The generation of the triple ligand cage also allowed spectroscopic 
confirmation of the cis geometry of the complex. Envisaging the three 
components of the reaction mixture (double ligand systems 
[Pd2(L6)2(L8)2]4+ and [Pd2(L6)2(L9)2]4+, and the triple ligand system 
[Pd2(L6)2(L8)(L9)]4+) as both the trans and cis isomer (Figure 4.17) 
shows that while both isomers of the double ligand systems are highly 
symmetric and thus hard to differentiate via NMR spectroscopies, this 
symmetry is broken in the triple ligand system. Comparison of the 
environments around the palladium(II) metal ion for the two isomers 
(Figure 4.15a and b) shows that the trans isomer possesses higher 
symmetry, with both L6 ligands within the complex having equivalent 
environments, while within the cis isomer they are non-equivalent. 
Inspection of the 1H NMR spectra of the reaction mixtures showed that 
there were four distinct NH2 environments, two coming from the double 
ligand systems [Pd2(L6)2(L8)2]4+ and [Pd2(L6)2(L9)2]4+. There were an 
additional two NH2 peaks (annotated NH2 and N’H2, see Figure 4.15a for 
the simplified labelling system used) intermediate in chemical shift from 




Figure 4.17 Scheme showing the three products from the combination of 
[Pd2(L6)2(L8)2]4+ and L9: [Pd2(L6)2(L8)2]4+, [Pd2(L6)2(L8)(L9)]4+ and 
[Pd2(L6)2(L9)2]4+, as either the trans or cis isomer.  
Inspection of the 2D ROESY 1H NMR spectrum of the reaction mixture 
showed that they were part of the same through-space ROE coupling 
system: the NH2 peak was coupled to Hb (the exohedral ortho proton of 
L8), while the N’H2 peak was coupled to Hd (the exohedral ortho proton 
of L9), with Hb and Hd in turn coupled through space to each other 
(Figure 4.18). The presence of two amino environments within the one 
species can only be adequately explained through the species existing 
in the cis isomer. Likewise, the coupling between Hb and Hd suggests 
that they lie in a cis arrangement with one another, as does the 
through-space coupling between the endohedral protons Ha from L8 




Figure 4.18 Partial 2D ROESY 1H NMR spectrum (298 K, d6-DMSO, 500 MHz, 
mixing time 400 ms) of the reaction mixture obtained from combination of 1 
eq. [Pd2(L6)2(L8)2]4+ with 3 eq. L9. Through space couplings identified 
pertaining to [Pd2(L6)2(L8)2]4+ or [Pd2(L6)2(L9)2]4+ are shown in green, those 
pertaining to  [Pd2(L6)2(L8)(L9)]4+ in red. 
 
4.9. The importance of preorganisation in the controlled 
formation of the heteroleptic cages 
The formation of mixed cages had been achieved through the treatment 
of a preformed cage with the L6 ligand. Two experiments were carried 
out to investigate whether the same structures could be obtained 
without the preorganisation thus afforded (Figure 4.7h and i, Figure 
4.19). Firstly, a 2:2:2 combination of L6, L8 and palladium(II) gave a 
reaction mixture that contained the cis-heteroleptic cage in addition to 
other mixed species, with no peaks belonging to homoleptic species 
(Figure 4.19b). In a similar fashion, combining the preformed cages 
[Pd2(L6)4]4+ and [Pd2(L8)4]4+ resulted in a slow mixing and gradual (if not 
complete) disappearance of the peaks pertaining to the homoleptic 
structures (Figure 4.19c). Heating in both cases over prolonged periods 
at 50 °C did not lead to coalescence into the cis-product. These results 
were interesting for two reasons. Firstly, they confirmed that the 
displacement strategy was necessary for clean formation of the cis-
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heteroleptic product. Secondly, it was of interest that in mixing the 
preformed cages, the highly thermodynamically favourable [Pd2(L6)44+ 
cage disappeared. This is attributable to low level ligand exchange 
facilitated by the coordinating DMSO solvent, combined with the steric 
impediment to reassociation of L6 to cages sterically protected by 
amino groups, and underscores the importance of the kinetic element 
in this system. 
 
Figure 4.19 Partial 1H NMR stacked spectra (298K, 400 MHz, d6-DMSO) of a) 
[Pd2(L8)4](BF4)4, b) reaction mixture showing 2:2:2 combination of L6, L8 and 
[Pd(CH3CN)4](BF4)2, c) reaction mixture showing 1:1 combination of 
[Pd2(L6)4](BF4)4 and [Pd2(L8)4](BF4)4, d) [Pd2(L6)2(L8)2](BF4), and e) 
[Pd2(L6)4](BF4)4. 
 
4.10. A general method for cis-heteroleptic palladium(II) cages 
With a deeper understanding of the process of formation of the cis-
heteroleptic cages now obtained, an exploration of whether the method 
was general was undertaken. Three preformed homoleptic cages were 
treated with L6 to evaluate whether cis-[Pd2(La)2(Lb)2]4+ cages were 
consistently formed. The ligands comprising these cages were L9, the 
PEG-substituted ligand, L1-Fc, the parent ligand with a triazole-linked 
ferrocene unit appended exohedrally  to the core pyridine, and L1-H, a 
ligand with a phenyl core instead of pyridine which thus had an 




Figure 4.20 a) Ligands used in preformed [Pd2(L)4](BF4)4 cages for treatment 
in displacement reactions with L6, b) partial HR ESI Mass spectrum 
(DMSO/CH3CN) of [Pd2(L6)2(L1-H)2](BF4)4. Sample obtained from combination 
of 4 eq. L1-H with 2 eq. [Pd(CH3CN)4](BF4)2, then addition of 3.1 eq. L6, all in 




The treatment of these cages with L6 brought about the same result as 
with [Pd2(L8)4](BF4)4; the formation of new species which mass spectral 
analysis revealed to be a 2:2:2 ratio of L6 with the respective ligand and 
palladium(II) ions (for example, with L1-H: [Pd2(L6)2(L1-H)2]4+ m/z = 
364.0660, calc. 364.0659; [Pd2(L6)2(L1-H)2 + H]3+ m/z = 485.0859, calc.  
485.0855; [Pd2(L6)2(L1-H)2(BF4)]3+ m/z = 514.4244, calc. 514.4227, 
Figure 4.20b). Inspection of the 1H NMR spectrum revealed the 
presence of L6, the relevant other ligand, and a new, distinct species, 
with integration confirming the 2:2 ratio between component ligands 
(Figure 4.21), with all components diffusing at a unified rate (D: 
[Pd2(L6)2(L9)2]4+ 1.16 x 10-10 m2 s-1; [Pd2(L6)2(L1-Fc)2]4+ 0.87 x 10-10 m2 
s-1; [Pd2(L6)2(L1-H)2]4+ 0.88 x 10-10 m2 s-1). Lastly, 2D ROESY 1H NMR 
spectroscopy revealed the same type of through-space coupling between 
the protons of neighbouring ligands as had previously been observed, 
between the amino group of L6 and the exohedral ortho proton of the 
other ligand, as well as between endohedral protons (Figure 4.22). Two 
of the cages ([Pd2(L6)2(L1-Fc)2]4+ and [Pd2(L6)2(L1-H)2]4+) were not 
isolated, and were analysed in situ, while the third ([Pd2(L6)2(L9)2]4+ was 
isolated again through selective precipitation by exploiting the solubility 
differences between the components in solution. 
 
4.11. Conclusions and future directions 
Methodologies for the predictable and controllable formation of guest-
free heteroleptic palladium(II) cages are very rare. It was demonstrated 
here that a ligand displacement approach where weaker ligands are 
displaced from a [Pd2(L)4]4+ architecture by a stronger 2-amino 
substituted ligand results in the controlled formation of a cis-
heteroleptic cage. Calculations and competition experiments suggest 
that this cage is a kinetically stable intermediate and that the steric 
bulk and lone pair of the L6 ligand within the cage system act as a 
barrier to additional substitution. The method is general, and a small 
family of cages with varied exohedral functionalities was created. In one 
case, a cage with a lower symmetry cavity (two phenyl hydrogen atoms 
and two pyridyl nitrogen atoms facing into the cavity) was formed. This 
serves as proof of concept that lower symmetry cages can be formed, 
and the next stage is to apply this method towards applications such as 





Figure 4.21 Partial stacked 1H NMR spectra (298 K, d6-DMSO, 500 MHz) of a) 
[Pd2(L9)4](BF4)4, b) reaction mixture showing free L6 and L9 and 
[Pd2(L6)2(L9)2](BF4)4, c) L6, d) [Pd2(L1-Fc)4](BF4)4, e) reaction mixture showing 
free L6 and L1-Fc and [Pd2(L6)2(L1-Fc)2](BF4)4, f) L6, g) [Pd2(L1-H)4](BF4)4, h) 
reaction mixture showing free L6 and L1-H and [Pd2(L6)2(L1-H)2](BF4)4, and i) 
L6. In all cases dotted lines going to the central spectrum denote (in black) 





Figure 4.22 Partial 2D ROESY 1H NMR spectra (298K, 500 MHz, d6-DMSO) of 
the reaction mixture obtained from combination of 2.5 eq. L6 with a) 
[Pd2(L9)4](BF4)4 b) [Pd2(1-Fc)4](BF4)4,  or c) [Pd2(1-H)4](BF4)4 (all spectra from 
compounds made and analysed in situ). Labels in green denote those peaks in 
the heteroleptic cage pertaining to L6, labels in black denote the relevant 
other ligand. 
There are many potential applications including biological targeting and 
the controlled assembly of photophysically compatible (i.e. donor and 
acceptor) groups that can benefit from the controlled combination of 
different functionalities. However, the ability to tune the cavity 
environment is also possibly of high utility with regards to catalysis, as 
different catalytic components can be brought into predefined positions. 
This, in combination with the ability to reversibly switch between a full 
cage and macrocycle (described in Chapter 3) gives rise to the promise 
of high control over catalytic cycles. Equally useful in this regard would 
be the capacity of a cage to interact with different guests in different 
parts of the assembly and thus introduce sequential catalytic 








Note: Within the discussion, the peaks in the NMR spectra belonging to 
mixed cages have been generally labelled in equivalence with those of 
their respective free ligands, for the sake of simplicity. In the 
experimental section, a proton labelling system which spans both 
component ligands in each of the mixed cages has been employed. 
  
4.12.1. Complex synthesis 
4.12.1.1. cis-[Pd2(L6)2(L8)2](BF4)4 
 
A solution of [Pd2(L8)4](BF4)4 (49 mg, 0.027 mmol) and L6 (20 mg, 0.059 
mmol) in d6-DMSO (1.5 mL) was left to stand for two days. After 
addition of DMSO (0.75 mL) and ethyl acetate (8 mL) with stirring the 
resultant suspension was centrifuged (13,000 rpm, 10 minutes) and the 
pellet discarded. The supernatant was added to ethyl acetate (16 mL), 
and the resultant suspension centrifuged (13,000 rpm, 10 minutes). 
The supernatant was discarded, and the pellet resuspended in CHCl3 (6 
mL) and left to stand overnight. The solid was collected by filtration and 
dried under vacuum to give the product as an off white powder (36 mg, 
0.019 mmol, 72%). 1H NMR (298 K d6-DMSO, 500 MHz) δ: 9.68 (4H, s, 
Hc), 9.38 (4H, s, Hi), 9.24 (4H, d, J = 5.7 Hz, Hf), 8.59 (8H, br, HNH), 8.41 
(4H, J = 8.0 Hz, Hd), 7.89 (4H, t, J = 6.9 Hz, He), 7.78 – 7.76 (8H, m, Hb 
& Hj), 7.56 (4H, s, Hh), 6.6 (4H, d, J = 8.7 Hz, Hk), 5.64 (2H, t, J = 5.3 
Hz, HOH), 5.55 (2H, t, J = 5.5 Hz, HOH2a), 4.59 (4H, d, J = 5.0 Hz, Ha), 
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4.52 (4H, d, J = 5.1 Hz, Hg). 13C NMR (298 K d6-DMSO, 125 MHz) δ: 
159.0, 154.0 153.4, 152.9 (Cc), 151.3 (Cf), 149.4 (Ci), 143.8 (Cd), 142.4, 
142.3, 141.7, 127.2 (Ce), 126.4, 124.9 (Ch), 121.5, 112.3 (Ck), 107.9, 
93.6, 90.6, 84.9, 83.5, 60.7, 60.6. HR ESI-MS (DMSO/CH3CN) from 
reaction mixture m/z = 379.5472 [M – 4BF4]+ (calc. for C80H56N16O4Pd2, 
379.5681), from isolated product m/z = 312.1232 [L8 + H]+ (calc. for 
C20H14N3O, 312.1131), 342.1452 [L6]+ (calc. for C20H16N5O, 342.1349), 
372.0782 [Pd2(L8)3(L6)]4+ (calc. for C80H54N14O4Pd2, 372.0634), 
379.5847 [M – 4BF4]+ (calc. for C80H56N16O4Pd2, 379.5681), 387.0883 
[Pd2(L8)(L6)3]4+ (calc. for C80H58N18O4Pd2, 387.0743), 399.0824 
[[Pd2(L6)4 + H2O]4+ (calc. for C80H62N20O5Pd2, 399.0824), 447.0395 
[Pd2(L6)2 – 2H]2+ (calc. for C40H28N10O2Pd2, 447.0238), 495.7667 
[Pd2(L8)3(L6) – H]3+ (calc. for C80H53N14O4Pd2, 495.7488), 505.7740 [M – 
H – 4 BF4]3+ (calc. for C80H55N16O4Pd2, 505.7560), 515.7754 
[Pd2(L6)(L8)3 – H]3+ (calc. for C80H57N18O4Pd2, 515.7633), 531.7517 
[Pd2(L6)4 + Cl]3+ (calc. for C80H60NClN2O4Pd2, 531.7517), 587.5862 
[Pd2(L8y)2(L6) – 2H]2+ (calc. for C60H39N11O3Pd2, 587.5662), 602.5977 
[Pd2(L8)(L6)2 – 2H]2+ (calc. for C60H41N13O3Pd2, 602.5771, 758.1554 [M – 
2H – 4BF4]2+ (calc for C80H54N16O4Pd2, 758.1304). IR: ν (cm-1) 3367, 
3212, 3085, 2222, 2030, 1651, 1546, 1054, 1027, 985. Anal. calcd. for 
C80H56B4F16N16O4Pd2∙2DMSO∙5H2O: C, 47.78; H, 3.72; N, 10.61%; 




To a solution of [Pd2(L9)4](BF4)4[96] (90 mg, 0.035 mmol) in d6-DMSO 
(1.50 mL) was added L6 (24 mg, 0.070 mmol). After one day, 
133 
 
[Pd(CH3CN)4](BF4)4 (16 mg, 0.035 mmol) was added, and then L6 (12 
mg, 0.035 mmol). After one more day, the solution was filtered through 
cotton wool, before addition of d6-DMSO (0.75 mL). While stirring, ethyl 
acetate (11 mL) was added, resulting in precipitation. After 
centrifugation (13,000 rpm, 10 minutes) the pellet was discarded, and 
ethyl acetate (15 mL) was added to the filtrate. After centrifugation 
(13,000 rpm, 10 minutes) there were two distinct liquid layers. The 
clear upper layer was removed by pipette, and the dark red lower layer 
was retained, and a 1:4 acetone/DCM solvent mixture (3 mL) was 
added. After sonication and centrifugation (13,000 rpm, 10 minutes) 
the pellet was discarded and the filtrate retained. Addition of diethyl 
ether (4 mL) brought about precipitation. The precipitate was collected 
through filtration, washed with diethyl ether (2 x 10 mL) and dried 
under vacuum to give the product as a yellow solid (55 mg, 0.028 
mmol, 54%). 1H NMR (298 K, CD3CN, 400 MHz) δ: 8.77 (2H, s, Hc), 8.74 
(2H, s, Hm), 8.68 (2H, s, Ha), 7.88 (1H, t, J = 7.9 Hz, He), 7.82 (2H, s, 
Hb), 7.70 – 7.65 (4H, m, Hd, Hl), 7.49 (2H, s, Hn), 7.25 (45H, br, HNH), 
6.73 (2H, d, J = 8.9 Hz, Hk), 4.59 (2H, d, J = 5.4 Hz, Ho), 4.29 – 4.27 
(4H, m, Hf), 3.83 – 3.81 (4H, m, Hg), 3.62 – 3.60 (4H, m, Hh), 3.53 (1H, t, 
J = 5.7 Hz, HOH), 3.48 – 3.46 (4H, m, Hi), 3.27 (6H, s, Hj). 13C NMR (298 
K, CD3CN, 100 MHz) δ: 159.3, 156.8, 152.9, 148.9 (Cm), 144.8 (Ca), 
142.7, 142.7, 142.3, 140.2 (Cc), 137.8, 128.6, 128.6, 124.4 (Cn), 123.0, 
113.1 (Ck), 110.5, 93.3, 90.8, 83.6, 82.5, 71.6 (Ci), 70.3 (Ch), 69.5 (Cf), 
68.8 (Cg), 61.3 (Co), 57.9 (Cj). HR ES-MS (DMSO/CH3CN) m/z = 964. 
2424 [M – 4BF4 – 2H]2+ (calc. for C98H92N16O14Pd2, 964.2433), 705.6333 
[M – L9 – 4BF4 – 2H]2+ (calc. for C69H59N13O8Pd2, 705.6336), 643.1664 
[M – H]3+ (C98H91N16O14Pd2, 643.1666), 518.2252 [L9 + H]+ (calc for 
C29H32N3O6, 518.2286), 482.6281 [M – 4BF4]4+ (calc. for 
C98H92N16O14Pd2, 482.6268), 393.5745 [Pd(L6)2 – H]2+ (calc. for 
C40H29N10O2Pd, 393.5756),  342.1341 [L6 + H]+ (calc. for C20H16N5O, 
342.1350). IR: ν (cm-1) 3336, 3217, 3082, 2877, 2221, 1656, 1583, 
1549, 1051, 975. IR: ν (cm-1) 3336, 3217, 3082, 2877, 2221, 1656, 
1583, 1549, 1051, 975. Anal. calcd. for C98H92B4F16N16O14Pd2∙5DMSO: 











A solution of [Pd2(L1-Fc)4](BF4)4[58c] (4 mg, 2 µmol) in d6-DMSO (0.5 mL) 
was combined with a solution of L6 (1 mg, 4 µmol) in  d6-DMSO (0.25 
mL) and left to stand for two days. The resulting mixed cage, 
[Pd2(L6)2(L1-Fc)2](BF4)4, was not isolated. 1H NMR (400 MHz, d6-DMSO, 
298 K) δ: 9.62 (4H, s, Hg), 9.34 (4H, s, Hm), 9.23 (4H, d, J = 3.3 Hz, Hj), 
8.56 (8H, br, HNH), 8.33 (4H, d, J = 7.2 Hz, Hh), 8.26 (4H, s, Hd), 7.85 
(4H, J = 6.5 Hz, Hi), 7.75 (4H, d, J = 9.1 Hz, Hl), 7.59 – 7.49 (multiplet 
containing 8H, Hf & Hn), 6.63 (d, J = 9.8 Hz, Hk), 5.78 (4H, s, He), 5.56 
(2H, t, J = 5.7 Hz, HOH), 4.71 (4H, s, Hc), 4.55 – 4.52 (multiplet 
containing 4H, Hn) 4.30 (4H, s, Hb), 4.00 (10H, s, Ha HR ES-MS 
(DMSO/CH3CN) m/z = 994.1669 [M – 4BF4]2+ and [Pd(L6)(L1-Fc)]+ (calc. 
for C104H74Fe2N22O2Pd2, 994.6580, calc. for C52H37FeN11OPd, 993.1562), 
720.6032 [M – L6 – H – 4BF4]2+ (calc. for C72H51FeN16O2Pd2, 720.5897), 
617.5989 [Pd2(L6)3 – H]2+ (calc. for C60H44N15O3Pd2, 617.5922), 
546.1284 [L1-Fc]+ (calc. for C32H22FeN6, 546.1255), 448.0361 [M – 2L1-
Fc– 4BF4]4+ (calc. for C40H30N10O2Pd2, 448.0308), 394.0837 [Pd(L6)2]2+ 
(calc. for C40H30N10OPd, 394.0796), 342.1365 [L6 + H]+ (calc. for 










To a solution of L1-H (4 mg, 14 µmol) and [Pd(CH3CN)4](BF4)2 (3 mg, 7 
µmol) in d6-DMSO (0.4 mL) was added L6 (4 mg, 11 µmol) in d6-DMSO 
(0.1 mL), and the solution left to stand for 3 days. The resulting mixed 
cage, [Pd2(L6)2(L1-H)2](BF4)4, was not isolated. 1H NMR (400 MHz, d6-
DMSO, 298 K) δ: 9.49 (8H, s, Hd), 9.32 (8H, s, Hg), 9.24 (8H, d, J = 5.4 
Hz, Hd), 8.56 (16H, br, HNH), 8.30 (8H, d, J = 8.1 Hz, He), 7.89 – 7.83 (12 
H, m, Hc, Hf), 7.76 – 7.70 (16 H, m, Hb, Hi), 7.60 – 7.45 (multiplet 
including Ha and Hk), 6.64 (8H, d, J = 5.7 Hz, Hh), 5.52 (2H, br, HOH), 
4.49 (8H, s, Hl). HR ES-MS (DMSO/CH3CN) m/z = 587.0754 [M – L1-H 
– 4BF4 – 2H]2+ (calc. for C60H40N12O2Pd2, 586.0742), 556.5633 
[Pd2(L6)2(L1-H) – 2H]2+ (calc. for C60H40N12O2Pd), 514.4244 [M – 3BF4]3+ 
(calc. for C80H54BF4N14O2Pd2, 514.4227), 485.0859 [M + H]3+ (calc. for 
C80H61N14O2Pd, 485.0855), 447.0246 [M –2L1-H – 4BF4 – 2H]2+ (calc. for 
C40H28N10O2Pd2, 447.0238), 371.7106 [Pd2(L6)(L1-H)2]3+ (calc. for 
C60H39N9OPd2, 371.7120),   364.0660 [M – 4BF4]4+ (calc. for 
C80H54N14O2Pd2, 364.0659), 342.1340 [L6 + H]+ (calc. for C20H16N5O, 






















Some parts of this chapter have been published: 
D. Preston, J. E. M. Lewis, J. D. Crowley,  “Multicavity [PdnL4]2n+ cages 
with controlled segregated binding of different guests,” J. Am. Chem. 
Soc., 2017, accepted manuscript, DOI: 10.1021/jacs.6b11982. 
 
The early synthetic and crystallographic work of Dr. James Lewis 
establishing the route to, and identity of, the unsubstituted double cage 
([Pd3(L10)4](BF4)6) provided proof of concept paving the way for all 
subsequent work with the solubilised double and triple cages, 
[Pd3(L11)4](BF4)6 and [Pd4(L12)4](BF4)8. 
    
5.1. Big metallosupramolecular assemblies 
Large naturally occurring assemblies such as proteins have the 
capacity to interact with multiple guests simultaneously, whether with  
homostructural guests as in the transport of oxygen by haemoglobin[107] 
and the storage of iron by ferritin,[108] or of concurrent binding of 
different guests, for catalysis[109] or in molecular signaling pathways.[110] 
From the outset of metallosupramolecular chemistry, there has been a 
drive to push the limits of self-assembly through the formation of ever-
larger architectures, driven in part by the hope to replicate the 
capabilities of natural macromolecules. At the forefront of this crusade 
has been the Fujita group, which has published a series of 
cuboctahedral structures based around dipyridyl ligands and 
coordinatively saturated palladium(II) metal ions, of the general 
formulae [Pdn(L)2n]2n+ where n is 6, 12, 24 or 30 (Figure 5.1),[111] in 
addition to a [Pd30(L)60]60+ Goldberg polyhedron.[112]  
 
Figure 5.1 Depictions of the X-ray crystal structures of a series of compounds 
(general formula of [Pdn(L)2n]2n+ reported by the Fujita group of increasing size 
(n = 6, 12, 24, and 30). Hydrogen atoms, counterions and solvent molecules 
omitted for clarity.[111] 
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These impressive structures have commensurately huge cavities which 
have been utilised for host-guest chemistry involving large guests, such 
as controlling size in nanoparticle and polymer synthesis.[113] 
Additionally, they have been functionalised with endohedral threads 
capable of forming multiple encapsulated pseudorotaxanes with 
cyclobis-(paraquat-p-phenylene) macrocycles,[114] or even to encapsulate 
large guests such as the 8.6 kDA protein ubiquitin via a thiol 
linkage.[115] Nonetheless, large cavity size tends to reduce specificity of 
binding for small guests. Therefore, in the design of architectures for 
the binding of multiple small guests, other targets must be pursued. 
 
5.2. Binding of multiple homostructural guests 
Several architectural types have exhibited the capacity to bind multiple 
homostructural guests concurrently.[116] These employ a variety of 
structural designs to create assemblies of sufficient size to bind 
multiple guests that retain the short contact supramolecular 
interactions characteristic of a small-cavity architecture. One such 
approach is the creation of long tube-like complexes, which have 
cavities linearly extended in a single dimension, several of which have 
been reported by Fujita and coworkers.[116a-c] A dodecapyridyl ligand 
(Figure 5.2a) could be combined in a 1:6 ratio with cis-protected 
[Pd(en)(NO3)2] in D2O at 70 °C for 3 hours forming, in the presence of a 
sodium biphenylcarboxylate, a host-guest adduct  
[(biphenylcarboxylate)2Pd12(L)2]22+ with two guests inserted into each 
end of the tubed structure with the hydrophobic phenyl groups buried 
deeply within the structure, and the carboxylate groups at the entry 
points (Figure 5.2b).[116a] This adduct was formed as a minor product 
(the major being the entropically favoured smaller 
[(biphenylcarboxylate)Pd6(L)]11+ sock-like assembly) and was only 
formed at higher concentrations ([L] > 8 mM). It was isolated through 
crystallisation, and once isolated was kinetically stable in D2O solution 
for months. Similar host-guest adducts have been formed with a 
hexapyridyl ligand and a dianthracenyl guest, giving a 
[(guest)Pd12(L)4]24+ tube,[116b] and a pentapyridyl ligand with a biphenyl 
dicarboxylate guest in creation of a [(guest)Pd10(L)4]20+ assembly.[116c] 
However, the formation of these adducts was dependent on guest 
templation, and thus by necessity the cavity of the cages were 
permanently filled, lowering the potential applications of the system. 
 An alternative approach was reported by Bosnich and coworkers with 
the formation of large palladium(II) assemblies with multiple clefts.[116d] 
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The author developed a dipalladium(II) tweezer complex with the 
palladium(II) or platinum(II) metal ions bound within a cofacial 
arrangement in terpyridine (terpy) binding pockets. These 
metallotweezers were found to bind two guest molecules of 9-
methylanthracene: one within the tweezers and another outside.[98]  
 
Figure 5.2 a) The dodecapyridyl ligand reported by Fujita and coworkers 
which combined in a 1:6 ratio with [Pd(en)(NO3)2] in the presence of 
biphenylcarboxylate gives b) a [(biphenylcarboxylate)2Pd12(L)2]22+ host-guest 
adduct (X-ray crystal structure, solvent and counterions excluded for clarity, 
guests shown in spacefilling view with carbon atoms orange).[116a]  
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This tweezer complex could additionally be used to formulate larger 
assemblies via coordination to the vacant site of each palladium(II) ion, 
with coordination to bis-monodentate 4,4’-bipyridine giving a 
metallorectangle,[98] and to tris-monodentate 4-pyridyl-1,2,3-triazine 
giving a hexapalladium(II) prism (Figure 5.3).[116d] The prism 
demonstrated the same capacity to bind 9-methylanthracene (hence, 
six guests bound per complex) as the precursor tweezer complex, while 
a larger central linking ligand, 4-ethynylpyridyl-1,2,3-benzene, bound a 
seventh, probably within the larger central cavity.  
 
Figure 5.3 The hexapalladium(II) triple-cleft cage (MMFF model) reported by 
Bosnich and coworkers,[116d] capable of binding six 9-methylanthracene guests 
(three endohedrally, three exohedrally) from a) above and b) the side. 9-
methylanthracene guests depicted in spacefilling view with black carbon 
atoms, with only the endohedrally bound guests shown. 
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5.3. Concurrent binding of multiple different guests 
Other efforts have targeted the concurrent binding of different guests 
within a single architecture. The ability to bring two guests together has 
advantageous ramifications regarding interguest chemical reactivity 
(some examples of this have been previously mentioned in Chapter 1)[44, 
117] and tuning of photophysical characteristics.[118] Reek and coworkers 
have coencapsulated rhodium(I) and iridium(I) cyclopentadienyl 1,8-
cyclooctadiene complexes alongside PAHs within hexapalladium(II) and 
hexaplatinum(II) cages, with resulting metal-to-ligand (MLCT) charge 
transfers between the guests.[118] Two aromatic guests with electronic 
complementarity have also been encapsulated within a 
hexapalladium(II) prism by Fujita and coworkers, with one donor 
triphenylene guest and one acceptor naphthalenediimide guest 
preferentially bound over two triphenylene molecules (Figure 5.4), 
presumably due to favourable electronic complementarity between the 
guests.[119]  
 
Figure 5.4 Coencapsulation of triphenylene and naphthalenediimide within a 
hexapalladium(II) prism: depictions of the X-ray crystal structure of the 
ternary adduct with guests shown in spacefilling view from a) above and b) the 
side. Hydrogen atoms from the host, solvent molecules and counterions are 
omitted for clarity. Carbon colours: host in green, triphenylene in black, and 
naphthalenediimide in light blue. 
The principles of complementary guest interactions have also been 
capitalised upon by Shionoya and coworkers with a [Pt2(L)4]4+ cage  
containing a indoline-1,3-dione-linked dipyridyl ligand (Figure 5.5a).[120] 
Magnus-salt interactions utilising platinum(II)-platinum(II) interactions 
between stacked electron rich anionic and electron deficient cationic 
platinum(II) complexes are well known in the literature.[121] The authors 
envisaged that the cavity of this cage would be of good size to 
encapsulate two anionic platinum(II) guests surrounding a cationic 
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platinum(II) guest, with the cationic platinum(II) centres of the cage 
additionally contributing to the Magnus-salt stacking interactions. This 
proved to be an astute hypothesis: the cage did not bind either 
tetrachloroplatinate(II) nor tetrakis-pyridineplatinum(II) guests singly in 
CD3CN, but upon addition of both guests to the cage, the solution 
phase evidence garnered from 1H NMR spectroscopy confirmed 
concurrent guest binding. A ratio of 1:1:2 of cage, cationic guest and 
anionic guest was required for clean conversion, and X-ray 
crystallography of the host-guest adduct confirmed this stoichiometry 
and revealed the expected alternating stacking arrangement within the 
cavity (Figure 5.5).[120]   
 
Figure 5.5 a) The dipyridyl ligand reported by Shionoya and coworkers, used 
in the formation of a [Pt2(L)4]2+ cage which demonstrated concurrent Magnus-
salt-type guest binding of tetrachloroplatinate(II) and tetrakis-
pyridineplatinum(II) guests, in both CD3CN solution and in solid state; b) 
depiction of the X-ray crystal structure of the host-guest adduct, 
[(Pt(Cl)4)2(Pt(pyridine)4)Pt2(L)4]6+. Hydrogen atoms, solvent molecules and 
counterions are omitted for clarity, carbon colours: cage in blue, cationic 




5.4. Multicavity architectures 
The abovementioned examples of heteroguest encapsulation rely upon 
complementarity between the guests due to their binding within a 
single cavity, but equally useful for other purposes would be 
independent binding of different guests. For this to be accomplished in 
a controlled manner, assemblies with multiple cavities would appear to 
be required.    
 
5.4.1. Interpenetrated multicavity architectures 
Interpenetrated [Pd2(L)4]4+ cages provide architectures that not only 
have multiple cavities but also confer varied character upon the 
cavities, in that the central cavity differs from those at the periphery. 
The Clever group has exploited this for coencapsulation of different 
guests within the separate cavities. Investigation of a doubly-
interpenetrated cage with three BF4- counterions within the three 
pockets via variable temperature NMR spectroscopies revealed that the 
anions in the outer pockets were subject to faster exchange than the 
counterion within the more protected central pocket. Introduction of 
chloride lead to the replacement of the peripheral BF4- counterions for 
chloride, with no evidence of an intermediate adduct with only a single 
chloride entering, suggesting an allosteric effect where the reduction in 
peripheral cavity size upon encapsulation of the first chloride brought 
about an immediate switch (Figure 5.6a).[103d] This new mixed host 
guest adduct could then be treated with excess benzene or other 
neutral organic guests, resulting in displacement of the remaining BF4- 
from the central cavity.[103f] The resulting adduct was characterised 
through NMR spectrocopies, mass spectrometry, and X-ray 
crystallography which revealed the expected occupancy of the 
respective pockets (Figure 5.6c).  In contrast, the tris-tetrafluoroborate 
adduct was not susceptible to displacement by benzene. It seems that 
solvation and dispersion effects are responsible for the encapsulation of 
the neutral guest, which requires a central cavity of sufficient size for 
encapsulation, and that the decrease in peripheral cavity size upon 
chloride entry is accompanied by an associated increase in the central 
cavity.  
 The inability of these systems to interpenetrate with shorter ligands 
has already been noted in Chapter 3.[100] But the use of ligands with 
bulky endohedral groups (aryl substituent as opposed to a ketone) was 
also shown by Clever and coworkers to give a stable non-interlocked 




Figure 5.6 Clever and coworkers’ binding of multiple guests within 
interpenetrated cages: a) displacement of BF4- by chloride to give a 
[(Cl)2(BF4)Pd2(L)4]+ host-guest system[103e] can then be followed by 
displacement with benzene and formation of a [(Cl)2(benzene)Pd2(L)4]2+ 
adduct;[103f] b) an endohedrally-bulky ligand forms a non-interpenetrated cage 
as the BF4- salt, which can be converted into a interpenetrated [(Cl)Pd2(L)4]3+ 
system. The larger peripheral cavities can now host larger anions such as 
ReO4-;[103f] c) a depiction of the X-ray crystal structure of 
[(BF4)2(Cl)2(benzene)Pd4(L)8]4+.[103f] Note that the BF4- anions are exohedrally 
bound. Hydrogen atoms, solubilising alkyl chains, non-bound counterions 
and solvent molecules are omitted for clarity, and guests are shown in 
spacefilling view. Carbon colours: grey and black for cage carbons, orange for 
the benzene guest. 
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However, the introduction of the smaller chloride anion to a solution of 
this cage in CD3CN brought about interpenetration and encapsulation 
of chloride within the central cavity (Figure 5.6b). In contrast to the 
previous system, with chloride now in the central cavity the peripheral 
cavities increased in size, and were now able to bind introduced larger 
anions such as ReO4-.[103e] 
 
5.4.2. Discrete multicavity architectures 
The beauty of the interpenetrated adducts discussed above lies in the 
capacity for the cavities to resize in response to the dimensions of their 
respective guests. Elegant as this is for complementarity of multiple 
guest binding, it is less suited to independent guest binding, which 
would be better served by a system with multiple independent cavities 
within a single discrete architecture. Examples of multicavity 
architectures of this sort have indeed been reported in the literature. 
Lehn and coworkers reported a series of cylindrical cages composed of 
Cu(I) metal ions, hexaphenylhexaazatriphenylene (HAT) ligands in 
segmenting roles, and linearly long poly-bipyridyl ligands spanning the 
cavities.[122] The resulting cages had one, two, or three cavities 
depending on the number of bipyridyl units in the spanning ligand, 
providing access to multicavity architectures with highly similar 
chemical environments, shown to encapsulate two PF6- anions within 
each cavity (Figure 5.7).[123] 
 
Figure 5.7 Depiction of the X-ray crystal structure reported by Lehn and 
coworkers of a multicavity [(PF6)6Cu12(HAT)4(L)3]6+ architecture. Hydrogen 
atoms, exohedral counterions and solvent moleules omitted for clarity. 
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An approach for multicavity discrete palladium(II)-based assemblies 
was suggested by McMorran and Steel, who proposed that linearly-long 
polytopic ligands could be used to form quadruply-stranded cages with 
individual cavities of the same size and character as their single cavity 
analogues (Figure 5.8).[124]  
 
 
Figure 5.8 McMorran and Steel’s proposed use of polytopic ligands to form 
quadruply-stranded multicavity palladium(II) cages in an analogous fashion to 
single cavity [Pd2(L)4]4+ cages. 
Experimental realisation of this strategy was subsequently made by the 
groups of Chand[125] and Pfeffer and Clever[126] in the formation of 
double-cavity palladium(II) cages. The Crowley group has also 
investigated whether the tripyridyl ligand system used in the formation 
of the parent [Pd2(L1)4]4+ could be extended in this fashion in the 
construction of a multicavity architecture. A tritopic pentapyridyl ligand 
(L10) was synthesised, and complexation with Pd(II) in a 4:3 ratio of 
ligand to metal ion brought about clean formation of a double-cavity 
cage as confirmed by NMR spectroscopies, mass spectrometry, and the 
X-ray crystal structure of the complex (Figure 5.9).††  The crystals of the 
complex were obtained through vapour diffusion of diethyl ether into a 
solution of the cage in DMF, and the solved structure showed a double-
cavity structure with each of the cavities occupied by two DMF solvent 
molecules in the same head-to-tail arrangement as previously 
observed.[96]   
                                       
†† The synthesis of this tritopic ligand, its palladium(II) double-cavity cage, and the 





Figure 5.9 Formation of a double cavity [Pd3(L10)4]6+ cage by Crowley and 
coworkers. In the depiction of the X-ray crystal structure of the cage, 
counterions and non-encapsulated solvent molecules have been omitted for 
clarity, and the carbon atoms of the DMF solvent molecules are coloured 
black.  
Proof of concept was now obtained, showing that this strategy was 
effective in the creation of multicavity architectures in this family. 
However, as with the other double-pocketed assemblies discussed, all 
cavities were identical in character, preventing the controlled 
encapsulation of different guests. The most facile approach to obtaining 
cavities of different character would be a triple-cavity system with a 
different central cavity, thereby avoiding problems with ligand 
orientation that might be present in an asymmetric double-cavity 
system. The low solubility of the highly conjugated polypyridyl ligands 
prevented the extension of this system to a triple-cavity member of the 
family. With this in mind, it was planned to add solubilising elements to 
the ligand to allow the formation of larger structures. A solubilised 
tritopic system was targeted first, to ensure that exohedral alteration of 
the ligand structure did not interfere with complexation, and to more 
fully probe the host-guest behaviour of a potentially more simple 
system with uniform cavity character. 
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5.5. Synthesis of a solubilised tritopic system 
The asymmetric building block 3,5-bis((6-((5-(2-(2-methoxyethoxy) 
ethoxy)pyridin-3-yl)ethynyl)pyridin-2-yl)ethynyl)pyridine (9) was 
synthesised in an analogous fashion to L9, under standard 
Sonogashira conditions, but with a fourfold excess of 2,6-
dibromopyridine to prevent disubstitution (Scheme 5.1, 45%). It was 
then combined with 3,5-diethynylpyridine[127] in a second Sonogashira 
to give the solubilised tritopic ligand, L11 (49%).  
 
Scheme 5.1 Synthetic conditions: (i) 2,6-dibromopyridine, [Pd(PPh3)2Cl2], CuI, 
diisopropylamine, under N2, RT for 18 hours (45%); (ii) 3,5-diethynylpyridine, 
[Pd(PPh3)2Cl2], CuI, diisopropylamine/THF, under N2, RT for 18 hours (49%); 




The 1H NMR spectrum of the ligand (d6-DMSO, Figure 5.10a) had the 
correct number of peaks with the expected integrations for L11, and 
mass spectral analysis confirmed identity (m/z = 742.2577 [M + Na]+, 
calc. 742.2636). As with the unsubstituted ligand, the combination of 
L11 with [Pd(CH3CN)4](BF4)2 in a 4:3 ratio required heating in d6-DMSO 
to facilitate the self-correction process and bring about clean 
complexation as shown in the 1H NMR spectrum, which showed 
downfield shifts of the peaks pertaining to proton environments 
proximal to the coordinating pyridyl nitrogen atoms (Δδ(Ha) = 0.82 ppm, 
Δδ(Hb) = 0.86 ppm, Δδ(Hc) = 0.39 ppm, Δδ(Hg) = 0.90 ppm, Δδ(Hh) = 0.36 
ppm, Figure 5.10b).  
 
Figure 5.10 Stacked partial 1H NMR spectra (298 K, d6-DMSO, 400 MHz) of a) 
L11, and b) [Pd3(L11)4](BF4)6.  
2D DOSY 1H NMR spectroscopy gave further evidence of the formation 
of the desired structure. The diffusion coefficients for both L11 and 
[Pd3(L11)4](BF4)6 were similar to those of L10 and [Pd3(L10)4](BF4)6 
respectively (DL10 = 1.88 x 10-10 m2 s-1, DL11 = 1.43 x 10-10 m2 s-1, 
D[Pd3(L10)4](BF4)6 = 0.80 x 10-10 m2 s-1, D[Pd3(L11)4](BF4)6  = 0.66 x 10-10 m2 s-1, 
Figure 5.11) and the diffusional ratio between free ligand and cage was 
roughly 2:1, in good agreement with previously obtained data.[57, 84, 106] 
Furthermore, a plot of log(D) against log(MW) gave a good linear fit for 
the respective components. 
 After isolation of the cage through precipitation with ethyl acetate 
(64%), mass spectrometry provided strong additional evidence for 
formation of the [Pd3(L11)4](BF4)6 cage (Figure 5.12). Peaks pertaining to 
hexa-, penta- and tetracationic species were clearly visible in the 
spectrum, corresponding to a loss of all, five, or four counterions. The 
hexacationic species was a good match with regards to the isotopic 
distribution (m/z = 532.9727, calc. 532.9684), and while the other 
peaks were complicated by mixtures of associated chloride or formate 
counterions, they nonetheless corroborated the presence of the intact 




Figure 5.11 Plot of log(D) against log(MW) for reported ligands and cages (298 
K, CD3CN, 500 MHz, units D: x 10-10 m2 s-1, Mw: g mol-1). 
 
Figure 5.12 Partial HR-ESI mass spectrum (DMSO/CH3CN) of 
[Pd3(L11)4](BF4)6, showing observed isotopic distributions in black above and 
calculated distributions in colour below.   
 
5.6. Host-guest chemistry of the double-cavity cage 
With the cage synthesised, its host-guest chemistry was investigated. 
Similar to both the parent system[5] and the unsubstituted double 
cage,[128] introduction of excess cisplatin into a solution of 
[Pd3(L11)4](BF4)6 in CD3CN brought about downfield shifting of the 
internally directed protons of the cage (Δδ(Ha) = 0.10 ppm, Δδ(Hg) = 0.15 




Figure 5.13 Partial 1H NMR spectra (298 K, CD3CN, 400 MHz) of a) 
[Pd3(L11)4]6+, b) [(cisplatin)4Pd3(L11)4]6+, c) [(TfO)2Pd3(L11)4]4+, and d) 
[(cisplatin)4(TfO)2Pd3(L11)4]4+. 
With an eye towards the eventual target of a multiple differentiated 
cavity structure, it was important to identify an additional guest that 
had no affinity for pyridyl-lined cavities such as those in the double 
cage, but might potentially bind in a subtly altered cavity. Triflate 
appeared to be a good candidate for this, having previously been 
demonstrated to not bind in the parent system,[57] but being 
encapsulated in the phenyl-lined cavity of the analogous system 
reported by Hooley and coworkers.[129] The appeal of this combination of 
guests was reinforced by the fact that cisplatin had been observed 
within our group to not bind in phenyl-lined cavities, giving the 
potential non-competition in both cavity environments. To confirm that 
triflate did not bind internally in a PEGylated system, two equivalents of 
[NBu4]OTf were added to a solution of the cage. No shifts of the 1H NMR 
resonances of the internally directed cage protons were observed, while 
the exohedral protons ortho to the peripheral coordinating nitrogen 
atoms (Hb) shifted downfield (Δδ = 0.13 ppm, Figure 5.13c), suggesting 
interaction with the external faces of the cage. In addition, the 19F NMR 
spectrum revealed a downfield shift of the triflate fluorine peak relative 
to free triflate (Δδ = 0.13 ppm), confirming the existence of the 
interaction, while the fluorine peak of the tetrafluoroborate anion 
shifted upfield relative to that present with solely the cage in solution 
(Δδ = -0.31 ppm), implying that BF4- was displaced from the exohedral 
cage faces by the triflate. A titration for cisplatin, which is essentially 
insoluble in acetonitrile, was not possible. But the 1:2 host/guest ratio 
that would be expected for triflate binding on the external faces of the 
two peripheral palladium(II) faces could be confirmed via a mole ratio 
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titration[97] using NMR spectroscopy. The 1H and 19F NMR spectra of 
solutions of the cage in CD3CN (0.2 mM) with varying amounts of 
triflate (0 – 20 equivalents) were obtained (Figure 5.14, Figure 5.15) and 
the changes in the chemical shifts of Hb, FTfO- and FBF4- were extracted.      
 
Figure 5.14 Stacked partial 1H NMR spectra (298 K, CD3CN, 400 MHz) of a) 
[Pd3(L11)4]6+, b) [Pd3(L11)4]6+ + 0.25 eq. TfO-, c) [Pd3(L11)4]6+ + 0.50 eq. TfO-, d) 
[Pd3(L11)4]6+ + 0.75 eq. TfO-, e) [Pd3(L11)4]6+ + 1.00 eq. TfO-, f) [Pd3(L11)4]6+ + 
1.25 eq. TfO-, g) [Pd3(L11)4]6+ + 1.50 eq. TfO-, h) [Pd3(L11)4]6+ + 1.75 eq. TfO-, i) 
[Pd3(L11)4]6+ + 2.00 eq. TfO-, j) [Pd3(L11)4]6+ + 3.00 eq. TfO-, k) [Pd3(L11)4]6+ + 
4.00 eq. TfO-, l) [Pd3(L11)4]6+ + 5.00 eq. TfO-, m) [Pd3(L11)4]6+ + 6.50 eq. TfO-, n) 
[Pd3(L11)4]6+ + 8.00 eq. TfO-, o) [Pd3(L11)4]6+ + 10.00 eq. TfO-, p) [Pd3(L11)4]6+ + 





Figure 5.15 Stacked partial 13F NMR spectra (298 K, CD3CN, 376 MHz) of a) 
[Pd3(L11)4]6+, b) [Pd3(L11)4]6+ + 0.25 eq. TfO-, c) [Pd3(L11)4]6+ + 0.50 eq. TfO-, d) 
[Pd3(L11)4]6+ + 0.75 eq. TfO-, e) [Pd3(L11)4]6+ + 1.00 eq. TfO-, f) [Pd3(L11)4]6+ + 
1.25 eq. TfO-, g) [Pd3(L11)4]6+ + 1.50 eq. TfO-, h) [Pd3(L11)4]6+ + 1.75 eq. TfO-, i) 
[Pd3(L11)4]6+ + 2.00 eq. TfO-, j) [Pd3(L11)4]6+ + 3.00 eq. TfO-, k) [Pd3(L11)4]6+ + 
4.00 eq. TfO-, l) [Pd3(L11)4]6+ + 5.00 eq. TfO-, m) [Pd3(L11)4]6+ + 6.50 eq. TfO-, n) 
[Pd3(L11)4]6+ + 8.00 eq. TfO-, o) [Pd3(L11)4]6+ + 10.00 eq. TfO-, p) [Pd3(L11)4]6+ + 
12.50 eq. TfO-, q) [Pd3(L11)4]6+ + 20.00 eq. TfO-, r) [N(Bu)4](OTf), s) LiBF4. Hb is 
annotated (refer Scheme 5.1). 
Plots of Δδ as a function of equivalency for these resonances gave good 
agreement via the mole ratio method for a 1:2 host/guest relationship 
(Figure 5.16). The chemical shifts from the 1H NMR spectra (298 K, 
CD3CN) were also used to obtain binding constants of K1 = 4800  400 
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M-1 and K2 = 20  10 M-1 via a curve-fitting procedure.[130] It was also 
observed that introduction of both guests simultaneously resulted in 
downfield shifts of all relevant peaks of the host (Δδ(Hb) = ~0.23 ppm, 
indicating exohedral interaction with triflate, Δδ(Ha) = ~0.07 ppm and 
Δδ(Hg) = 0.08 ppm, suggesting internal encapsulation of cisplatin, 
Figure 5.13d) and thus demonstrated concurrent interactions between 
the two guests and the cage. 
 
Figure 5.16 Plots of δF for BF4- and TfO- (above) and δH for proton Hb (below) 
for the titration of [N(Bu)4]OTf into [Pd3(L11)4](BF4)6 (298 K, CD3CN, 1H 400 
MHz, 19F 376 MHz), at cage concentration of 0.2 mM. ΔδF is relative to the 19F 
NMR chemical shift of the free anions, LiBF4 and [N(Bu)4]OTf. 
 
5.7. Synthesis of a tetratopic ligand and triple-cavity cage 
With the host-guest properties of the simpler double cage system now 
investigated, a triple cavity cage with differentiated binding pockets was 
pursued. It was decided to attempt the synthesis of a complex in which 
the peripheral cavities were pyridyl-lined and the central cavity was 
phenyl-lined, in the hope that selective binding of cisplatin in the 
peripheral cavities and triflate in the central cavity would be observed. 
To this end, a Sonogashira reaction between 9 and a tenfold excess of 
3,5-diethynylpyridine under standard conditions was undertaken to 
provide 2-((5-ethynylpyridin-3-yl)ethynyl)-6-((5-(2-(2-methoxyethoxy) 





Scheme 5.2 Synthetic conditions: (i) 3,5-diethynylpyridine, [Pd(PPh3)4], CuI, 
diisopropylamine/THF, under N2, RT for 18 hours (69%); (ii) 1,3-
diiodobenzene, [Pd(PPh3)2Cl2], CuI, diisopropylamine/THF, under N2, RT for 18 
hours, 45 °C for 6 hours, then 70 °C for 2 days (70%); (iii) [Pd(CH3CN)4](BF4)2, 





This extended precursor was then coupled twice to 1,3-diodobenzene in 
another Sonogashira reaction to give the tetratopic ligand L12 in 
reasonable yield (70%), with confirmation of product identity given by 
NMR spectroscopies, including an 1H NMR spectrum with the correct 
number and integration of peaks (Figure 5.17a), which 2D DOSY 1H 
NMR spectroscopy revealed to be diffusing at D = 1.42 x 10-10 m2 s-1, a 
coefficient consistent with the expected molecular weight in comparison 
to the other compounds in the series (Figure 5.11). Mass spectrometry 
firmly identified product composition (m/z = 921.3342 [L12 + H]+, calc. 
921.3395). 
 
Figure 5.17 Stacked partial 1H NMR spectra (298 K, d6-DMSO, 400 MHz) of a) 
L12, and b) [Pd4(L12)4](BF4)8. 
The ligand L12 was then combined in a 4:4 ratio with 
[Pd(CH3CN)4](BF4)2 in d6-DMSO. The complexation required forcing 
conditions (70 °C for seven hours) to avoid the kinetic trapping of 
unwanted polymeric byproducts.  The 1H NMR spectrum after seven 
hours at 70 °C showed appropriately downfield shifted peaks (Figure 
5.17b), which were diffusing at a rate roughly half that of L12 (D = 0.62 
x 10-10 m2 s-1). This rate is again consistent with the trend of log(D) 
versus log(Mw) for the family of compounds (Figure 5.12). The 
[Pd4(L12)4]8+ stoichiometry was confirmed via mass spectrometry. The 
spectrum (DMSO/CH3CN) was similar in nature to that of 
[Pd3(L11)4](BF4)6, and revealed an isotopically well-defined distribution 
for the octacationic [Pd4(L12)4]8+ species (m/z = 513.5066, calc. 
513.4957) in addition to hepta-, hexa- and penta-cationic species with 
mixed counterions (BF4-, chloride and formate) which could nonetheless 
be deconvoluted to a large degree (Figure 5.18). 
 
5.8. Segregated binding of different guests  
With the triple cavity cage successfully synthesised, the host-guest 
chemistry was explored using the same guests as with the model 




Figure 5.18 Partial HR-ESI mass spectrum (DMSO/CH3CN) of 
[Pd4(L12)4](BF4)8, showing observed isotopic distributions in black above and 
calculated distributions in colour below.   
The introduction of excess cisplatin to a solution of the cage in CD3CN 
showed the characteristic signs of cisplatin-binding: the downfield shift 
and broadening of the peaks belonging to Ha ((Δδ = 0.07 ppm) and Hg 
(Δδ = 0.09 ppm), with no shift of the equivalent proton resonance in the 
central cavity, Hi (Figure 5.19a and b). Hence, cisplatin was 
encapsulated in the peripheral cavities but not in the central pocket. 
This can be rationalised as being due to the lack of the hydrogen-
bonding interactions between the amino groups of cisplatin and the 
core pyridyl nitrogen atoms, in conjunction with steric clash with the 
internally directed phenyl hydrogen. In contrast, introduction of three 
equivalents of triflate to a solution of the cage brought about downfield 
shifting of the peaks pertaining to Hb (Δδ = 0.13 ppm), again indicating 
exohedral binding, and Hi (Δδ = 0.05 ppm), showing binding in the 
central cavity. No shifts were observed for the peripheral endohedral 
protons Ha and Hg (Figure 5.19c), and thus the 1H NMR spectra 
suggested that the two guests bound in separate cavities: cisplatin on 






Figure 5.19 Partial 1H NMR spectra (298 K, CD3CN, 400 MHz) of a) 
[Pd4(L12)4]8+, b) [(cisplatin)4 Pd4(L12)4]8+, c) [(triflate)3 Pd4(L12)4]5+, and d) 
[(triflate)3(cisplatin)4 Pd4(L12)4]5+.  
The 19F NMR spectrum also indicated binding in the same manner as 
with the double cavity system: a downfield shift of the triflate fluorine 
peak relative to free triflate (Δδ = 0.3 ppm), and an upfield shift of the 
tetrafluoroborate fluorine peak relative to the cage alone (Δδ = -0.3 
ppm).  
The size of the downfield shift for Hi was smaller in magnitude than 
that of Hb, suggesting that only one triflate anion could be encapsulated 
within the central cavity at one time, and thus interacting with only one 
of the two internal palladium(II) metal ions. An 1H and 19F NMR 
spectroscopic titration in CD3CN holding the concentration of cage 
constant at 0.3 mM with 0 to 15 equivalents of triflate was able to show 
through the mole ratio method that there was a 1:3 binding 
relationship between host to guest, consistent with the binding of a 
single guest within the aryl-lined centre (Figure 5.20, due to the 
presence of different binding sites within the assembly and a 1:3 host to 
guest stoichiometry, binding constants could not be calculated). This is 
presumably due to the size constraints of the cavity coupled with the 
electrostatic repulsion that would be encountered with two guests 
bound. Pleasingly, both triflate and cisplatin could be introduced 
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concurrently, with downfield shifts of all ortho pyridyl peaks, showing 
concurrent binding of both guests simultaneously within different 
internal cavities and exohedral faces of the assembly (for cisplatin: 
Δδ(Ha) =  0.06 ppm, Δδ(Hg) = 0.10 ppm, for triflate: Δδ(Hb) = 0.09 ppm, 
Δδ(Hi) = 0.07 ppm, Figure 5.19d).  
 
Figure 5.20 Plots of δF for BF4- and TfO- and δH for protons Hb and Hi for the 
titration of [N(Bu)4]OTf into [Pd4(L12)4]8+ (298 K, CD3CN, 1H 400 MHz, 19F 376 
MHz), at cage concentration of 0.3 mM. ΔδF is relative to the 19F NMR chemical 
shift of the free anions, LiBF4 and [N(Bu)4]OTf. 
 
5.9. Conclusions and future directions 
A triple cavity quadruply-stranded palladium(II) cage was synthesised 
with binding pockets of varied character: the peripheral cavities were 
lined with pyridyl units, while the central cavity was phenyl-lined. The 
external cavities bound cisplatin, while triflate bound in the centre and 
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on the exohedral faces of the architecture. Hence, there was segregated 
guest binding in different locations of the cage, which could be filled 
individually, or, in the presence of both guests, concurrently. 
 In combination with the ability to introduce lower symmetry into 
individual cavities as described in Chapter 4, this provides access to 
powerful complexity regarding cavity environments. For example, a 
heteroleptic triple cavity cage might be designed with two endohedral 
binding sites for palladium(II) in each of the peripheral cavities, with a 
uniform hydrophobic environment in the central cavity, with larger 
cavities than those described in this chapter (Figure 5.21). The 
palladium(II) metal ions bound in the peripheries would be held by 
necessity in a cis–configuration. 
 
Figure 5.21 Depiction of a triple-cavity cage with low symmetry peripheral 
cavities which bind palladium(II) metal ions in a cis-configuration, and a 
different central cavity with a hydrophobic environment. 
This cis-configuration of the palladium(II) metal ion within the 
peripheral cavities would facilitate palladium(II)-catalysed carbon-
carbon bond formation, as in the Sonogashira reaction between an 
alkyne and aryl halide. At the same time, hydrophobic aryl substituents 
on the substrates would have high affinity for the cavity, and irradiation 
of the host-guest adduct in the central cavity could lead to photo-
induced cycloaddition, for example of anthracene, giving a controlled 
two-step reaction (Figure 5.22). Lastly, it might be possible to use the 
chloride-induced switching to metallocyclic form to switch off both 




Figure 5.22 Proposed two-step reaction process with both a Sonogashira 
palladium(II)-catalysed carbon-carbon bond formation and photo-induced 












5.10.1. Precursor synthesis 
5.10.1.1. 3,5-bis((6-((5-(2-(2-methoxyethoxy)ethoxy)pyridin-3-
yl)ethynyl)pyridin-2-yl)ethynyl)pyridine (9) 
A RBF containing diisopropylamine (20 mL) and THF (5 mL) was 
degassed with N2, and 8 (2.00 g, 9.04 mmol), 2,6-dibromopyridine (8.57 
g, 36.2 mmol), [Pd(PPh3)2Cl2] (0.37 g, 0.45 mmol) and CuI (0.17 g, 0.90 
mmol) were added against positive N2 flow, before stirring the reaction 
at room temperature for 18 hours. After addition of aqueous 0.1 M 
EDTA/NH4OH solution (50 mL) and stirring for 2 hours, the mixture 
was extracted into DCM (3 x 50 mL) and the combined organic phases 
dried (Na2SO4), filtered and the solvent removed under vacuum. After 
purification by column chromatography on silica (eluting with 1:10 
acetone/DCM then 1:3 acetone/DCM) the product was obtained as a 
white solid (1.53 g, 4.07 mmol, 45%). 1H NMR (298 K, CDCl3, 400 MHz) 
δ: 8.30 (1H, s, Ha), 8.22 (1H, s, Hb), 7.47 (1H, t, J = 7.7 Hz, He), 7.38 
(2H, m, Hd, Hf), 7.26 (1H, s, Hc), 4.09 (2H, m, Hg), 3.79 (2H, m, Hh), 3.60 
(2H, m, Hi), 3.48 (2H, m, Hj), 3.28 (3H, s, Hk). 13C NMR (298 K, CDCl3, 
100 MHz) δ: 154.2, 144.7 (Ca), 142.9, 141.7, 138.9 (Cb), 138.4 (Ce), 
127.8, 126.1, 123.1 (Cc), 118.9, 90.0, 86.9, 71.8 (Cj), 70.7 (Ci), 69.3 
(Ch), 67.9 (Cg), 58.9 (Ck). HR-ES-MS (CDCl3/MeOH): m/z = 377.0464 [M 
+ H]+ (calc. for C17H18N2BrO3, 377.0495), m/z = 399.0297 [M + Na]+ 
(calc. for C17H17N2NaBrO3, 399.0315). Anal. calc. for C17H17N2BrO3: C, 
54.13; H, 4.54; N, 7.43%. Found: C, 54.53; H, 4.49; N, 7.32%. IR (ATR): 
v (cm-1) 3046, 2969, 2880, 2209, 1567, 1544, 1421, 1099, 785. 
 
5.10.1.2. Synthesis of 2-((5-ethynylpyridin-3-yl)ethynyl)-6-((5-
(2-(2-methoxyethoxy)ethoxy)pyridin-3-
yl)ethynyl)pyridine (10) 
A RBF containing 9 (900 mg, 2.39 mmol), 3,5-diethynylpyridine[127] 
(3030 mg, 23.86 mmol), [Pd(PPh3)4] (138 mg, 0.110 mmol) and CuI (45 
mg, 0.24 mmol) was purged with N2, and a mixture of diisopropylamine 
(50 mL) and THF (50 mL) degassed with N2 was added via syringe, 
before stirring the reaction at room temperature for 18 hours. After 
addition of aqueous 0.1 M EDTA/NH4OH solution (100 mL) and stirring 
for 1 hour, the mixture was extracted into DCM (3 x 50 mL) and the 
combined organic phases dried (Na2SO4), filtered and the solvent 
removed under vacuum. After purification by column chromatography 
on silica (1:10 acetone/DCM then 1:5 acetone/DCM), the product was 
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obtained as a tan solid (693 mg, 1.65 mmol, 69%). 1H NMR (298 K, 
CDCl3, 400 MHz) δ: 8.76 (1H, d, J = 1.9 Hz, Hg), 8.68 (1H, d, J = 1.8 Hz, 
Hi), 8.43 (1H, s, Ha), 8.33 (1H, d, J = 1.6 Hz, Hb), 7.95 (1H, t, J = 2.0 Hz, 
Hh), 7.74 (1H, t, J = 2.5 Hz, He), 7.55 – 7.51 (2H, m, Hd, Hf), 7.40 (1H, t, 
J = 2.1 Hz, Hc), 4.20 – 4.18 (2H, m, Hk), 3.90 – 3.87 (2H, m, Hl), 3.73 – 
3.71 (2H, m, Hm), 3.59 – 3.57 (2H, m, Hn), 3.39 (3H, s, Ho), 3.26 (1H, s, 
Hj). 13C NMR (298 K, CDCl3, 100 MHz) δ: 154.5, 152.3 (Cg), 151.9 (Ci), 
145.1 (Ca), 143.5, 143.1, 141.8 (Ch), 139.1 (Cb), 136.6, 127.1, 126.9, 
123.4 (Cc), 119.3, 119.2, 119.1, 91.8, 90.8, 86.4, 85.2, 81.7 (Cj), 79.5, 
72.1 (Cn), 71.0 (Cm), 69.6 (Cl), 68.1 (Ck), 59.2 (Co). IR (ATR): v (cm-1) 
3237, 3041, 2881, 2824, 2215, 2186, 2167, 1570, 1555, 1457, 1442, 
1417, 1253, 1102, 1065, 1019. HR-ES-MS (CDCl3/MeOH): m/z = 
424.1643 [M + H]+ (calc. for C18H20N2BrO, 424.1656),  m/z = 446.1460 
[M + Na]+ (calc. for C18H19N2NaBrO, 446.1475), m/z = 869.2970 [2M + 
Na]+ (calc. for C36H38N4NaBr2O2, 869.3064). Anal. calc. for 
C18H19N2BrO∙0.2acetone: C, 73.43; H, 5.19; N, 9.66%. Found: C, 73.64; 
H, 4.97; N, 9.32%. 
 
5.10.2. Ligand synthesis 
5.10.2.1. Synthesis of 1,3-bis((6-((5-(2-(2-methoxyethoxy) 
ethoxy)pyridin-3-yl)ethynyl)pyridin-2-yl)ethynyl) 
benzene (L11) 
A RBF was charged with 9 (430 mg, 1.14 mmol), 3,5-diethynylpyridine 
(50 mg, 0.39 mmol), [Pd(PPh3)2Cl2] (14 mg, 0.020 mmol) and CuI (7 mg, 
0.04 mmol) and purged with N2. THF (5 mL) and diisopropylamine (5 
mL) were added via syringe and the reaction stirred at RT for 18 hours. 
After the solvent was removed under vacuum, 3:1 CHCl3/IPA (50 mL) 
and aqueous 0.1 M EDTA/NH4OH solution (10 mL) were added and 
stirred for 1 hour. After further extracting with 3:1 CHCl3/IPA (50 mL) 
(2 x 25 mL), the combined organic extracts were dried (Na2SO4), filtered, 
and the solvent removed under vacuum. Following purification by 
column chromatography on silica (DCM to 1:3 acetone/DCM) the 
product was obtained as a tan solid (140 mg, 0.190 mmol, 49%). 1H 
NMR (298 K, CDCl3, 400 MHz)δ: 8.79 (2H, d, J = 1.8 Hz, Hg), 8.43 (2H, 
s, Ha), 8.34 (2H, d, J = 2.0 Hz, Hb), 8.05 (1H, s, Hh), 7.76 (2H, t, J = 6.8 
Hz, He), 7.56 (4H, m, Hd, Hf), 7.42 (2H, s, Hc), 4.20 (4H, m, Hi), 3.89 (4H, 
m, Hj), 3.73 (4H, m, Hk), 3.58 (4H, m, Hl), 3.39 (6H, s, Hm). 13C NMR 
(298 K, CDCl3, 100 MHz)δ: 154.1, 152.1 (Cg), 145.1 (Ca), 143.5, 143.2, 
141.5 (Ch), 139.0 (Cb), 137.0 (Ce), 127.7, 127.1, 123.6 (Cc), 119.4, 
119.3, 92.0, 90.9, 86.4, 85.3, 72.1 (Cl), 71.0 (Ck), 69.7 (Cj), 68.2 (Ci), 
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59.3 (Cm). HR-ES-MS (CDCl3/MeOH): m/z = 742.2577 [M + Na]+ (calc. 
for C43H37N5NaO6, 742.2636). Anal. calc. for C43H37N5O6∙0.5H2O: C, 
70.87; H, 5.26; N, 9.61%. Found: C, 70.86; H, 5.16; N, 9.76%. IR (ATR): 
v (cm-1) 3046, 2968, 2880, 2814, 2210, 1569, 1545, 1421, 1102. 
 
5.10.2.2. Synthesis of 1,3-bis((5-((6-((5-(2-(2-
methoxyethoxy)ethoxy)pyridin-3-yl)ethynyl)pyridin-
2-yl)ethynyl)pyridin-3-yl)ethynyl)benzene (L12) 
A RBF containing diisopropylamine (25 mL) and THF (25 mL) was 
degassed with N2, and 10 (168 mg, 0.400 mmol), 1,3-diiodobenzene (64 
mg, 0.19 mmol), [Pd(PPh3)2Cl2] (5 mg, 0.01 mmol) and CuI (4 mg, 0.02 
mmol) were added against positive N2 flow, before stirring the reaction 
at room temperature for 18 hours, at 45 °C for 6 hours, then 70 °C for 
48 hours. After addition of aqueous 0.1 M EDTA/NH4OH solution (10 
mL) and stirring for 1 hour, CHCl3 (50 mL) was added. The organic 
layer was washed with brine (50 mL), dried (Na2SO4), filtered, and 
pumped down. The resultant residue was suspended in 1:4 
acetone/DCM, and the precipitate collected and washed with diethyl 
ether to give the product as a tan solid (125 mg, 0.136, 70%). When the 
compound required additional purification, this was carried out via 
preparative thin layer chromatography (1:9:190 aqueous NH4OH 
solution/methanol/DCM). 1H NMR (298 K, CDCl3, 400 MHz) δ: 8.76 
(2H, d, J = 1.9 Hz, Hi), 8.73 (2H, d, J = 1.9 Hz, Hg), 8.43 (2H, s, Ha), 8.33 
(2H, d, J = 2.7 Hz, Hb), 8.00 (2H, t, J = 1.8 Hz, Hh), 7.77-7.73 (3H, m, 
He, Hl), 7.57-7.53 (6H, m, Hd, Hf, Hj), 7.43-7.39 (3H, m, Hc, Hk),  4.20-
4.18 (4H, m, Hm), 3.89-3.87 (4H, m, Hn), 3.73-3.71 (m, 4H, Ho), 3.59-
3.57 (m, 4H, Hp), 3.39 (s, 6H, Hq). 13C NMR (298 K, CDCl3, 100 MHz) δ:  
154.5, 151.8, 151.5, 145.2 (Ca), 143.5, 143.2, 141.1 (Ch), 139.1 (Cb), 
136.9 (Ce), 135.0 (Cl), 132.3, 128.9, 120.1, 119.4, 119.1, 92.5, 91.8, 
90.9, 86.4, 85.9, 85.4, 72.1 (Cp), 71.0 (Co), 69.6 (Cn), 68.1 (Cm), 59.2 
(Cq). HR-ESI-MS (CDCl3/MeOH): m/z = 921.3342 [M + H]+ (calc. for 
C58H45N6O6, 921.3395). Anal. calc. for C58H44N6O6∙0.75H2O:  C, 74.51; 
H, 4.74; N, 9.10%. Found: C, 74.54; H, 4.91; N, 8.99%. IR (ATR): v (cm-







5.10.3. Complex synthesis 
5.10.3.1. Synthesis of [Pd3(L11)4](BF4)6 
A solution of L11 (60 mg, 0.083 mmol) and [Pd(CH3CN)4](BF4)2 (28 mg, 
0.063 mmol) in d6-DMSO (1.5 mL) was heated at 60 °C for 3 h. The light 
brown solution was filtered through celite prior to addition of ethyl 
acetate (20 mL) and the subsequent precipitate isolated by filtration, 
washed with ethyl acetate (20 mL) and diethyl ether (20 mL) and dried 
under vacuum to give the product as a tan solid (50 mg, 0.013 mmol, 
64%). 1H NMR (298 K, d6-DMSO, 400 MHz) δ: 9.72 (s, 2H, Hg), 9.24 (s, 
2H, Ha), 9.14 (d, J = 2.1 Hz, 2H, Hb), 8.74 (s, 1H, Hh), 8.09-8.05 (m, 4H, 
Hc, He), 7.85-7.79 (m, 4H, Hd, Hf), 4.37 (s, 4H, Hi), 3.84 (s, 4H, Hj), 3.64-
3.62 (m, 4H, Hk), 3.48-3.25 (m, 4H, Hl), 3.25 (s, 6H, Hm). 13C NMR (298 
K, d6-DMSO, 100 MHz) δ: 156.1, 153.2 (Cg), 145.7 (Ch), 145.0 (Ca), 
141.9, 141.8, 140.2 (Cb), 138.4 128.8, 128.7, 127.8, 121.6, 94.1, 93.1, 
83.6, 83.2, 71.3 (Ck), 69.8 (Cl), 68.9 (Cj), 68.5 (Ci), 58.1 (Cm). HR-ES-MS 
(DMSO/CH3CN): m/z = 532.9727 [Pd2(L11)4]6+ (calc. for 
C172H148N20O24Pd3, 532.9684), m/z = 646.7648 [Pd2(L11)4Cl]5+ (calc. for 
C172H148ClN20O24Pd3, 646.7544), m/z = 648.5622 [Pd2(L11)4CO2H]5+   
(calc. for C173H149N20O26Pd3, 648.5629), m/z = 819.7102 
[Pd2(L11)4ClCO2H]4+ (calc. for C173H149ClN20O26Pd3,  819.6936), m/z = 
821.9534 [Pd2(L11)4(CO2H)2]4+ (calc. for C175H1519N20O30Pd3, 821.9508. 
Anal. calc. for [Pd3(C43H37N5O6)4](BF4)6∙7DMSO: C, 52.37; H, 4.49; N, 
6.57%. Found: C, 51.98; H, 4.27; N, 6.97%. IR (ATR): v (cm-1) 3079, 
2870, 2212, 1648, 1581, 1442, 1050, 808. 
 
5.10.3.2. Synthesis of [Pd4(L11)4](BF4)8 
A solution of L12 (20 mg, 0.022 mmol) and [Pd(CH3CN)4](BF4)2 (10 mg, 
0.022 mmol) in   d6-DMSO (3 mL) was heated at 70 °C for 8 hours. The 
light brown solution was filtered through cotton wool, before addition of 
ethyl acetate (25 mL), and the subsequent precipitate was isolated by 
filtration, washed with ethyl acetate (20 mL) and diethyl ether (20 mL) 
and dried under vacuum to give the product as a brown solid (18 mg, 
0.0040 mmol, 70%). 1H NMR (298 K, 500 MHz, CDCl3, 500 MHz) δ: 9.76 
(2H, s, Hi), 9.62 (2H, s, Hg), 9.15 (4H, m, Ha, Hb), 8.68 (2H, s, Hh), 8.10-
8.03 (6H, m, Hc, He, Hl), 7.85-7.79 (6H, m, Hd, Hf, Hj), 7.68 (1H, t, J = 
8.3 Hz, Hk), 4.37 (4H, s, Hm), 3.85 (4H, s, Hn), 3.64-3.62 (4H, m, Ho), 
3.48-3.46 (4H, m, Hp), 3.25 (6H, s, Hq). 13C NMR (298 K, 500 MHz, 
CDCl3, 125 MHz) δ: 171.4, 156.1, 152.6, 145.1, 144.9, 141.8, 141.8, 
140.2, 138.5, 133.9, 133.7, 130.4, 128.8, 127.8, 122.3, 121.7, 121.6, 
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94.7, 93.9, 93.0, 84.9, 83.6, 83.1, 71.3 (Cp), 69.8 (Co), 68.9 (Cm), 68.5 
(Cn), 58.1 (Cq). HR-ES-MS (DMSO/CH3CN): m/z = 513.5066 
[Pd4(L12)4]8+ (calc. for C232H176N24O24Pd4, 513.4957), m/z = 592.1363 
[Pd4(L12)4Cl]7+  (calc. for C232H176ClN24O24Pd4, 592.1305), m/z = 
593.1426 [Pd4(L12)4CO2H]7+ (calc. for C233H177N24O26Pd4, 593.1347), 
m/z = 698.3274 [Pd4(L12)4ClCO2H]6+   (calc. for C233H177ClN24O26Pd4, 
698.3176), m/z = 700.0105 [Pd4(L12)4(CO2H)2]6+ (calc. for 
C234H178N24O28Pd4, 700.1553), m/z = 705.3427 [Pd4(L12)4ClBF4]6+ (calc. 
for C232H176BF4ClN24O24Pd4, 705.3202), m/z = 706.8312 
[Pd4(L12)4CO2HBF4]6+  (calc. for C233H177BF4N24O26Pd4, 706.8239), m/z 
= 846.9988 [Pd4(L12)4Cl2CO2H]5+ (calc. for C233H177Cl2N24O26Pd4, 
846.9834), m/z = 848.7988 [Pd4(L12)4(CO2H)3]5+  (calc. for 
C235H179N24O30Pd4, 848.7878). Anal. calc. for 
[Pd4(C58H44N6O6)4](BF4)8∙3DMSO: C, 56.73; H, 3.88; N, 6.67%. Found: 
C, 56.68; H, 3.97; N, 6.82%. IR (ATR): v (cm-1) 3080, 2873, 2220, 1648, 







































A1.1  Data collection and refinement 
All data were collected at 100 K on an Agilent Technologies Supernova 
system using Cu Kα radiation with exposures over 1.0°, and data were 
treated using CrystAlisPro software. The structures were solved using 
Sir-97,[131] Superflip,[132] or SHELXT[133] and weighted full-matrix 
refinement on F2 was carried out using SHELXL-97, SHELXTL-6.14 
running within the WinGX package, or X-Seed. All non-hydrogen atoms 
were refined anisotropically (except where noted in the crystallographic 
information file). Hydrogen atoms were placed in calculated positions 
and refined using a riding model (except on selected heteroatoms, as 
noted in the crystallographic information file). 
 
A1.2  Ellipsoid plots of reported X-ray crystal structures 
Structures are shown in the order discussed in the text. Ellipsoids are 
shown at 50% probability level. 
 
Figure A1.1  L2 
 




Figure A1.3  [Pd3(NHC)3(L1)Br6]∙4CHCl3 
 
Figure A1.4  [Pd2(NHC)2(L4)Br4] 
 





Figure A1.6  [Pd(NHC)(L3mono)Br2] 
 
Figure A1.7  [Pd(NHC)(L4mono)Br2]∙DCM 
 




Figure A1.9  [Pd(NHC)(L6mono)Br2] 
 
Figure A1.10  [Pd(NHC)(L7mono)Br2] 
 




Figure A1.12 L7 
 
Figure A1.13  [Pd2(L6)4]4+ 
 
 




Figure A1.15  L9 
 




Figure A1.17 [Pd2(L9)2Cl4] 
 





A1.3 Crystallographic data 
 L2 [Fe2(L2)3](BF4)4∙4.4CH3CN 
Empirical formula C15H12N8 C53.80H49.20B4F16Fe2N28.40 
Formula weight 304.33 1552.56 
Temperature 100.01(10) K 100.02(10) K 
Wavelength 1.54184 Å 1.54184 Å 
Crystal system Monoclinic Triclinic 
Space group I 2/a P1̅ 
Unit cell dimensions 
a = 28.6281 Å 
 = 90° 
b = 4.21800(10) Å 
= 108.352(4)° 
c = 24.0685(10) Å  
 = 90° 
a =12.5175(2) Å 
= 84.878(2)° 
b = 14.7657(3) Å 
= 78.200(2)° 
c = 18.2903(3) Å 
 = 85.572(2)° 
Volume 2758.53(17) Å3 3289.91(10) Å3 
Z 8 2 
Absorption coefficient 0.795 mm-1 4.494 mm-1 
F(000) 1264 1574 
Theta range for data 
collection 
3.25 to 76.56° 3.01 to 76.81° 
Index ranges 
-35 ≤ h ≤ 35, 
-5 ≤ k ≤ 5,  
-30 ≤ l ≤ 27 
-15 ≤ h ≤ 15,  
-18<=k ≤ 18,  
-19 ≤ l ≤ 22 
Reflections collected 7866 52255 
Independent reflections 
2839  
[R(int) = 0.0309] 
13738  
[R(int) = 0.0357] 
Completeness  
99.60 %  
to theta = 67.684° 
99.0 %  
to theta = 76.81° 






Data / restraints / 
parameters 
2839 / 0 / 208 13738 / 48 / 1021 
Goodness-of-fit on F2 1.361 1.189 
Final R indices 
[I>2sigma(I)] 
R1 = 0.0505,  
wR2 = 0.1546 
R1 = 0.0971,  
wR2 = 0.2413 
R indices (all data) 
R1 = 0.0545,  
wR2 = 0.1637 
R1 = 0.0977,  




Largest diff. peak and 
hole 







 [Pd3(NHC)3(L1)Br6]∙4CHCl3 [Pd2(NHC)2(L4)Br4] 
Empirical formula C62H69Br6Cl12N9Pd3 C50H56Br4N10Pd2 
Formula weight 2164.32 1329.49 
Temperature 100.0(1) K 100.(2) K 
Wavelength 1.54184 Å 1.54184 Å 
Crystal system Triclinic Triclinic 
Space group P1̅ P1̅ 
Unit cell dimensions 
a = 9.3316(3) Å 
 = 72.281(2)° 
b = 16.9562(5) Å 
 = 80.109(2)° 
c = 25.8379(5) Å  
 = 88.820(3)°  
a = 12.2308(5) Å 
= 75.175(2)° 
b = 12.6784(4) Å 
= 85.812(3)° 
c = 20.4542(5) Å 
 = 81.398(3)° 
Volume 3834.27(18) Å3 3029.69(17) Å3 
Z 2 2 
Absorption coefficient 13.481 mm-1 8.177 mm-1 
F(000) 2112 1316 
Theta range for data 
collection 
3.72 to 76.75° 3.64 to 74.98° 
Index ranges 
-11 ≤ h ≤ 11,  
-20 ≤ k ≤ 21, 
 -25 ≤ l ≤ 32 
-13 ≤ h ≤ 15,  
-15 ≤ k ≤ 15,  
-25 ≤ l ≤ 24 
Reflections collected 62918 44918 
Independent reflections 
16012  
[R(int) = 0.1009] 
12182  
[R(int) = 0.0745] 
Completeness  
100.0 %  
to theta = 67.00° 
97.5 %  
to theta = 74.98° 




 Full-matrix least-squares 
on F2 
Data / restraints / 
parameters 
16012 / 57 / 841 12182 / 0 / 603 
Goodness-of-fit on F2 1.235 1.538 
Final R indices 
[I>2sigma(I)] 
R1 = 0.1103  
wR2 = 0.3006 
R1 = 0.0728  
wR2 = 0.2181 
R indices (all data) 
R1 = 0.1382  
wR2 = 0.3333 
R1 = 0.0863  




Largest diff. peak and 
hole 
6.796 and 
 -2.458 e.Å-3 






 [Pd(NHC)(L1mono)Br2] [Pd(NHC)(L3mono)Br2] 
Empirical formula C20H23Br2N3Pd C26H35Br2N5O2Pd 
Formula weight 571.63 715.81 
Temperature 100.0(1) K 100.0(1) K 
Wavelength 1.54184 Å 1.54184 Å 
Crystal system Monoclinic Orthorhombic 
Space group C 2/c Pna21 
Unit cell dimensions 
a = 27.3117(2) Å 
 = 90° 
b = 9.98140(10) Å 
= 96.5170(10)° 
c = 16.12290(10) Å  
 = 90° 
a = 9.10290(10) Å 
= 90° 
b = 30.3010(4) Å 
= 90° 
c = 10.33980(10) Å 
 = 90° 
Volume 4366.85(6) Å3 2852.00(6) Å3 
Z 8 4 
Absorption coefficient 11.199 mm-1 8.784 mm
-1
 
F(000) 2240 1432 
Theta range for data 
collection 
3.26 to 74.20° 4.52 to 76.74° 
Index ranges 
-33 ≤ h ≤ 33, 
-12 ≤ k ≤ 12,  
-20 ≤ l ≤ 20 
-8 ≤ h ≤ 11,  
-37 ≤ k ≤ 37,  
-11 ≤ l ≤ 13 
Reflections collected 31042 22580 
Independent reflections 
4419  
[R(int) = 0.0408] 
5612  
[R(int) = 0.0406] 
Completeness  
99.2 %  
to theta = 74.20° 
99.2 %  
to theta = 76.74° 






Data / restraints / 
parameters 
4419 / 6 / 239 5612 / 1 / 330 
Goodness-of-fit on F2 1.122 1.052 
Final R indices 
[I>2sigma(I)] 
R1 = 0.0231,  
wR2 = 0.0587 
R1 = 0.0347,  
wR2 = 0.0874 
R indices (all data) 
R1 = 0.0233,  
wR2 = 0.0600 
R1 = 0.0360,  




Largest diff. peak and 
hole 
0.662 and  
-0.545 e.Å-3 






 [Pd(NHC)(L4mono)Br2] [Pd(NHC)(L5mono)Br2] 
Empirical formula C29H33Br2Cl2N5Pd C27H37Br2N5Pd 
Formula weight 788.72 697.84 
Temperature 100.(2) K 100.0(1) K 
Wavelength 1.54184 Å 1.54184 Å 
Crystal system Orthorhombic Orthorhombic 
Space group Pna21 Pna21 
Unit cell dimensions 
a = 8.9759(2) Å 
= 90° 
b = 29.9396(6) Å 
= 90° 
c = 11.4183(3) Å 
 = 90° 
a = 8.90910(10) Å   
 = 90° 
b = 30.6079(4) Å 
 = 90° 
c = 10.68450(10) Å   
 = 90° 
Volume 3068.51(11) Å3 2913.54(6) Å3 
Z 4 4 
Absorption coefficient 9.747 mm-1 8.528 mm
-1
 
F(000) 1568 1400 
Theta range for data 
collection 
4.14 to 76.64° 4.38 to 76.76° 
Index ranges 
-11 ≤ h ≤ 8,  
-37 ≤ k ≤ 32,  
-14 ≤ l ≤ 11 
-11 ≤ h ≤ 10, 
-34 ≤ k ≤ 37, 
-13 ≤ l ≤ 8 
Reflections collected 12155 16208 
Independent reflections 
5281  
[R(int) = 0.0303] 
4004  
[R(int) = 0.0306] 
Completeness  
99.2 %  
to theta =76.64° 
97.1 %  
to theta = 76.76° 






Data / restraints / 
parameters 
5281 / 1 / 356 4004 / 1 / 321 
Goodness-of-fit on F2 1.102 1.025 
Final R indices 
[I>2sigma(I)] 
R1 = 0.0326,  
wR2 = 0.0796 
R1 = 0.0268, 
wR2 = 0.0702 
R indices (all data) 
R1 = 0.0341,  
wR2 = 0.0805 
R1 = 0.0276, 














 [Pd(NHC)(L6mono)Br2] [Pd(NHC)(L7mono)Br2] 
Empirical formula C18H24Br2N4Pd C18H24Br2N4Pd 
Formula weight 562.63 562.63 
Temperature 100.01(14) K 100.01(10) K 
Wavelength 1.54184 Å 1.54184 Å 
Crystal system Orthorhombic Monoclinic 
Space group Pna21 P21/c 
Unit cell dimensions 
a = 15.1985(2) Å
 = 90° 
b = 13.87140(10) Å
= 90° 
c = 9.61950(10) Å
 = 90° 
a = 16.9990(5) Å
= 90° 
b = 10.7499(3) Å
= 105.796(3)° 
c = 11.9570(3) Å
 = 90° 
Volume 2028.03(4) Å3 2102.48(10) Å3 
Z 4 4 
Absorption coefficient 12.056 mm-1 11.629 mm-1 
F(000) 1104 1104 
Theta range for data 
collection 
4.32 to 76.42° 4.92 to 76.79° 
Index ranges 
-18 ≤ h ≤ 18, 
-15 ≤ k ≤ 17, 
-12 ≤ l ≤ 11 
-21 ≤ h ≤ 20, 
-10 ≤ k ≤ 13, 
-14 ≤ l ≤ 14 
Reflections collected 13427 15414 
Independent reflections 4123 [R(int) = 0.0333] 4384 [R(int) = 0.0928] 
Completeness  99.2% to theta = 76.42° 98.6% to theta = 76.79° 






Data / restraints / 
parameters 
4123 / 19 / 230 4384 / 0 / 231 
Goodness-of-fit on F2 0.649 1.119 
Final R indices 
[I>2sigma(I)] 
R1 = 0.0225,  
wR2 = 0.0695 
R1 = 0.0590,  
wR2 = 0.1509 
R indices (all data) 
R1 = 0.0227,  
wR2 = 0.0701 
R1 = 0.0662,  




Largest diff. peak and 
hole 





 L6∙CH3CN L7 
Empirical formula C22H18N6O C20H15N5O 
Formula weight 382.42 341.37 
Temperature 100.00(18) K 100.00(10) K 
Wavelength 1.54184 Å 1.54184 Å 
Crystal system Monoclinic Monoclinic 
Space group C 2/c Pna21 
Unit cell dimensions 
a = 7.78230(10) Å
 = 90° 
b = 15.54850(10) Å
 = 102.1270(10)° 
c = 16.30990(10) Å 
 = 90° 
a = 20.1233(12) Å
= 90° 
b = 5.3492(4) Å 
 = 110.111(8)° 
c = 16.4925(15) Å 
 = 90° 
Volume 1929.51(3) Å3 1667.1(2) Å3 
Z 4 4 
Absorption coefficient 0.691 mm-1 0.714 mm-1 
F(000) 800 712 
Theta range for data 
collection 
3.97 to 76.72°. 4.68 to 76.73°. 
Index ranges 
-9 ≤ h ≤ 9, 
-19 ≤ k ≤ 19, 
-20 ≤ l ≤ 20 
-25 ≤ h ≤ 25, 
-6 ≤ k ≤ 6, 
-20 ≤ l ≤ 20 
Reflections collected 36967 14099 
Independent  
reflections 
4057 [R(int) = 0.0293] 3485 [R(int) = 0.2689] 
Completeness  99.6% = 76.72° 99.1%  to theta = 76.73° 
Absorption correction Gaussian Gaussian 
Refinement method 
Full-matrix least- 
squares on F2 
Full-matrix least- 
squares on F2 
Data / restraints / 
parameters 
13832 / 0 / 673 4057 / 0 / 264 
Goodness-of-fit on F2 1.26 2.682 
Final R indices 
[I>2sigma(I)] 
R1 = 0.1446, 
wR2 = 0.3340 
R1 = 0.0653, 
wR2 = 0.2760 
R indices (all data) 
R1 = 0.1617, 
wR2 = 0.3536 
R1 = 0.0672, 




Largest diff. peak and 
hole 





 [Pd2(L6)4]4+ [(cisplatin)2Pd2(L8)4](BF4)4∙4DMF 
Empirical formula C80H52N16O4Pd2 C92H92B4Cl4F16N20O8Pd2Pt2 
Formula weight 1514.8 2697.88 
Temperature 100(1) K 100.0(1) K 
Wavelength 1.54184 Å 1.54184 Å 
Crystal system Tetragonal Monoclinic 
Space group P4/m P21/n 
Unit cell dimensions 
a = 11.3213(11) Å 
 = 90° 
b = 11.3212(11) Å 
= 90° 
c = 34.953(4) Å  
 = 90° 
a = 13.6110(4) Å
= 90° 
b = 13.7665(6) Å 
 = 98.466(3)° 
c = 35.7207(12) Å
 = 90° 
Volume 4480.0(10) Å3 6620.3(4) Å3 
Z 2 2 
Absorption coefficient 3.643 mm-1 7.387 mm-1 
F(000) 1536 2656 
Theta range for data 
collection 
3.794 to 73.702° 3.34 to 81.21°. 
Index ranges 
-3 ≤ h ≤ 14,  
-3 ≤ k ≤ 12,  
-39 ≤ l ≤ 43 
-14 ≤ h ≤ 17,  
-17 ≤ k ≤ 15,  
-45 ≤ l ≤ 44 
Reflections collected 34358 33335 
Independent 
reflections 
4572 [R(int) = 0.1650] 13832 [R(int) = 0.1054] 
Completeness  
100.0% to theta = 
67.684° 
94.6% to theta = 81.21° 
Absorption correction Gaussian Semi-empirical from equivalents 
Refinement method 
Full-matrix least-
squares on F2 
Full-matrix least- 
squares on F2 
Data / restraints / 
parameters 
4572 / 97 / 237 13832 / 0 / 673 
Goodness-of-fit on F2 1.179 1.26 
Final R indices 
[I>2sigma(I)] 
R1 = 0.1445, 
wR2 = 0.4487 
R1 = 0.1446,  
wR2 = 0.3340 
R indices (all data) 
R1 = 0.2249, 
wR2 = 0.4447 
R1 = 0.1617,  




Largest diff. peak and 
hole 





 L9 [(H2O)4Pd2(L9)4](BF4)4 
Empirical formula C29 H31 N3 O6 C116 H132 B4 F16 N12 O28 Pd2 
Formula weight 517.57 2702.38 
Temperature 100.0(2) K 100.0(1) K 
Wavelength 1.54184 Å 1.54184 Å 
Crystal system Monoclinic Triclinic 
Space group P21/c P1̅ 
Unit cell dimensions 
a = 19.2486(2) Å
 = 90° 
b = 10.91640(10) Å   
= 93.1170(10)° 
c = 12.41140(10) Å 
 = 90° 
a = 14.8562(5) Å
= 117.401(3)° 
b = 16.5839(5) Å 
 = 93.110(2)° 
c = 16.9982(4) Å
 = 114.691(3)° 
Volume 2604.09(4) Å3 3216.53(16) Å3 
Z 4 1 
Absorption coefficient 0.763 mm-1 3.098 mm-1 
F(000) 1096 1392 
Theta range for data 
collection 
4.60 to 76.78° 3.08 to 76.54° 
Index ranges 
-23 ≤ h ≤ 24,  
-13 ≤ k ≤ 13,  
-15 ≤ l ≤ 11 
-18 ≤ h ≤ 18,  
-20 ≤ k ≤ 20,  
-19 ≤ l ≤ 21 
Reflections collected 40606 39257 
Independent 
reflections 
5459 [R(int) = 0.0409] 13327 [R(int) = 0.0675] 
Completeness  
100.00% 
to theta = 67.00° 
100.00% 
to theta = 77.03° 
Absorption correction Gaussian Gaussian 
Refinement method 
Full-matrix least-
squares on F2 
Full-matrix least- 
squares on F2 
Data / restraints / 
parameters 
5459 / 0 / 345 13327 / 30 / 869 
Goodness-of-fit on F2 1.098 1.121 
Final R indices 
[I>2sigma(I)] 
R1 = 0.0413,  
wR2 = 0.1046 
R1 = 0.0749,  
wR2 = 0.2070 
R indices (all data) 
R1 = 0.0444,  
wR2 = 0.1066 
R1 = 0.1015,  




Largest diff. peak and 
hole 








Empirical formula C58 H62 Cl4 N6 O12 Pd2 C126 H150 N16 O38 Pd2 S4 
Formula weight 1389.74 2837.66 
Temperature 100.01(10) K 100.01(10) K 
Wavelength 1.54184 Å 0.71073 Å 
Crystal system Monoclinic Monoclinic 
Space group C2/m P1 21/n  
Unit cell dimensions 
a = 13.8958(6) Å 
 = 90° 
b = 21.0537(7) Å 
= 101.982(4)° 
c = 11.1192(5) Å 
 = 90° 
a = 13.099 Å
= 90° 
b = 17.179 Å 
= 91.566(2)° 
c = 32.2500(10) Å
 = 90° 
Volume 3182.1(2) Å3 7254.4(2) Å3 
Z 2 2 
Absorption coefficient 6.618 mm-1 0.384 mm-1 
F(000) 1416 2956 
Theta range for data 
collection 
3.87 to 76.32° 2.90 to 26.02° 
Index ranges 
-11 ≤ h ≤ 17,  
-26 ≤ k ≤ 26,  
-11 ≤ l ≤ 13 
-14 ≤ h ≤ 16,  
-21 ≤ k ≤ 21,  
-39 ≤ l ≤ 39 
Reflections collected 7617 105476 
Independent 
reflections 
3299 [R(int) = 0.0258] 14267 [R(int) = 0.0381] 
Completeness  
98.80% to theta = 
67.00° 
99.80% to theta = 26.02° 
Absorption correction Gaussian Gaussian 
Refinement method 
Full-matrix least-
squares on F2 
Full-matrix least- 
squares on F2 
Data / restraints / 
parameters 
3299 / 0 / 191 14267 / 58 / 838 
Goodness-of-fit on F2 1.086 1.86 
Final R indices 
[I>2sigma(I)] 
R1 = 0.0552,  
wR2 = 0.1589 
R1 = 0.1103,  
wR2 = 0.3733 
R indices (all data) 
R1 = 0.0627,  
wR2 = 0.1674 
R1 = 0.1201,  
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A2.1  Reagents  
MTT and cell culture reagents were purchased from Invitrogen 
(Auckland, NZ). Antibodies were purchased from Santa Cruz 
Biotechnology (CA, USA). All other chemicals were obtained from 
Sigma-Aldrich (Auckland, NZ) unless stated otherwise. 
 
A2.2   Cell culture  
All cell lines were purchased from the American Type Culture Collection 
(ATCC, Manassas, VA, USA) and maintained in Dulbecco’s Modified 
Eagles Medium (DMEM) enriched with 2% FBS and 1% antibiotic. 
Additionally, the medium for MCF 10A cells was supplemented with 10 
µg mL-1 insulin, 20 ng/mL EGF, 100 ng mL-1 cholera toxin and 0.5 µg 
mL-1 hydrocortisone. All cells were cultured at 37°C in a humidified 
atmosphere with 5% CO2 levels. 
 
A2.3  Cytotoxicity evaluation  
Cell viability was assessed using the MTT (3-[4,5-dimethylthiazol-2-yl]-
2,5-diphenyltetrazolium bromide) assay.[86] 96 well plates were seeded 
with 5,000 cells per well, and the cells left to adhere for 24 hours prior 
to treatment. Cells were then exposed to compound solubilised in 
DMSO. To control for the effects of DMSO, all cell culture medium had 
a constant DMSO concentration of 0.5% (v/v). Following compound 
administration, cells were washed with PBS and MTT (0.4 mg⁄mL in 
DMEM) added for 3 hours. After MTT incubation, the medium was 
aspirated and the residual crystals dissolved in DMSO. Cell number 
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